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The principal focus in malaria research is the development of an effective malaria vaccine 
which will help to prevent death and eliminate the disease. This study investigated two 
plasmodial glycolytic enzymes as possible malaria vaccine candidates. Plasmodium yoelii 
glyceraldehyde-3-phosphate (rPyGAPDH) and lactate dehydrogenase (rPyLDH) 
recombinantly as His-tagged fusion proteins were affinity purified using a cobalt affinity matrix. 
Ethanol has been reported to enhance expression of recombinant proteins in E. coli bacteria. 
Concentrations of 1%, 2% and 3% (v/v) ethanol were tested for enhancement of rPyLDH and 
rPyGAPDH expression in both lysogenic broth and terrific broth. Ethanol reduced the overall 
expression of proteins by inhibiting the growth of PyLDH and PyGAPDH E. coli host cells. The 
recombinant proteins were evaluated using a metal ion gel shift assay. Both rPyLDH and 
rPyGAPDH did not show a size shift on the gel following incubation with Cu2+, Co2+ or Ni2+. 
Both the reduced and non-reduced forms of rPyLDH and rPyGAPDH had similar migration on 
a 10%, 12.5% and 15% SDS-PAGE gels. Recombinant PyLDH and rPyGAPDH were 
prepared in Freund’s adjuvants and mice were immunized to evaluate immunogenicity. Both 
rPyGAPDH and rPyLDH were immunogenic in mice and produced high antibody titers. Mice 
were immunized with rPyLDH or rPyGAPDH and challenged with P. berghei infection. All 
PyLDH immunized mice developed high parasitemia and 1/5 of the PyGAPDH immunized 
mice maintained low parasitemia below 5% throughout the study. Further work includes 
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1.1 Malaria background    
Malaria is a parasitic disease that is responsible for killing approximately 438 000 people 
annually (World Health Organization, 2016). Most of the deaths are reported in poor African 
countries, approximately 90% in tropical regions of  Africa, while the remainder occured in South 
East Asia and South America (World Health Organization, 2016). Malaria is caused by the 
protozoan parasite that belongs to the genus Plasmodium. The survival of Plasmodium 
parasites requires two hosts, the vertebrate host (including humans) and the mosquito which 
transmits the parasites. Out of hundreds of Plasmodium parasites, only five of these infect 
humans. These are Plasmodium falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. 
These parasites only infect humans apart from P.  knowlesi whose host is the long-tailed and 
pig-tailed macaques (Luchavez et al., 2008; White, 2008). P. falciparum causes most of the 
disease in sub-Saharan Africa, while P. vivax is mostly dominant in Asia and South America 
(World Health Organization, 2016). P. falciparum has a short erythrocyte cycle that leads to the 
production of a high number of merozoites and a high parasitemia associated with the disease 
(Bozdech et al., 2003; van Dooren et al., 2005).  
During the feeding of an infected Anopheles mosquito on the human blood, the 
infectious sporozoites are injected into the skin (Cowman et al., 2016). The sporozoites then 
pass through the bloodstreams to the liver where they infect liver cells. Sporozoites mature into 
merozoites in hepatocytes, merozoites are liberated in the bloodstreams to invade red blood 
cells in order to begin their asexual cycle (Cowman et al., 2016). The asexual cycle of malaria 
inside the human erythrocytes causes the clinical symptoms of the disease. Depending on the 
species that causes the infection and the immunity of the infected individual, the disease 
symptoms typically appear between 8-14 days after infection (Cowman et al., 2016; World 
Health Organization, 2016). Malaria manifests as fever symptoms, headache, chills, sweats, 
fatigue, nausea and vomiting (Cowman et al., 2016; World Health Organization, 2016). 
Plasmodium falciparum is the most lethal parasite, which progresses to cerebral malaria, which 
can be deadly. 
Animal models, commonly rodents are used when conducting clinical and laboratory 
studies of malaria. The reason for this is because there are ethical restrictions to use humans 
for many studies. Rodents are commonly used as they are cheap and easy to work with. They 
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also make it possible to investigate the disease progression which is a challenge in humans, 
and studying of the parasites sequester in organs e.g. brain, liver and spleen is possible in 
rodents (Wykes and Good, 2009). There are four plasmodia species that infect rodents, 
Plasmodium berghei, P. chaubaudi, P. vinkei and P. yoelii (lethal and non-lethal strain). 
Plasmodium berghei and P. yoelii infects both mature red blood cells and reticulocytes, this 
allows for investigation of vaccine candidates (Wykes and Good, 2009). Plasmodium vinkei and 
P. chabaudi only infect mature red blood cells, these parasites are used when studying the 
immune responses of malaria and drug susceptibility (Wykes and Good, 2009).  
1.1 Malaria life cycle  
 
Figure 1.1: Plasmodium life cycle between the mosquito vector and a human host. The malaria life 
cycle begins with the mosquito vector which deposits the sporozoites into a human host. The sporozoites 
invade the hepatocytes where they develop and invade the erythrocytes to begin their asexual cycle. The 
asexual stage generates schizonts which infect more erythrocytes. Male and female gametocytes also 
develop from schizonts and are taken in by the mosquito when it feeds on a human host. Taken from 
Winzeler (2008). 
 
1.1.1 Development of sporozoites inside the mosquito vector of Plasmodium species 
Sporozoites develop from oocysts inside the mosquito midgut (Kappe et al., 2003). Once 
the oocyst matures, it ruptures liberating sporozoites into the hemolymph. The sporozoites then 
travel to the mosquito salivary glands until a mosquito feeds on the vertebrate host (Kappe et 




1.1.2 Invasion of hepatocytes by plasmodial sporozoite 
Human malaria infection begins when an infected Anopheles female mosquito bites a 
human host. The mosquito deposits the sporozoites in the skin. These sporozoites move to the 
liver and invade hepatocytes (Kappe et al., 2003). During  hepatocytes invasion, the sporozoites 
surface receptors which include the thrombospondin domains of the circumsporozoite protein 
(CSP) and the thrombospondin-related adhesion proteins (TRAP) attaches to the heparan 
sulfate proteoglycan on the surface of the liver cells (Kappe et al., 2003). Immediately after the 
sporozoite receptors have successfully attached to the hepatocyte surface, sporozoites enter 
the hepatocytes and multiply into thousands of merozoites. Merozoites are then released to 
invade erythrocytes and initiate the asexual cycle (Figure 1.1).   
1.1.3 Erythrocytes invasion by plasmodial merozoites  
Erythrocytes invasion is initiated by an increase in pressure in the parasite, which 
causes the parasitophorous vacuole to break open to release the merozoites (Cowman & 
Crabb, 2006). The erythrocytes membranes are then disrupted by the Serine repeat antigens 
(SERA) which belong to the family of serine proteases (Cowman & Crabb, 2006). Four events 
are involved in erythrocytes invasion. Firstly, the merozoites bind to the erythrocyte surface; this 
binding is through the glycosylphosphatidylinositol (GPI) anchored membrane proteins found on 
the merozoite surface. Nine GPI anchored proteins which include Merozoite surface protein 1 
(MSP1), MSP2, MSP4, MSP5, MSP10, Pf12, Pf38, Pf92 and Pf113 have been identified in 
Plasmodium falciparum (Cowman & Crabb, 2006). Following binding, the merozoite reorientates 
it’s apical end on the erythrocyte surface. Apical membrane antigen 1 (AMA1) facilitates the 
reorientation (Mitchell et al., 2004).   Invasion is sparked by the signalling pathways which 
implicate both calcium and potassium ions levels (Singh et al., 2010). When merozoites are 
released in the blood which has low potassium ion concentration, the cytosolic calcium levels of 
the blood are elevated, and this triggers the movement of microneme proteins to the merozoite 
surface. These microneme proteins include AMA1 and erythrocyte binding antigen 175 (EBA 
175) and their role involves stimulating the invasion process by interacting with erythrocyte 
receptors. EBA 175 attaches to glycophorin A on the red blood cell surface creating a junction 
for invasion (Singh et al., 2010). Inside the erythrocytes, the parasites go through structural 
changes between the ring stage and the trophozoite stage. During the trophozoite stage, the 
parasites digest the erythrocyte cytoplasm and destroy haemoglobin followed by multiple 
nuclear divisions to produce schizonts that rupture erythrocytes and infect new erythrocytes 
(Figure 1.1) (Cowman & Crabb, 2006). 
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1.1.4 Plasmodial gametocyte development 
During the development of parasites inside the erythrocytes, some parasites develop 
into sexual stages in a process called gametocytogenesis (Duffy & Avery, 2013). During this 
process, two sexual forms of parasites, the male and female gametocytes are produced. 
Gametocytogenesis is divided into five developmental stages (I-V) with distinct morphologies. In 
stage V of development, the gametocytes have fully developed, and male and female 
gametocytes can be easily differentiated (Baker, 2010). Plasmodium falciparum 
gametocytogenesis takes about 8-12 days (Sinden, 2009). During the feeding of an Anopheles 
mosquito on the blood of an infected host, matured gametocytes (male and female) are 
ingested and fertilization occurs in the mosquito gut forming an ookinete (Baker, 2010). In the 
mosquito gut, the ookinete matures forming an oocyst enclosing sporozoites which 
consequently move to the salivary glands of the mosquito where they fully develop. The 
sporozoites are subsequently deposited onto the skin of the next person the mosquito feeds on.  
1.2 Transmission of Plasmodium parasites 
 
Figure 1.2: Malaria transmission in South Africa. Pink areas are places of high malaria transmission 




There are hundreds of mosquito species that exist and about 30 species are malaria 
vectors (World Health Organisation, 2016). The disease is prevalent in tropical areas of the 
world including sub-Saharan Africa where the disease transmission is more robust than other 
parts of the world (Kiszewski et al., 2004).  Malaria transmission is reported to be contributed by 
the mosquito density, human activities, human and vector genetics and as well as climate 
conditions (Craig, 1999).  
1.3 .1 Influence of climate on malaria 
Climate, particularly warm temperatures and rainfall provide favourable breeding 
conditions for mosquitoes. This results in an increased density of mosquitoes that transmit the 
disease. High density of complementary mosquito vectors is problematic as these vectors 
maintain malaria transmission throughout the year. Kiszewski et al (2004) reported Anopheles 
gambiae to breed during the wet season, while Anopheles funestus breeds during the dry 
season maintaining malaria transmission. Different Mosquito species live in different habitats; 
some prefer puddles e.g. Anopheles gambiae, while some prefer permanent water e.g.  
Anopheles funestus. These conditions are abundant during the rainy season in tropical 
countries and that is why 90% of malaria infections are reported in sub-Saharan Africa (Craig, 
1999).  
1.3.2 Human immunity to malaria 
Human genetics is one of the crucial influences of malaria transmission. In malaria 
endemic areas where transmission occurs almost throughout the year, people who live in these 
areas acquire partial immunity that prevents the development of severe malaria. Immunity to 
malaria is acquired after multiple infections and it has been observed to increase with age 
leaving the younger children vulnerable to the disease (World Health Organization, 2016). 
Children under the age of five years, first time pregnant women and visitors to malaria-endemic 
areas are susceptible to malaria (Bloland & Organization, 2001). People of all ages are at risk in 
non-endemic areas e.g. Asia and Latin America as they do not have immunity to malaria since 
they are not continuously exposed to the disease (World Health Organization, 2016). In South 
Africa, malaria is seasonal and occurs during the rainy season, which is between September 
and May (World Health Organization, 2016). Areas at risk of malaria in South Africa include 
North-eastern Kwazulu-Natal, Limpopo and Mpumalanga, especially areas that are close to 
Zimbabwe, Mozambique and Swaziland borders (Figure 1.2). Almost all South African residents 
are non-immune and therefore are at high risk of getting severe malaria, which is deadly if it is 
left untreated (World Health Organization, 2016).  
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1.3.3 Human activities influencing malaria 
Urbanization and intercontinental travelling are the major contributors to the transmission 
of malaria (Kiszewski et al., 2004). Developing countries, particularly in sub-Saharan Africa, are 
being continuously urbanized. Urbanization results in high malaria transmission due to improper 
housing, hygiene and absence of proper plumbing. Usage of water tanks in developing 
countries increases the contact of people with mosquitoes and that increase malaria  
transmission (Kiszewski et al., 2004). Anopheles stephensi has been reported in water tanks in 
India (Kiszewski et al., 2004). Intercontinental travelling occasionally leads to the transportation 
of infected mosquitoes to non-endemic countries, thereby increasing malaria transmission 
(World Health Organization, 2016).  
1.4 Malaria control  
1.4.1 Mosquito vector control  
The key approach of preventing malaria transmission is by minimising the interactions 
between infected mosquitoes and the people (World Health Organisation, 2016). The use of 
Dichlorodiphenyltrichloroethane (DDT) to spray homes in order to kill mosquitoes was 
implemented in the early 1960s. This practice had a huge influence on the complete elimination 
of malaria in most parts of the continent including Southern Europe, Russia and parts of Asia 
(Guerin et al., 2002).  
Mosquitoes usually bite during the night, therefore avoiding being out at night and using 
insecticide-treated bednets (ITNs) has been the best strategy to reduce human and mosquito 
contact in malaria-endemic areas. ITNs and indoor residual spraying (IRS) were introduced as 
early as the 1940s during World War II. Pyrethroids including permethrin and lambdacyhalothrin 
are chemicals commonly used in ITNs and IRS that have shown high insecticidal activity and 
are not harmful to humans (World Health Organisation, 2016).  Bhatt et al (2015) reported a 
decrease in P. falciparum infection in endemic African countries of 68% during 2000-2015 due 
to ITNs. Alonso et al (1991) showed that employing permethrin-treated bed nets reduced 
malaria infection and deaths of children by 30% during the malaria transmission season in 
Gambia. ITNs had been reported as a cost-effective approach for preventing malaria in a clinical 
trial in Gambia (Alonso et al., 1991). 
 
1.4.2 Mosquito vector resistance to insecticides  
Though, malaria control had been difficult in tropical countries due to the lack of access 
to health services, poor health infrastructure and the occurrence of insecticide resistance 
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(Guerin et al., 2002). Pyrethroid and DTT resistance by Anopheles gambiae has been reported 
in East and West African countries (N’Guessan et al., 2007; Ranson & Lissenden, 2016). This 
makes it a challenge to control malaria as ITNs and IRS are the main methods of prevention. In 
South Africa, an invasion by Anopheles funentus, which was resistant to pyrethroid, was 
reported in 1999 (Barnes et al., 2005). This resulted in a rapid increase in malaria transmission. 
ITNs have also been reported to be less effective in non-endemic areas and regions where 
mosquito vectors bite people in the late afternoon and morning (Kroeger et al., 1999). Kroeger 
et al (1999) reported a low protective efficacy of ITNs in Latin America where Anopheles 
albimanus the vector for P. vivax was observed to bite people during the late afternoon.  
1.5 Diagnosis of malaria 
Early and correct detection of malaria is important in order to administer the correct 
treatment to prevent deaths due to the disease (Amir et al., 2018). Commonly used technique 
for diagnosis includes microscopy which is the gold standard, Polymerase Chain Reaction 
(PCR), Loop-mediated isothermal amplification (LAMP) and Rapid Diagnostic Tests (Amir et al., 
2018). 
1.5.1 Microscopic diagnosis of malaria 
Microscopic detection is based on the identification of malaria parasites inside red blood 
cells (Warhurst & William, 1996). Blood samples are obtained from the patient’s finger by 
pricking it with a needle, and stained with Wright’s, Field’s or Giemsa stain (Warhurst & William, 
1996). A thin or thick blood film is spread over a microscopic slide; the parasites are stained and 
counted under 100 microscope fields (Warhurst & William, 1996; Amir et al., 2018). Giemsa is 
the most commonly used stain for routine malaria diagnosis owing to its stability at different 
temperature (Warhurst & William, 1996).  
For microscopic examination of parasites, thick and thin films are used to estimate the 
parasite burden (Amir et al., 2018). Thick blood films have an enhanced sensitivity, which allows 
for the detection of 50 parasites/μl of blood and it is 20-30 times denser than the thin film 
(Payne, 1988). A thin film is a preferred method as parasites can be identified by their 
morphology which cannot be seen using a thick film preparation (Warhurst & William, 1996). 
Morphological identification of parasites enables a microscopist to accurately distinguish 
different Plasmodium species, as this is important for the administration of correct treatment 
(Warhurst & William, 1996). The asexual stages of the parasites are unique and can be 
identified under the microscope. Unlike other Plasmodium species, both P. falciparum and P. 
malariae have a uniform trophozoite cytoplasm and non-enlarged infected red blood cells. 
8 
 
These two malaria parasites are distinguished from each other by the presence of hemozoin 
pigment, which is a characteristic of P. falciparum (Noland et al., 2003). The trophozoite 
cytoplasm of P. vivax and P. ovale appear irregular, while the infected red blood cells are 
enlarged and distorted. P. ovale has a unique trophozoite cytoplasm that is partially fragmented, 
while P. vivax is distinguished by its oval-shaped infected red blood cells. Microscopy 
disadvantages include the misdiagnosis of P. knowlesi parasites for P. malariae as they have 
similar morphologies (Antinori et al., 2013). The technique is also expensive as it costs a lot of 
money to maintain microscopes and employ trained personnel. Consequently, it cannot be used 
routinely in remote areas of sub-Saharan Africa. 
1.5.2 Polymerase chain reactions (PCR) to detect plasmodia parasites 
The polymerase chain reaction (PCR) is used to amplify specific DNA to make multiple 
copies. This technique is employed when diagnosing Plasmodium malaria (Snounou, 1996). 
The circumsporozoite (CS) gene and small subunit 18s ribosomal RNA are commonly used as 
the target DNA for amplification when diagnosing malaria (Snounou, 1996). Following the 
amplification of genes in the infected blood, PCR results are evaluated by agarose gel 
electrophoresis stained with ethidium bromide (Tirasophon et al., 1991).  
PCR has been used to detect P. vivax infections by amplifying the VK210 and VK247 
CS variants in a study in Thailand (Kain et al., 1993). PCR has been reported to be useful when 
monitoring the response of treatment in P. falciparum-infected patients (Sethabutr et al., 1992). 
Nested PCR (nPCR) has been observed to detect microscopically-negative samples and mixed 
infections of P. vivax and P. falciparum that was diagnosed as mono-infections by microscopy 
(Morassin et al., 2002). PCR is the most sensitive malaria diagnostic method, detecting < 5 
parasites/μl while microscopy detects 50 parasites/μl of blood (Moody, 2002). Tirasophon et al 
(1991) reported PCR to detect 1 parasite/μl of blood. However, PCR cannot be used for routine 
malaria diagnosis as it is expensive, and the technique requires trained personnel (Amir et al., 
2018).  
1.5.3 Loop-mediated isothermal amplification (LAMP) to detect plasmodia parasites 
The Loop-mediated isothermal amplification (LAMP) technique detects malaria infections 
through the detection of 18S RNA gene (Poon et al., 2006). The LAMP technique has been 
described to detect all human Plasmodium species with high sensitivity (Han et al., 2007). A 
sensitivity of 95% and specificity of 99% has been described with LAMP assays. In contrast to 
PCR, LAMP does not require DNA amplification steps, hence does not require expensive DNA 
amplification reagents and it is more robust compared to PCR (Poon et al., 2006). LAMP is 
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more sensitive than microscopy and up to 6 parasites/μl of blood can be detected (Poon et al., 
2006). LAMP assays are visualized with a naked eye by observing a magnesium pyrophosphate 
precipitate that forms as a by-product of the amplification. The technique does not require 
trained personnel or sophisticated equipment as the results are easy to interpret and can be 
used routinely in rural endemic areas (Amir et al., 2018).   
1.5.4 Rapid diagnostic tests to detect plasmodia parasites 
Rapid diagnostic tests (RDTs) is a technique that is based on the interaction of the 
parasite antigen from the infected patient’s blood and a monoclonal antibody against the protein 
of interest in the mobile phase. The monoclonal antibody in the mobile phase is conjugated to 
gold particles. A second monoclonal antibody on the nitrocellulose strip functions to catch the 
antigen-antibody complex in the mobile phase and the colour develops as a visible line (Figure 
1.3). The test has a control line to show that the test is working (Murray et al., 2008). Migration 
of the mobile phase on the nitrocellulose paper moves by capillary action which depends on the 
absorbency of the membrane. RDTs produce results in 10-15 minutes, unlike microscopy which 
takes almost a day to obtain accurate results (Murray et al., 2008; Amir et al., 2018). An efficient 
RDT detects 100 parasites/ µl of blood samples. RDTs are easy to perform therefore they can 
be used by inexperienced individuals. The common malaria RDT’s target Histidine-rich protein 2 
(HRP-2) which is only found in P. falciparum and P. lactate dehydrogenase (pLDH) and 









Figure 1.3: A representation of a malaria dipstick RDT. Adapted from World Health Organisation, 
2000. 
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1.5.4.1 Histidine-rich protein 2 based RDTs to detect plasmodia parasites  
Blood stage Plasmodium falciparum parasites produce Histidine-rich protein 2 (HRP-2); 
this protein is abundant in the blood during schizont rupture (Rock et al., 1987). HRP-2 is only 
synthesized by P. falciparum malaria parasites and the levels of HRP-2 have been found to 
correlate with parasitemia (Rubach et al., 2012). HRP-2 was the first plasmodial antigen to be 
used in RDTs and was targeted because of its abundance in P. falciparum infections (Iqbal et 
al., 2004). Commercially available P. falciparum malaria RDTs targeting HRP-2 include 
Parasight-F test (Benton Dickinson), Paracheck® Pf (Orchard biomedical systems) and 
Diagnostic malaria Pf (ICT Diagnostics).  The tests have been assessed in many clinical trials 
and the sensitivity and specificity range between 86.7% to 93.4% and 98.2% to 99.3% 
respectively (Ajumobi et al., 2015; Azazy et al., 2018; Shiff et al., 1993). The HRP-2 based RDT 
may give false positives as the HRP-2 protein remains in the blood of the host even after the 
parasites have been cleared with anti-malarial drugs (Mayxay et al., 2001). P. falciparum 
infections lacking HRP-2 protein have been identified in many African countries (Berhane et al., 
2018; Kozycki et al., 2017), Brazil and Bolivia (Viana et al., 2017) and in Indian isolates (Kumar 
et al., 2013). The deletion of Pfhrp-2 gene in patients results in a false negative diagnosis of P. 
falciparum infections with HRP-2 based malaria RDTs. 
1.5.4.2 Lactate dehydrogenase based RDTs to detect plasmodia parasites 
Plasmodial lactate dehydrogenase (pLDH) is an enzyme of the glycolytic pathway and it 
is found in high levels during the blood stages of plasmodial parasites (Vander Jagt et al., 
1990). The mRNA levels of the glycolytic enzymes including pLDH have been observed to 
increase during the blood stages of Plasmodium parasites (Le Roch et al., 2003).  The enzyme 
is present in all human malaria species and has a unique catalytic site compared to the human 
enzyme. Plasmodial LDH can use 3-acetylpyridine nucleotide (ADAP) substrate, which is the 
analogue of NAD (Makler & Hinrichs, 1993). This enables the detection of plasmodial LDH. The 
pLDH activity can be measured from plasma, serum and hemolysates of infected patients and 
the activity correlate with the levels of parasitaemia (Markwalter et al., 2018). Unlike HRP-2, 
which remains in the blood of the host after parasite clearance, pLDH clears immediately 
following the parasite clearance (Oduola et al., 1997; Markwalter et al., 2018). Therefore, pLDH 
is a good diagnostic marker and can be used to accurately measure the effectiveness of 
antimalarial drugs.  Piper et al (1999) developed monoclonal antibodies for an 
immunochromatographic test that detect pLDH (OptiMAL dipstick test). The OptiMAL dipstick 
tests uses a combination of pan-specific pLDH antibody that recognises the common epitope of 
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all four Plasmodium species and P. falciparum LDH specific antibody (Piper et al., 1999). This 
RDT can diagnose and distinguish between the infections caused by P. falciparum and non-
falciparum infections. The OptiMAL-IT test sensitivity has been reported to be low for P. 
falciparum infections compared to the HRP-2 RDT. A sensitivity of 83.6% - 95.3% for P. 
falciparum infections and 91.0% - 96% for P. vivax infections were reported for the OptiMAL test 
(Swarthout et al., 2007). The pLDH test (HRP-2/pLDH combination) offers increased sensitivity 
of 94% for P. falciparum infections (Hawkes et al., 2014). Singh et al (2010) reported the First 
Response® Malaria Combo (pLDH/HRP-2) card test had a 94.7% sensitivity for P. falciparum 
and 84.2% sensitivity for non-falciparum infections. Reduced sensitivities of RDTs have been 
reported for HRP-2 /pLDH in pregnant women in Ghana (Kyabayinze et al., 2016).  
1.5.4.3 Aldolase based RDTs to detect plasmodia parasites 
Plasmodial aldolase a glycolytic enzyme has been targeted for malaria diagnosis in 
RDTs (Cloonan et al., 2001). Aldolase specific antibodies are pan antibodies that detect all 
Plasmodium species and in combination with HRP-2 monoclonal antibodies can differentiate 
between P. falciparum and non-P. falciparum infections (Murray et al., 2008). An ICT P.f/P. v 
test has been assessed to be 95.5% sensitive and 89.8% specific for detection of P. falciparum 
infections and 94.8% sensitive and 98.2% specific for detecting P. vivax (Tjitra et al., 1999). The 
sensitivity of detection of P. vivax and P. falciparum infection by the test correlates with the 
parasitemia as the overall sensitivity is 96% at parasites >500/μl and is reduced to 29% in 
parasites <500/μl (Tjitra et al., 1999). The disadvantages of ICT P.f/P. v includes the inability to 
differentiate between non-falciparum when used in regions where all parasites prevail. The test 
has been reported to fail when detecting P. malariae infections in East Timor, Indonesia and 
Irian Jaya patients. BinaxNOW and HRP-2/Aldolase RDT have been reported to have 95.3% for 
P. falciparum and 68.9% for P. vivax malaria infections for >5,000 parasites/μl. The levels of 
Plasmodium aldolase decrease with infection during treatment (Tjitra et al., 2001). Therefore, 
aldolase can be used to monitor parasite clearance. Although, the sensitivity of aldolase based 
RDTs is low compared to pLDH RDTs.   
1.6 Treatment of malaria 
Treatment of malaria should be started immediately after diagnosis to reduce sickness 
and death due to the disease. When treating malaria, it is important to know the Plasmodium 
species that caused the infection, severity of infection and host factors including pregnancy 
status and age (World Health Organization, 2015). The type of Plasmodium species is crucial as 
some species are resistant to certain antimalarial drugs and P. falciparum infections should be 
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treated instantly as they can rapidly progress to severe malaria. Chloroquine was initially used 
as the first-line antimalarial treatment (Ridley, 2002). Chloroquine-resistant P. falciparum 
parasites were identified in South America, Columbia and Africa (Young & Moore, 1961). 
Chloroquine resistance is associated with the Pfcrt gene mutation which results in an altered 
PfCRT protein with reduced chloroquine binding abilities (Sidhu et al., 2002). The resistance of 
P. falciparum malaria to chloroquine, mefloquine, quinine and halofantrine have also been 
reported (Reed et al., 2000). This resistance is associated with the polymorphism on Pfmdr1 
gene which encodes P-glycoprotein homologue 1 (Pgh1) protein of P. falciparum. Chloroquine 
P. vivax infections were also reported (Baird, 2004; Dua & Sharma, 1996; Schuurkamp et al., 
1992). Resistance of P. falciparum and P. vivax parasites against pyrimethamine-sulphadoxine, 
a commonly used replacement of chloroquine has been observed (Rønn et al., 1996) 
Consequently, artemisinin-based combination therapies (ACTs) is recommended for 
malaria treatment to reduce the development of resistant parasites (Koenderink et al., 2010; 
World Health Organization, 2015). Artemisinin and its derivatives artesunate, artemether and 
artemotil decrease numbers of asexual parasites by 10000-fold in each life cycle, unlike 
antimalarial drugs which decrease asexual parasites by 100-fold to 1000-fold (World Health 
Organization, 2015). Artemether-lumefantrine, the main ACT has been an effective treatment for 
P. falciparum infections and prevention of re-infection (Mårtensson et al., 2005). P. falciparum 
infections are treated with artemether-lumefantrine plus primaquine or quinine with doxycycline 
or climandycin for pregnant women and infants (World Health Organization, 2015). Chlroquine 
alone is used for treating P. malariae and P. knowlesi, while it is used in combination with 
primaquine in P. vivax and P. ovale infections (World Health Organization, 2015). Mixed malaria 
infections of P. vivax and P. falciparum are treated with ACT and primaquine for P. falciparum 
and P. vivax infections respectively.  
Primaquine is the only known antimalarial drug that acts against hypnozoites, high doses 
of primaquine are recommended to be taken for 14 days to prevent P. vivax malaria relapses 
(World Health Organization, 2015). Although, primaquine induces erythrocyte haemolysis which 
results in anaemia in individuals lacking glucose-6-phosphate dehydrogenase. Primaquine is 
not recommended for pregnant women (World Health Organization, 2015). The drug was also 
reported to clear gametocytes in cases of uncomplicated and acute P. falciparum infections in 




1.7 Malaria vaccines   
1.7.1 Pre-erythrocyte stage vaccines  
1.7.1.1 Whole irradiated Plasmodium falciparum sporozoite vaccine  
During malaria infections in the human host, the infectious Plasmodium sporozoites 
develop and invades liver cells. The liver stage of Plasmodium parasite is called the pre-
erythrocyte stage and does not have clinical symptoms.  Pre-erythrocyte stage vaccines could 
potentially prevent the development of erythrocytic stages of the disease thereby eliminating the 
parasites before they cause symptoms.  The idea of developing a malaria vaccine that targets 
the pre-erythrocyte stage has been around for many decades. Nussenzweig et al (1967) 
observed that immunization of mice with X-ray irradiated P. berghei sporozoites offered 
protection against challenge infection with non-irradiated sporozoites from mosquito bites. The 
P. knowlesi irradiated sporozoites also protected monkeys from P. knowlesi sporozoite 
challenge (Gwadz et al., 1979). Antibodies against the whole sporozoite and a circumsporozoite 
protein (CSP) the opulent antigen on the surface of sporozoites were induced by the vaccine 
(Egan et al., 1993). Both anti-CSP antibodies and sporozoite specific CD8+ T cells inhibited the 
development of infections from sporozoite challenge thus affording protection. Protection was 
observed in human volunteers following immunization with irradiated P. falciparum sporozoites 
(Clyde et al., 1973). This protective immunity persisted for 42 weeks (Hoffman et al., 2002). The 
previously protected individuals sustained the immunity even from repeat exposure to infectious 
sporozoites.  
1.7.1.2 Whole irradiated sporozoite chemoprophylaxis vaccine 
Immunization of mice that were on chloroquine treatment with irradiated P. berghei 
sporozoites protected the mice from challenge infection (Beaudoin et al., 1977). Chloroquine 
inhibited the blood stages of P. berghei parasites, which are reported to suppress the pre-
erythrocyte stage immunity (Orjih et al., 1985). Additionally, Orjih et al (1985) reported high 
antibody titers against sporozoites in immunized mice that are under chloroquine treatment 
compared to immunized mice that are not given chloroquine. Human volunteers were also 
vaccinated with non-irradiated P. falciparum sporozoites, while taking chloroquine during the 
immunization course (Roestenberg et al., 2009). All the individuals (100%) under chloroquine 
treatment were fully protected and protection correlated with memory T cells, IFNγ, TNFα and 




1.7.1.3 Sanaria® PfSPZ vaccine 
Sanaria has produced a Plasmodium falciparum sporozoite (PfSPZ) vaccine also known 
as Sanaria® PfSPZ (Hoffman et al., 2015). The PfSPZ vaccine was produced from irradiated, 
purified, aseptic, cryopreserved sporozoites (Epstein et al., 2011).  The PfSPZ vaccine-induced 
CD8+ T cells and gamma interferon (IFN-γ) response in monkeys and rodents (Epstein et al., 
2011).  The PfSPZ vaccine was tested in humans, 6 volunteers were immunized four times with 
1.35 × 105 PfSPZ and were all protected against controlled human malaria infection (CHMI) 
(Seder et al., 2013). The PfSPZ vaccine has been assessed in phase 1 clinical trials and 
demonstrated safety and immunogenicity (Roestenberg et al., 2013; Shekalaghe et al., 2014). 
The PfSPZ vaccine-induced protective antibodies against sporozoites, Pf-specific T cells that 
lasted for 59 weeks (Ishizuka et al., 2016). Lyke et al (2017) observed the vaccine offer 
protection against heterologous strains after a repeat exposure to CHMI P. falciparum 
sporozoites 33 weeks post-immunization. The 48% vaccine efficacy was observed following the 
immunization with five doses of 2.7 × 105 PfSPZ in Malian healthy adults (Sissoko et al., 2017).  
1.7.1.4 RTS, S/AS01 malaria vaccine 
Circumsporozoite protein (CSP) is found in the sporozoite surface of Plasmodium 
parasites and it is highly conserved (Zhao et al., 2016). It is a membrane protein that is inserted 
in the surface of sporozoites by a GPI anchor in its C-terminus (Coppi et al., 2011). Functions of 
CSP include the attachment of sporozoite to liver cells (Pinzon-Ortiz et al., 2001) and the 
invasion of hepatocytes (Tewari et al., 2002).  Both functions aid in the establishment of the pre-
erythrocyte stage infection. The RTS, S/AS01 is the first subunit vaccine that targets the pre-
erythrocyte stage of P. falciparum infections (Stoute et al., 1997). The vaccine is made up of 
PfCSP antigen combined with a hepatitis B surface antigen and is prepared with a liposome 
derived adjuvant AS01 (Stoute et al., 1997).  The RTS, S/AS01 vaccine has shown protection in 
malaria naïve adults and semi-immune adults (Stoute et al., 1997), young children (5-17 
months) and infants (6-12 weeks) (Gosling & von Seidlein, 2016; RTS, 2015). Phase 3 clinical 
trials of the vaccine showed the overall efficacy of 45.1% in young children and 31.3% efficacy 
in infants (RTS, 2015). Booster doses of the vaccine have been observed to increase the 
efficacy, although, the immunity provided by the vaccine lasts for up to 3-4 years (RTS, 2015). 
The vaccine has recently been approved by the European Medicines Agency for its use for 
vaccinating young children in endemic regions in Africa. The vaccine was not approved for 




1.7.2 Blood stage malaria vaccines 
Morbidity and mortality caused by human Plasmodium infections is the consequence of 
the erythrocytic stages of Plasmodium parasites (Good & Miller, 2018).  A malaria vaccine that 
is directed against the erythrocyte stage could potentially reduce the parasite burden, thus 
prevent death. Plasmodium antigens expressed on the parasite surface during blood stages in 
the human host are the focus for vaccine development (Good et al., 1998). This is because 
these antigens appear to be the target for the immune response against the disease (Good et 
al., 1998). The leading blood-stage malaria vaccine candidates for P.  falciparum includes an 
apical membrane antigen-1 (PfAMA-1) (Thera at al., 2011), merozoite surface protein-1 
(PfMSP1-42) (Ellis et al., 2010), PfMSP3 (Lusingu et al., 2009), GMZ2 vaccine based on 
PfMSP3 and glutamate-rich protein (PfGLURP) (Esen et al., 2009), and reticulocyte-binding 
protein homolog 5 (PfRH5) (Jin et al., 2018). 
 
1.7.2.1 Plasmodium falciparum apical membrane antigen-1 (PfAMA1) 
Plasmodium falciparum apical membrane antigen-1 (AMA-1) is a type 1 integral 
transmembrane protein. PfAMA1 is located on the merozoites surface during the blood stages 
of Plasmodium parasites and expressed by the infectious Plasmodium sporozoites that invade 
hepatocytes (Mitchell et al., 2004; Polhemus et al., 2007). The 83 kDa protein is synthesized 
and localises in the micronemes of developing merozoites (Nair et al., 2002). During the 
erythrocyte invasion, PfAMA1 is degraded by proteases into a 66 kDa polypeptide and released 
to the merozoite surface (Nair et al., 2002). PfAMA1 interacts with P. falciparum rhoptry neck 
protein (PfRON2) and the complex initiates the formation of a junction for invasion (Srinivasan 
et al., 2011). Antibodies against AMA1 alone and AMA1-RON2 complex abolish erythrocyte 
invasion (Srinivasan et al., 2011). A relationship between anti-PfAMA1 antibodies and protection 
against P. falciparum infections has been reported (Gray et al., 2007; Osier et al., 2007). 
PfAMA1 protein is a target of acquired immunity and anti-PfAMA1 antibody titres correlate with 
age (Kusi et al., 2012). PfAMA1 has been targeted for the development of an erythrocyte stage 
malaria vaccine. Vaccination of monkeys with PfAMA1 prepared in Freund’s adjuvant (Stowers 
et al., 2002) or Montanide ISA 720 adjuvant (Dutta et al., 2009) protected monkeys from 
challenge infection. Anti-PfAMA-1 antibody in the vaccinated monkeys correlated with 
protection.  Immunization of mice with PbAMA1 or passive immunization with antibodies 
protected mice from challenge infection with P. berghei parasites (Crewther et al., 1996). 
The PfAMA1 vaccine has been tested in multiple clinical trials since it showed protection 
in rodents and monkeys. The FMP2.1/AS02 vaccine is made from PfAMA-1 from the 3D7 strain 
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in AS02 adjuvant. The vaccine was harmless and induced an immune response in phase 1 
clinical trial in US adults (Polhemus et al., 2007) and in Malian children (Thera et al., 2010). The 
vaccine induced anti-PfAMA1 antibodies, IFN-γ and IL-5. A 64.3% vaccine efficacy against a 
3D7 P. falciparum infections and 17.4% efficacy against infections with FVO P. falciparum 
parasites was observed in Malian children (Thera et al., 2011). The strain-specific efficacy of the 
vaccine was not sustainable as there was no efficacy after 24 months even though the anti-
AMA1 antibody levels were still high (Payne et al., 2016). The strain-specific immunity induced 
by FMP2.1/AS02 was due to the excessive genetic variation in the PfAMA1 amino acid 
sequence (Duan et al., 2008). Therefore, a multivalent vaccine could offer better protection. To 
overcome the strain specificity of AMA1 vaccine-induced antibodies, new AMA1 vaccines 
contain peptides that are highly conserved between P. falciparum strains. Diversity-Covering 
antigens (DiCo) AMA1 vaccine is composed of three AMA1 variants (Remarque et al., 2008). 
The PfAMA1 Dico-mix vaccine was shown to induce high antibody titres that inhibit the growth 
of many P. falciparum strains (Remarque et al., 2008). The Dico mix vaccines formulated with 
CoVaccine HT™ or Montanide ISA 51 have shown to be safe and immunogenic in monkeys 
(Kusi et al., 2011) and in European and African naïve adults when formulated with Alhydrogel or 
GLA-SE (Sirima et al., 2017). 
 
1.7.2.2 Plasmodium falciparum merozoite surface protein-1 (PfMSP1) 
Merozoite surface protein-1 (MSP1) is a 195 kDa glycoprotein that is found in all 
Plasmodium species (Holder et al., 1992). MSP1 is the most abundant proteins amongst the 
nine GPI anchored membrane proteins found on the merozoite surface (Holder, 2009). MSP1 is 
produced as a 195 kDa protein in the schizont stage of the asexual parasites inside the infected 
erythrocytes and is expressed by merozoites (Holder et al., 1992). The protein is cleaved into 
83, 28-30, 38-45 and 42 kDa fragments during the late stages of schizonts before the 
merozoites are released from the infected erythrocytes (Holder & Freeman, 1984; Holder et al., 
1992). After processing, MSP1 fragments are expressed on the surface of merozoites where 
they interact with sialic acid on erythrocytes surface and facilitate the erythrocyte invasion by 
merozoites (Holder & Freeman, 1984). The 42 kDa (MSP1-42) fragment is further processed 
into 33 kDa (MSP1-33) and 19 kDa (MSP1-19) fragments before the invasion is completed 
(Pichyangkul et al., 2004). The MSP1-33 resides on the merozoite surface whereas the MSP1-
19 fragment is transported into the newly infected erythrocyte (Blackman et al., 1990). The 
antibodies against the MSP1 and its fragments MSP1-19 and MSP1-42 have been reported in 
the serum of malaria-infected patients and antibodies against MSP1 and its fragments have 
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been observed in immune individuals in endemic areas (Daly & Long, 1993). Anti-PfMSP1-42, 
demonstrated to be inhibitory against the P. falciparum parasites in Aotus monkeys (Chang et 
al., 1996). Antibodies against PfMSP1-19 have been demonstrated to inhibit erythrocyte 
invasion by P. falciparum parasites (Blackman et al., 1990). The PyMSP1-19 vaccine prepared 
in Freund’s adjuvant completely protected mice from lethal P. yoelii infections (Hirunpetcharat et 
al., 1997; Ling et al., 1994). Baculoviral expressed PfMSP1-42 (Chang et al., 1996) and E. coli 
expressed PfMSP1-19 vaccines (Kumar et al., 1995) protected monkeys against P. falciparum 
challenge. The vaccine induced antibodies blocked the invasion of merozoites into new red 
blood cells (Kumar et al., 1995). These phenomena have led researchers to investigate PfMSP1 
as a human malaria blood-stage vaccine candidate. 
Many PfMSP1 vaccine designs have been investigated in phase 1 safety clinical trials. 
These vaccines include FMP1/AS02 vaccine based on 3D7 PfMSP1-42 (Stoute et al., 2007) 
and MSP1-42C1/Alhydrogel which is made from both FVO and 3D7 PfMSP1-42 (Ellis et al., 
2010) have shown to be safe and immunogenic in Kenyan and United states healthy adults 
respectively. A strong T cell (CD4+ and CD8+) response and anti-PfMSP1 IgG antibodies were 
induced by a PfMSP1 vaccine formulated with chimpanzee adenovirus 63 (ChAd63) and 
modified vaccinia virus Ankara (MVA) (Sheehy et al., 2011). A multi-antigen vaccine JAIVAC-1 
composed of PfMSP1-19, C-terminus region of MSP1 and EBA-175 domain also demonstrated 
to be nontoxic and induced an immune response in phase 1 clinical trial (Chitnis et al., 2015).   
1.7.2.3 Plasmodium falciparum merozoite surface protein 3 (PfMSP3) 
Plasmodium falciparum merozoite protein 3 (PfMSP3) is a soluble GPI-anchored 
transmembrane protein expressed on the merozoite surface (Tsai et al., 2009). MSP3 was first 
discovered by McColl et al (1994) in P. falciparum isolates in Papua New Guinea when it was  
observed as a membrane protein on the merozoite surface. MSP3 is produced as a 43 kDa 
protein in the parasitophorous vacuole of schizonts. It is then released to the merozoite surface 
during schizont rupture and it remains on the merozoite surface during the invasion of 
erythrocytes. The function of MSP3 is currently unknown. Anti-PfMSP3 antibodies induced by 
natural P. falciparum infections in humans and vaccine induced mice antibodies have been 
found to promote monocyte dependent killing of parasites in an in vitro study (Oeuvray et al., 
1994).  The protein has been reported to be a target for protective immunity against P. 
falciparum natural infections and the induced antibodies against MSP3 were independent of age 
unlike other malaria antigens (Roussilhon et al., 2007). The PfMSP3 vaccine produced from a 
full-length PfMSP3 sequence has been reported to protect monkeys against P. falciparum 
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infections and protection was associated with anti-PfMSP3 antibodies (Hisaeda et al., 2002). 
Passive transfer of immune sera with anti-MSP3 antibodies reduced parasitemia in P. 
falciparum infected mice (Druilhe et al., 2005).  
PfMSP3 vaccine formulated in Montanide ISA 720 / aluminium hydroxide has been 
assessed in phase 1 clinical trial in adults (Druilhe et al., 2005) and in children 12-24 months in 
Tanzania (Lusingu et al., 2009). The vaccine was safe and induced both cellular and humoral 
immunity. The vaccine induced antibodies lasted for up to 1 year (Druilhe et al., 2005). Strain-
specificity has been observed in anti-MSP3 antibodies (Polley et al., 2007). The vaccine has not 
yet been tested in phase 2 trial.  
1.7.2.4 GMZ2 malaria vaccine  
The GMZ2 malaria vaccine is composed of PfMSP3 and glutamate-rich protein 
(GLURP). GLURP is a 220 kDa protein found in both the liver stage and blood stages of the 
malaria parasites (Theisen et al., 1998). GLURP associates with matured schizonts on the 
infected erythrocytes. The function of GLURP is not yet known. Antibodies against PfGLURP 
have been associated with protection against P. falciparum infections (Amoah et al., 2017; 
Theisen et al., 2004). Anti-PfGLURP isolated from immune adults living in high malaria 
transmission regions have been shown to inhibit parasite growth in a monocyte-dependent 
manner like PfMSP3 (Theisen et al., 1998). A malaria vaccine targeting GLURP could 
potentially provide multi-stage specific immunity as the protein is produced in two life stages of 
the parasites (Theisen et al., 1994). GLURP and MSP3 expressed together produced a vaccine 
that protected monkeys from P. falciparum infections and the protection was associated with 
high antibody titers against both proteins (Carvalho et al., 2004). A human vaccine (GMZ2) has 
been produced from PfMSP3 and PfGLURP and prepared in alhydrogel®. The vaccine has 
been tested in phase 1a clinical trials in German adults (Esen et al., 2009) and in young children 
in Gabon (Belard et al., 2011) and has shown to be safe and immunogenic. The GMZ2 vaccine 
induces high levels of antibodies that inhibit the P. falciparum parasite growth in vitro (Jepsen et 
al., 2013). Memory B cells are also induced by the vaccine and have been reported to last for up 
to 12 months (Esen et al., 2009).  A GMZ2 vaccine-induced antibodies that reduced the 
incidence of both uncomplicated and severe malaria in a phase 2b clinical trial in African 
children, a 14% vaccine efficacy was reported (Sirima et al., 2017).  
1.7.2.5 Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) 
P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) is expressed on the 
merozoite surface during erythrocyte invasion (Rodriguez et al., 2008). PfRH5 is the 6th member 
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of the PfRH family which consist of PfRH1, PfRH2a, PfRH2b, PfRH3, PfRH4 and PfRH5 
(Rodriguez et al., 2008).  PfRH5 is the smallest of them all and has a molecular weight of 62,5 
kDa while the average RfRH proteins are 250-300 kDa (Baum et al., 2009). PfRH5 lacks the C-
terminal transmembrane domain found in other PfRH proteins (Baum et al., 2009). Therefore, 
PfRH5 attaches to a PfRh5-interacting protein (PfRipr) and cysteine-rich protective antigen 
(CyRPA) to form a complex. This complex is critical for the formation of a crossing point for the 
merozoites to invade the erythrocytes (Reddy et al., 2015).  PfRH5 interacts with Basigin on the 
erythrocytes surface (Rodriguez et al., 2008). PfRH5 is essential for the survival of the parasites 
and gene knockout studies have failed to produce P. falciparum parasites without the protein 
(Hayton et al., 2008).  
PfRH5 is not a target for acquired immunity in malaria-exposed individuals in endemic 
regions (Douglas et al., 2011). Unlike other malaria vaccine antigens, PfRH5 has limited 
polymorphism and anti-PfRH5 vaccine-induced antibodies are not strain-specific (Douglas et al., 
2011).  Vaccine-induced anti-PfRH5 antibodies protected monkeys from both homologous and 
heterologous P. falciparum challenge (Douglas et al., 2014; Douglas et al., 2015). Passive 
transfer of anti-PfRH5 antibodies protected humanized mice from developing blood stage 
infections when infected with a controlled human malaria infection (Foquet et al., 2018). The 
RH5.1/AS01 vaccine based on PfRH5 3D7 is currently being tested in a phase 1/2a clinical trial 
for its safety, immunogenicity and efficacy in malaria naïve adults.  
 
1.8 Glycolysis in Plasmodium parasites  
Plasmodium falciparum, the deadliest malaria species has 48 hours to complete its 
asexual cycle inside human erythrocytes.  This rapid development of P. falciparum requires an 
effective synthesis of adenosine triphosphate (ATP) to support their development (Roth et al., 
1988). It has been reported that Plasmodium parasites lack some metabolic pathways found in 
higher eukaryotes including an active oxidative phosphorylation pathway which release energy 
used to produce ATP. Plasmodium parasites have been reported to exclusively depend on 
glycolysis to produce ATP. Roth et al (1988) demonstrated the increased levels of glycolytic 
enzymes inside the malaria-infected erythrocytes compared to uninfected erythrocytes. 
Glyceraldehyde-3-phosphate and lactate dehydrogenase are amongst these highly elevated 
glycolytic enzymes (Roth et al., 1988). The latter has brought a lot of attention to exploring the 





1.8.1 Plasmodium falciparum glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH) 
 
Figure 1.4: Ribbon model for GAPDH 3-dimensional structure. Adapted from Cowan-Jacob et al., 
2003. The subunits are represented by different colours (red, green, blue and yellow).  
 
Glyceraldehyde-3-phosphate dehydrogenase (E.C.1.2.12) is a 150 kDa homo-tetramer 
of 36 kDa subunits. The enzyme is found in all living organisms and it catalyzes the 6th step of 
glycolysis. In this reaction, GAPDH catalyzes the phosphorylation of glyceraldehyde-3-
phosphate to 1,3 bis-phosphoglycerate. The reaction involves a transfer of an electron from 
NAD+ to NADH (Daubenberger et al., 2000). The active site of GAPDH contains a cysteine 
residue (Cys 149) where its sulfhydryl group is essential for the catalytic activity (Daubenberger 
et al., 2000). The GAPDH 3-dimensional structure has a Rossman fold conformation which is 
made up of twisted parallel β-sheets which are surrounded by α-helices (Figure 1.4). The 
catalytic site of the enzyme is made up of eight stranded α-helices which are combined with 
parallel β-sheets.   
1.8.1.1 Comparison of Plasmodium GAPDH with human GAPDH 
Glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum has been 
sequenced and the crystal structure has been determined (Satchell et al., 2005). Unique amino 
acid residues have been observed in the amino acid sequence of Plasmodium GAPDH 
(Satchell et al., 2005) that are not found in the human GAPDH (hGAPDH) sequence.  
Plasmodium GAPDH sequence has an insert of two amino acid residues lysine-194 and 
glycine-195 within the active site (Figure 1.5) (Satchell et al., 2005). These inserted amino acid 
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residues could be targeted when developing antimalarial agents. Two unique PfGAPDH 
epitopes have been identified and the antibodies against these epitopes differentiated 
PfGAPDH from the GAPDH of other Plasmodium species (Krause et al., 2017). The anti-
pGAPDH antibodies could be potentially used for the development of a GAPDH based RDT that 
differentiates between P. falciparum infections and non- P. falciparum infections. The amino 
acid sequence alignment revealed 63 - 68% similarities between Plasmodium GAPDH and 
human GAPDH sequences. Therefore, antibodies made against Plasmodium GAPDH specific 
regions are unlikely to cross-react with hGAPDH.  
1.8.1.2 Plasmodium GAPDH is a malaria vaccine candidate  
PfGAPDH has been reported to interact with merozoite Duffy binding-like and 
reticulocyte homology ligands and the interaction is important for the erythrocyte invasion by 
merozoite (Pal-Bhowmick et al., 2012). The enzyme has also been identified on the surface of 
P. falciparum and P. berghei sporozoites where it interacts with CD68 on the Kupffer cell 
surface allowing the sporozoites to invade the Kupffer cells (Cha et al., 2016). Antibodies 
against PbGAPDH inhibits the sporozoite invasion and protects mice from P. berghei challenge 
(Cha et al., 2016). Together, these findings support Plasmodium GAPDH as a potential target 
for the liver stage and blood-stage malaria vaccine candidate. 
 
Trypanosoma      MGDDSMPICVGINGFGPIGRAVLFSSF-TDPLVNVTAINDASTSVDYIAYVVQRESPLST 59 
Escherichia      ------MSKVGINGFGRIGRLVLRRLLEVKSNIDVVAIND-LTSPKILAYLLKHDSNYGP 53 
Leishmania       ------MVKVGINGFGRIGRVVFRAAQ-MRPDIEIVGIND-LLDAEYMAYSLKYDSTHGR 52 
Homo sapien      ----MGKVKVGVNGFGRIGRLVTRAAF-NSGKVDIVAINDPFIDLNYMVYMFQYDSTHGK 55 
Rabbit           -------VKVGVNGFGRIGRLVTRAAF-NSGKVDVVAINDPFIDLHYMVYMFQYDSTHGK 52 
P. falciparum    ----MAVTKLGINGFGRIGRLVFRAAF-GRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQ 55 
P. berghei       ----MAITKVGINGFGRIGRLVFRSAQ-ERSDIEVVAINDPFMDISHLIYLLKHDSVHGK 55 
P. yoelii        ----MAITKVGINGFGRIGRLVFRSAQ-ERSDIEVVAINDPFMDINHLIYLLKHDSVHGK 55 
                          :*:**** *** *          :::..***   .   : * .: :*  .  
 
Trypanosoma      EERASVIVVGDYVCIQGTHKIRVTQKHDLVEIGWREAGVRYVVECSGLSSTRERCWGHIT 119 
Escherichia      FPWSVD--FTEDSLIVDGKSIAVYAEKEAKNIPWKAKGAEIIVECTGFYTSAEKSQAHLD 111 
Leishmania       FDGTVE--VIKGALVVNGKSIRVTSERDPANLKWDEIGVEVVVESTGLFLTQETAHKHIE 110 
Homo sapien      FHGTVK--AENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQ 113 
Rabbit           FHGTVK--AENGKLVINGKAITIFQERDPANIKWGDAGAEYVVESTGVFTTMEKAGAHLK 110 
P. falciparum    FPCEVT--HADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLK 113 
P. berghei       FPCEVT--PTEGGIMVGNKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIK 113 
P. yoelii        FPCEVT--PTEGGIMVGSKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIK 113 
                           .   : . : : :  :::  :: *       : *.:*.  : * .  *:  
 
Trypanosoma      GGASGVVIAGQS-ADAPTVIIGANETELKKAYPVICAGAPIAVALAPLIRLLHEQYGVEE 178 
Escherichia      AGAKKVLISAPAG-EMKTIVYKVNDDTLDGNDTIVSVASCTTNCLAPMAKALHDSFGIEV 170 
Leishmania       AGARRVVMTGPPKDDTPMFVMGVNHTTYKG-QPIISNASCTTNCLAPLAKVVNEKYGIVE 169 
Homo sapien      GGAKRVIISAPS-ADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVE 172 
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Rabbit           GGAKRVIISAPS-ADAPMFVMGVNHEKYDNSLKIVSNASXTTNCLAPLAKVIHDHFGIVE 169 
P. falciparum    GGAKKVIMSAPPKDDTPIYVMGINHHQYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVE 173 
P. berghei       GGAKKVIMSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVE 173 
P. yoelii        GGAKKVIMSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVE 173 
                 .**  *:::.    :    :   *.   .    ::. .:  : .***: : ::: :*:   
 
Trypanosoma      CSYTAIHGMRTVE-PTAGRSKNTQDWRQTRAAADAIIPYSQTGNKTLEKIFPFLAERISG 237 
Escherichia      GTMTTIHAYTGTQSLVDGPR--GKDLRASRAAAENIIPHTTGAAKAIGLVIPELSGKLKG 228 
Leishmania       GLMTTVHATTATQKTVDGPS--LKDWRGGRGASQNIIPSSTGAPKAVGKVYPALDGKLTG 227 
Homo sapien      GLMTTVHAITATQKTVDGPS--GKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTG 230 
Rabbit           GLMTTVHAITATQKTVDGPS--GKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTG 227 
P. falciparum    GLMTTVHASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTG 233 
P. berghei       GLMTTVHASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTG 233 
P. yoelii        GLMTTVHASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTG 233 
                    *::*.    :  . *     :  *  * *   *** :  . *::  : * *  ::.* 
 
Trypanosoma      SAFQVPVTKGCAVDMLVRLAQPVSKELLDGTIKEAAGGQLREVLMYSGADLISRDCVPNG 297 
Escherichia      HAQRVPVKTGSVTELVSILGKKVTAEEVNNALKQATTN--NESFGYTDEEIVSSDIIGSH 286 
Leishmania       MAFRVPTPNVSVVDLTVRLEKPATYKDICAAIKAAAEGEMKGILGYTDDEVVSSDFNGVA 287 
Homo sapien      MAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDT 290 
Rabbit           MAFRVPTPNVSVVDLTCRLEKAAKYDDIKKVVKQASEGPLKGILGYTEDQVVSCDFNSDT 287 
P. falciparum    VAFRVPIGTVSVVDLVCRLQKPAKYEEVALEIKKAAEGLLKGVLGYTEDEVVSQDFVHDN 293 
P. berghei       VAFRVPIGTVSVVDLVCRLEKPAKYEDVAKKISQDFVHDSRSSIFYTEEEVVSQDFVHDS 293 
P. yoelii        VAFRVPIGTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTDEEVVSQDFVHDS 293 
                  * :**  . ...::   * : .. . :   :.       .  : *:  :::* *      
 
Trypanosoma      KL-CYDTTS--SQCLRDGEVHKLLLWFNFDGSYANRLLSLVPFLQKMNAAEEM 347 
Escherichia      FGSVFDATQTEITAVGDLQLVKTVAWYDNEYGFVTQLIRTLEKFAKL------ 333 
Leishmania       LTSVFDVKAGIS---LNDHFVKLVSWYDNETGYSHKVLDLILHTSAR------ 331 
Homo sapien      HSSTFDAGAGIA---LNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE----- 335 
Rabbit           HSSTFDAGAGIA---LNDHFVKLISWYDNEFGYSNRVVDLMVHMASKE----- 332 
P. falciparum    RSSIFDMKAGLA---LNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN------ 337 
P. berghei       RSSIFDLKAGLA---LNDNFFKIVSWYDNEWGYSNRLLDLAIHITKN------ 337 
P. yoelii        RSSIFDLKAGLA---LNDNFFKIVSWYDNEWGYSNRLLDLAIHITKH------ 337 
                 :*          : .. * : *:: : .:  :::            
Figure 1.5: Amino acid alignment of GAPDH from different species. The active site cysteine (Cys-
149) (green), pGAPDH two amino acid insert –KG- (purple), S loop residues (188-203) for NAD+ binding 
(box). The alignment was generated by clustal omega on 17th of November 2018. 
 
1.8.2 Plasmodium lactate dehydrogenase (pLDH) 
Plasmodium lactate dehydrogenase (EC 1.1.1.27) is a 135 kDa tetramer of four identical 
34 kDa subunits (Figure 1.6) (Vander Jagt et al., 1981). The enzyme is involved in the final step 
of glycolysis (Berwal et al., 2008). Glycolysis is crucial for Plasmodium parasites to generate 
energy to support its rapid development inside the host erythrocytes (Roth et al., 1998).  The 
reaction catalyzed by pLDH involves the conversion of pyruvate to lactate and the reduction of 
nicotinamide adenine dinucleotide (NADH) to NAD+. NAD+ generated by this reaction is used to 












Figure 1.6: Ribbon model for PfLDH 3-dimensional structure. PfLDH homotetramer showing four 
NAD+ bound to the active site of the enzyme. Created using SWISS-MODEL. 
https://swissmodel.expasy.org/  
1.8.2.1 Comparison of pLDH with human LDH 
Lactate dehydrogenase from all human Plasmodium species exhibits 90-92% sequence 
identity to P. falciparum (Brown et al., 2004). Plasmodium LDH possesses 33 out of 316 (10%) 
unique amino acids residues compared to the LDH from other organisms (Bzik et al., 1993). The 
amino acid sequence of pLDH has a unique five amino acid insert in the active site and the 
NADH binding pocket of the enzyme (Figure 1.7) (Bzik et al., 1993). The nicotine group in the 
NADH cofactor binding site of PfLDH is slightly loosened compared to human LDH (Bzik et al., 
1993; Read et al., 1998). These changes on pLDH have been reported to sustain the parasite in 
anaerobic conditions inside the erythrocyte and prevent pLDH from being inhibited by its 
substrate pyruvate unlike human LDH (Brown et al., 2004).  
Human LDH       MATIKSELIKNFAEEEAIHHNKISIVGTGSVGVACAISILLKGLSDELVLVDVDEGKLKG    60 
P. falciparum   ----------------MAPKAKIVLVGSGMIGGVMATLIVQKNLGD-VVLFDIVKNMPHG    43 
P. knowlesi     ----------------MAPKAKIVLVGSGMIGGVMATLIVQKNLGD-VVLFDIVKNMPHG    43 
P. vivax        ----------------MAPKPKIVLVGSGMIGGVMATLIVQKNLGD-VVMFDVVKNMPQG    43 
P. ovale        ----------------MTPKPKIVLVGSGMIGGVMATLIVQKNLGD-VVMFDVVKNMPQG    43 
P. reichenowi   ----------------------IVLVGSGMIGGLMATLIVQKNLGD-VVMFDVVKNMPQG    37 
                                      * :**:* :*   *  *: *.*.* :*:.*: :.  :* 
 
Human LDH       ETMDLQHGSPFMKM-PNIVSSKDYLVTANSNLVIITAGARQKKGETR-----LDLVQRNV    114 
P. falciparum   KALDTSHTNVMAYSNCKVSGSNTYDDLAGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNN    103 
P. knowlesi     KALDTSHTNVMAYSNCKVSGSNTYDDLAGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNN    103 





P. ovale        KALDTSHSNVMAYSNCKVTGSNSYDDLKGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNN    103 
P. reichenowi   KALDTSHSNVMAYSNCKVTGSNSYDDLKGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNN    97 
                :::* .* . :     :: .*: *    .:::**:***  :  *::       **:  *  
 
Human LDH       SIFKLMIPNITQYSPHCKLLIVTNPVDILTYVAWKLSGFPKNRVIGSGCNLDSARFRYFI    174 
P. falciparum   KIMIEIGGHIKKNCPNAFIIVVTNPVDVMVQLLHQHSGVPKNKIIGLGGVLDTSRLKYYI    163 
P. knowlesi     KIMIEIGGHIKKNCPNAFIIVVTNPVDVMVQLLHQHSGVPKNKIIGLGGVLDTSRLKYYI    163 
P. vivax        KIMIEIGGHIKKLCPNAFIIVVTNPVDVMVQLLFEHSGVPKNKIIGLGGVLDTSRLKYYL    163 
P. ovale        KIMIEIGGHIKNLCPNAFIIVVTNPVDVMVQLLFEHSGVPKNKIIGLGGVLDTSRLKYYI    163 
P. reichenowi   KIMIEIGGHIKNLCPNAFIIVVTNPVDVMVQLLFEHSGVPKNKIIGLGGVLDTSRLKYYI    157 
                .*:  :  :*.: .*:. :::******::. :  : **.***::** *  **::*::*:: 
 
Human LDH       GQRLGIHSESCHGLILGEHGDSSVPVWSGVNIAGVPLKDLNPDIGTDKDPEQWENVHKKV    234 
P. falciparum   SQKLNVCPRDVNAHIVGAHGNKMVLLKRYITVGGIPLQEFINNKLIS--DAELEAIFDRT    221 
P. knowlesi     SQKLNVCPRDVNAHIVGAHGNKMVLLKRYITVGGIPLQEFINNKLIS--DAELEAIFDRT    221 
P. vivax        SQKLNVCPRDVNALIVGAHGNKMVLLKRYITVGGIPLQEFINNKKIT--DEEVEAIFDRT    221 
P. ovale        SQKLNVCPRDVNALIVGAHGNKMVLLKRYITVGGIPLQEFINNKKIT--DEEVEGIFDRT    221 
P. reichenowi   SQKLNVCPRDVNALIVGAHGNKMVLLKRYITVGGIPLQEFINNKKIT--DEEVEGIFDRT    215 
                .*:*.:  .. :. *:* **:. * :   :.:.*:**:::  :        : * :..:. 
 
Human LDH       ISSGYEMVKMKGYTSWGISLSVADLTESILKNLRRVHPVSTLSKGLYGINEDIFLSVPCI    294 
P. falciparum   VNTALEIVNLHASPYVAPAAAIIEMAESYLKDLKKVLICSTLLEGQYGH-SDIFGGTPVV    280 
P. knowlesi     VNTALEIVNLHASPYVAPAAAIIEMAESYLKDLKKVLICSTLLEGQYGH-SDIFGGTPVV    280 
P. vivax        VNTALEIVNLLASPYVAPAAAIIEMAESYLKDIKKVLVCSTLLEGQYGH-KNIFGGTPLV    280 
P. ovale        VNTALEIVNLLASPYVAPAAAIIEMAESYLKDIKKVLVCSTLLEGQYGH-SNIFGGTPLV    280 
P. reichenowi   VNTALEIVNLLASPYVAPAAAIIEMAESYLKDIKKVLVCSTLLEGQYGH-SNIFGGTPLV    274 
                :.:. *:*:: .    . : :: :::** **::::*   *** :* **  .:** ..* : 
Human LDH       LGENGITDLIKVKLTLEEEACLQKSAETLWEIQKELKL 332 
P. falciparum   LGANGVEQVIELQLNSEEKAKFDEAIAETKRMKA-LA- 316 
P. knowlesi     LGANGVEQVIELQLNSEEKAKFDEAIAETKRMKA-LA- 316 
P. vivax        IGGTGVEQVIELQLTAEEKAKFDEAVAETKRMKA-LA- 316 
P. ovale        IGGTGVEQVIELQLNAEEKTKFDEAVAETKRMKA-LI- 316 
P. reichenowi   IGGTGVEQVIELQLNAEEKTKFDEAVAETKRMKA-LI- 310 
                :* .*: ::*:::*. **:: ::::     .::  *   
Figure 1.7: Amino acid sequence alignment of human LDH and Plasmodium LDH. The active site 
arginine-109 (red) and 5 unique pLDH amino acid insert (KSDKE) (box). The sequences were obtained 
from PubMed and PlasmoDB and aligned with Clustal Omega. 
 
1.8.2.2 Plasmodium LDH is a drug and a diagnostic target  
Plasmodium LDH has been targeted for the development of antimalarial drugs due to 
different amino acid residues compared to human LDH (Read et al., 1999; Saxena et al., 2018). 
Chloroquine was the first line antimalarial drug that is used all over the world (Yayon et al., 
1984). Chloroquine kills malaria parasites through binding to hematin in the malaria food 
vacuole preventing it from polymerisation to hemozoin (Chou & Fitch, 1992; Pulcini et al., 2015; 
Yayon et al., 1984). The accumulation of hematin has been reported to be toxic and resulting in 
the death of the parasites (Chou & Fitch, 1992; Pulcini et al., 2015). Although, studies have 
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failed to demonstrate the existence of free hematin. PfLDH showed that the enzyme binds to 
chloroquine and this binding prevents the binding of NADH, the cofactor of the enzyme (Read et 
al., 1999). Human LDH binds with lower affinity to chloroquine, this makes chloroquine to be 
safe for human use. Plasmodium LDH level correlates with malaria infections and has been 
used for rapid diagnosis of malaria using immunocapture assays or in a dipstick format. The 
Plasmodium LDH can use 3-acetylpyridine nucleotide (ADAP) substrate unlike human LDH, this 
substrate is used in immunocapture assays (Moody, 2002). Plasmodium LDH RDTs are more 
efficient than HRP-2 RDTs as LDH clears with parasites and can be used to accurately monitor 
the response of parasites to treatment (Oduola et al., 1997). 
 
1.9 Motivation , aims and objectives  
Many malaria blood-stage vaccine candidates have been presented over the years and 
none of the vaccines has demonstrated high efficacy in humans. Most blood stage malaria 
vaccines target the surface antigens that associate with the human erythrocytes during the 
blood stage of infection (Takala et al., 2009). Targetting surface antigens results in malaria 
vaccines that block the establishment of the erythrocytic stage of malaria that produces clinical 
symptoms. The leading blood-stage malaria vaccine candidates include MSP1, MSP2, MSP3, 
AMA1, GLURP, RH5 etc (Cockburn & Seder, 2018). The surface antigens are exposed to the 
immune system during the blood stage infections. Many of these antigens have been identified 
to have a high degree of genetic diversity. The vaccines made against polymorphic antigens 
have been shown to have low efficacies (Takala et al., 2009). Plasmodium falciparum apical 
membrane antigen 1 (PfAMA1) has been observed to possess 62 polymorphic amino acid 
residues (Takala et al., 2009) and they contribute to it inducing a strain-specific immune 
response with low efficacy (Thera et al., 2011). The same applies to MSP1, MSP2 and GLURP 
(Mohammed et al., 2018). In contrast, Plasmodium falciparum reticulocyte binding-like 
homology protein 5 (PfRH5) only has 10 polymorphic amino acid residues and has been 
reported to have no strain specificity (Ouattara et al., 2018). PfRH5 is highly conserved amongst 
Plasmodium parasites (Hayton et al., 2008) and RH5.1/AS0B is the most promising malaria 
blood-stage vaccine candidate that has been suggested for phase I/IIa clinical trials (Jin et al., 
2018).  
Glycolysis is the critical energy-producing pathway in Plasmodium parasites. An 
increase in glycolytic enzyme activity has been observed in Plasmodium falciparum infected-
erythrocytes when compared to uninfected erythrocytes. The levels of mRNA of glycolytic 
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enzymes have been reported to increase between the early ring stage and early schizonts stage 
of the parasite development (Le Roch et al., 2003). The protein levels also increase during the 
stages of development. These enzymes included Plasmodium falciparum glyceraldehyde-3-
phosphate dehydrogenase and lactate dehydrogenase. This implies that the glycolytic enzymes 
are important in the parasite. These enzymes are highly conserved (Bzik et al., 1993; Satchell et 
al., 2005) and are both diagnostic targets (Krause et al., 2017; Piper et al., 1999). PfGAPDH is a 
pre-erythrocyte stage malaria vaccine candidate (Cha et al., 2016).  
Plasmodium falciparum is the leading cause of malaria in humans compared to other 
four human Plasmodium species. The main focus of the World Health Organization is to 
develop an effective vaccine against P. falciparum infections.   Although, P. falciparum parasites 
cannot be used directly for initial vaccine studies as it is unethical to use humans in these 
studies. Rodent malaria is the alternative model for these studies. Plasmodium berghei and P. 
yoelii are the two malaria parasites that are widely used for investigation of vaccine candidates 
including the leading malaria vaccine candidate MSP1. The current study is going to use 
glycolytic enzymes from Plasmodium yoelii parasites to investigate them for potential malaria 
vaccine candidate.  Plasmodium berghei parasites are used in this study to infect the PyLDH 
and PyGAPDH vaccinated mice since the enzymes in these two parasites share 95 and 99%  
amino acid identity.. 
Aim of the current study: 
To investigate whether Plasmodium yoelii lactate dehydrogenase and P. yoelii 
glyceraldehyde-3-phosphate dehydrogenase could offer protection against blood-stage malaria 
infections in mice. 
Therefore, the objectives of the current study were: 
1. To optimise and evaluate different expression conditions for recombinant Plasmodium 
yoelii glyceraldehyde-3-phosphate dehydrogenase (rPyGAPDH) and lactate 
dehydrogenase (rPyLDH). 
2. To study the polymorphisms in PyGAPDH and PyLDH sequences. 
3. To evaluate the immunogenicity of rPyGAPDH and rPyLDH in mice.   
4. To assess whether immunization with rPyGAPDH and rPyLDH protects the mice from 
challenge with P. berghei parasites.  
5. To produce chicken antibodies against PfLDH.  




Materials and methods 
2.1 Materials  
2.1.1 Equipment 
Orbital shaking incubator (New Brunswick Scientific, USA), Autoflow Co2-water Jacketed 
incubator, orbital LS and revolver (labnet international, USA), Shimadzu UV spectrophotometer 
(GE Healthcare, England), AvantiTM J-26 XPI (Bechman counter, USA), Olympus light 
microscope (Japan), VersaMax™ ELISA plate reader (Molecular Devices Corporation, USA), 
Virosonic™ cell disruptor (VirTis, USA), VersaDoc™ imaging system (BioRad, USA). 
2.1.2 Reagents 
The reagents purchased from Sigma-Aldrich (Germany) were 2-mercaptoethanol, 4-
chloro-1-naphthol, acrylamide, ampicillin, bisacrylamide, sodium cyanoborohydride (NaBH3CN), 
ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, imidazole, sodium dodecyl 
sulfate (SDS), formaldehyde, sodium carbonate (Na₂CO₃), sodium azide (NaN3), sodium 
acetate, RPMI-1640 medium, Coomassie Brilliant Blue R-250, Freund’s complete adjuvant, 
Freund’s incomplete adjuvant, Ponceau S, Reactive black 5, N,N,N’,N’-
tetramethylethylenediamine (TEMED), Triton X-100, Tween-20 and ethidium bromide. The 
reagents purchased from Merck were potassium dihydrogen phosphate (KH2PO4), potassium 
hydrogen phosphate (K2HPO4), glycerol, agar bacteriological, sodium chloride (NaCl), 
bromophenol blue, acetic acid, sodium hydroxide (NaOH), silver nitrate and polyethylene glycol 
(PEG 6000). The reagents purchased from Saarchem were glucose, sodium dihydrogen 
phosphate (NaH2PO4) and gelatin. Tryptone, trisaminomethane (TRIS) and glycine were 
obtained from Melford laboratories. The reagents purchased from Fluka Analytical were yeast 
extract, kanamycin sulphate and Giemsa stain. Bovine serum albumin (BSA) was obtained from 
Roche Diagnostics (Mannheim, Germany), isopropyl β-D-1-thiogalactopyranoside (IPTG), 
ethanol and Aminolink® resin were purchased from ThermoFisher Scientific. Ammonium 
persulphate was purchased from Bio-Rad. Methanol was purchased from RAD CHEM and 
acetone was purchased from Associated Chemical Enterprises. The blotting filter papers were 
purchased from Separations Scientific PTY (South Africa) and the nitrocellulose blotting 
membrane was purchased from Life Sciences BioTraceTM (Mexico). The Whatman 1 filter 
papers were purchased from GE Healthcare limited (UK) and the Talon resin was obtained from 
Takara Bio (USA). The unstained protein molecular weight marker, containing: 116 kD β-
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galactosidase; 66.2 kD bovine serum albumin; 45 kD ovalbumin; 35 kD lactate dehydrogenase; 
25 kD REase Bsp981; 18.4 kD β-lactoglobulin and 14.4 kD lysozyme  was purchased 
Fermentas (Vilnius, Lithuania).  Low fat skimmed milk was purchased at Spar supermarket.  
Molecular biology reagents were purchased from Solis Biodyne (Tartu, Estonia) and they 
include Escherichia coli host cells, BL21 (DE3) (glycerol stock).  Mouse monoclonal anti-His-
Tag IgG, peroxidase conjugated rabbit anti-chicken antibodies, peroxidase conjugated goat anti-
mouse antibodies were purchased from Merck Biosciences (Germany) 
2.2 Method 
2.2.1 Expression vectors and expression host cells 
Plasmodium yoelii genomic DNA was isolated from infected mouse blood, PyLDH and 
PyGAPDH were amplified using their specific primers and purified using the pegGOLD 
Purification Kit (Hurdayal et al., 2010; Krause et al., 2017). Plasmodium falciparum gDNA was 
isolated from an infected patient (Hurdayal et al., 2010). The following purification, the product 
was ligated into pGEM-T easy vector and the vector was then propagated into E. coli JM 109 
bacterial cells. The insert was removed from the isolated plasmid using EcoRI and NotI 
restriction sites for PyLDH and PyGAPDH, then ligated into pET-28a vector which was 
transformed into and expressed in E. coli BL21 (DE3) cells. PfLDH insert was removed from the 
iusolated plasmid using EcoRI and PstI restriction sites and then ligated into pKK223-3 vector 
which was then transformed into and expressed in E. coli BL21 (DE3) cells.  
Table 2.1: Plasmid vector, expression host cells, site of insertion of proteins for recombinant 
expression in E. coli cells. 
Protein  Vector  Restriction sites  Antibiotic  Expression host 
PfLDH pKK223-3 EcoRI and PstI Ampicillin  E. coli BL21 
(DE3) 
PyLDH pET-28a EcoRI and NotI Kanamycin 
sulphate 
E. coli BL21 
(DE3) 
PyGAPDH pET-28a EcoRI and NotI Kanamycin 
sulphate 





2.2.2 Glycerol stocks 
The rPyLDH, rPyGAPDH, rPfLDH and transformed E. coli cells were harvested from an 
overnight culture which was grown in a terrific broth (TB) media (1.2% (w/v) tryptone, 2.4% (w/v) 
yeast extract, 0.4% (w/v) glycerol, 0.231% (w/v) KH2PO4, 1.254% (w/v) K2HPO4) which 
contained 25 µg/ml kanamycin sulphate for rPyLDH, rPyGAPDH and 100 μg/ml ampicillin for 
rPfLDH.  The antibiotic stocks were made in distilled water and filter sterilized. The cells were 
grown (16 h at 37°C) in a 200-rpm shaking incubator. One ml glycerol stocks of cells were made 
by adding 850 µl of overnight culture to 150 µl sterile 50 % (v/v) glycerol and stored at -80°C. 
 
2.2.3 Agar plates  
Luria broth (LB) agar was made by dissolving 1 % (w/v) tryptone; 0.5 % (w/v) yeast 
extract; 85 mM NaCl; 11 mM glucose and 1.5 % (w/v) agar prepared in distilled water and 
autoclaved (1 h at 120°C). The agar was supplemented with a final concentration of 25 µg/ml 
kanamycin sulphate or 100 μg/ml ampicillin and 3-way streaked with glycerol stocks of 
transformed E. coli cells and the colonies were grown overnight (37°C). 
 
2.2.4 Recombinant protein expression  
A single colony from the LB agar plates was inoculated into a terrific broth media (1.2% 
(w/v) tryptone, 2.4% (w/v) yeast extract, 0.4% (w/v) glycerol, 0.231% (w/v) KH2PO4, 1.254% 
(w/v) K2HPO4.) was supplemented with 25 µg/ml kanamycin sulphate or 100 μg/ ml ampicillin 
and grown overnight (37°C , 200-rpm).  The alternate media was Luria broth induced with 0.3 
mM IPTG. The cells were obtained by centrifugation (4000 x g, 10 min at 4°C). The cell pellets 
were suspended in resuspension buffer (50 mM NaH2PO4; 300 mM NaCl at pH 8.0) to 5% of the 
original cell culture volume. No bacterial culture volumes exceeded 20% of the culture flask 
volume. The suspended cells were sonicated (6 x 30 sec) each cycle keeping the samples on 
ice between cycles. The pellet and supernatant were separated by centrifugation (12000 xg for 
20 min at 4°C). The pellet was resuspended in phosphate buffered saline (PBS) (137 mM NaCl, 
3 mM KCl, 7 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2) equivalent to 5% of the original culture 
volume and both the supernatant and pellet.  
 
2.2.5 Talon® affinity resin preparation and recombinant proteins purification 
A 2 ml suspension of Talon® resin was placed in a 15 ml falcon tube, centrifuged (4000 
xg for 5 min) to remove the suspension buffer. The resin was washed twice with 5 column 
volumes of sodium phosphate buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 
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8.0). The E. coli supernatant containing the recombinant protein was incubated with the resin 
and mixed using an end-over-end (1 h at RT or 16 h at 4°C). The unbound proteins were 
collected, and the resin was washed with a sodium phosphate buffer (50 mM NaH2PO4, 300 mM 
NaCl, 10 mM imidazole at pH 8.0) until the buffer absorbance at 280 nm reaches 0.02. The 
bound proteins were eluted from the resin with 5 ml sodium phosphate buffer (50 mM NaH2PO4, 
300 mM NaCl, 250 mM imidazole at pH 8.0) collected in 1 ml fractions. Eluted fraction samples 
were analyzed by measuring the protein absorbance at 280 nm and on a 12.5% reducing SDS-
PAGE gel (Laemmli, 1970) and stained with Coomassie blue R-250. 
 
2.2.6 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
A discontinuous Tris-Glycine buffer and the SDS-PAGE gel system described by 
Laemmli (1970) were used. The gels were prepared (Table 2.1) and poured between  two glass 
plates: 81.5 mm x 101.5 mm and 72.5 mm x 101.5 mm. The gel was overlaid with 200 µl of 
distilled water and was removed once the running gel has polymerized. Stacking gel (1.5 ml) 
was added and a 15 well or 10 well combs were inserted. Afterwards, the gel plates were 
assembled in the casting gasket.  
Table 2.2: Reagents and recipe for 12.5 % running gel and 3% stacking gel. 
Reagents 12.5% running gel 3% stacking gel 
Monomer solution (4.1 M acrylamide and 52 mM N, 
N’-methylenebisacrylamide) 
6.25 ml 0.71 ml 
4 x running buffer (1.5 M Tris buffer at pH 8.8)  3.75 ml - 
4 x stacking gel buffer (500 mM Tris buffer at pH 
6.8) 
- 1.75 ml 
1.0% (w/v) SDS in distilled water 0.15 ml 0.075 ml 
10% (w/v) ammonium persulfate in distilliled water 0.070 ml 0.035 ml 
Distilled water 4.75 ml 4.53 ml 
TEMED 0.0075 ml 0.015 ml 
 
The sample preparation was done as follows:  an equal volume of sample reducing 
treatment buffer (125 mM Tris-HCl, 20 % (v/v) glycerol, 4% (m/v) SDS, (10% (v/v) 2-
mercaptoethanol at pH 6.8, with bromophenol blue) were mixed and boiled for 5 min. Standard 
molecular weight marker was run along with the samples to estimate the molecular weights of 
the proteins. Electrophoresis was performed using a Bio-Rad system at 20 mA per gel with tank 
buffer (250 mM Tris-HCl,192 mM glycine and 0.1 % (m/v) SDS, pH 8.3) for 1 h and the gels 
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were stained with Coomassie brilliant blue R- 250 (0.125% (w/v) Coomassie brilliant blue R-250, 
50 % (v/v) methanol and 10 % (v/v) acetic acid) and destained with 50% (v/v) methanol and 10 
% (v/v) acetic acid. 
 













Figure 2.1: Standard curve of the log molecular weight against relative mobility of the protein 
standards. The molecular weight marker which consisted of β- Galactosidase (116), Bovine serum 
albumin (66.2 kDa), Ovalbumin (45 kDa), Lactate dehydrogenase (35 kDa), Rease Bsp 981 (25 kDa), β-
Lactoglobulin (18.4 kDa) and Lysozyme (14.4 kDa) was resolved on 12.5% reducing SDS-PAGE gel. (A) 
rPyGAPDH and (B) rPyLDH standard curve. 
 
            The molecular weights of proteins on SDS-PAGE gels were estimated using the 
standard curves (Figure 2.1). 
 
2.2.8 Western blotting 
Western blotting was performed as described by Towbin (1979). The proteins were first 
resolved on an SDS-PAGE gel. The proteins in the SDS-PAGE gel were transferred to the 
nitrocellulose paper by sandwiching the gel and the nitrocellulose paper together between six-
layer filter paper in a transfer buffer (25 mM Tris, 190 mM glycine, 20% (v/v) methanol and 0.1% 
(w/v) SDS, pH 8.3). Air bubbles were removed by rolling the surface using a glass rod and the 
transfer was done for 16 h at 40 mA. After the overnight transfer, the nitrocellulose paper was 
stained with 0.1 % (w/v) Ponceau S in 1% (v/v) acetic acid and molecular weight markers were 
marked with a pencil. The Ponceau S stain was washed off with distilled water with few drops of 




















































(20 mM Tris; 200 mM NaCl, 0.1% (v/v) Tween, pH 7.4) solution (1 h at RT). All the washes were 
done with 0.1% (v/v) Tween 20-PBS (3 x 5 min). The nitrocellulose paper was washed and 
incubated in primary antibody prepared in 0.5% (w/v) BSA- 0.1% (v/v) Tween-TBS (2 h at RT or 
16 h at 4°C). The nitrocellulose paper was washed and incubated in secondary antibody 
prepared in 0.5% (w/v) BSA- 0.1% (v/v) Tween-TBS (1 h at RT). The nitrocellulose was then 
washed and incubated with substrate (2 ml (0.3% (w/v) 4-chloro-1-naphthnol in methanol, 8 ml 
TBS and 4 µl H2O2) and stored in the dark until colour develops after which it was washed with 
distilled water.  
All the washes were done with 0.1% (v/v) Tween 20-PBS and repeated three times. 
 
2.2.9 Thirty-minute silver stain  
The silver staining method was performed according to Nesterenko et al (1994). The gel 
was fixed for 5 minutes in 50% (v/v) acetone, 1.25% (w/v) TCA, 0.015% (w/v) formaldehyde, 
rinsed (3 x 5 sec) and washed for 5 minutes with distilled water and incubated for 5 minutes in 
50% (v/v) acetone. The gel was treated with (0.017% (w/v) sodium thiosulfate for 5 minutes and 
rinsed (3 x 5 sec) with distilled water. This was followed by incubation with 0.27% (w/v) silver 
nitrate, 0.37% (w/v) formaldehyde for 8 minutes. The gel was then rinsed (5 x 5 sec) with 
distilled water and developed for 20 seconds in 2% (w/v) sodium carbonate, 0.015% (v/v) 
formaldehyde, 0.004% (w/v) sodium thiosulfate. Band development was stopped by incubating 
the gel in 1% (v/v) acetic acid and kept in distilled water. The gel was visualized with the 
VersaDoc™ imaging system (BioRad, USA). 
 
2.2.10 Chicken immunization with recombinant PfLDH  
Polyclonal antibodies were raised in Hy-line chickens against rPfLDH. Two chickens 
were immunised with rPfLDH (100 µg) Freund’s complete adjuvant (1:1) whilst the second, third 
and fourth immunization was prepared in Freund’s incomplete adjuvant (1:1).  Each chicken 
was injected twice with 250 µl of an oil emulsion containing 50 µg rPfLDH in each breast 
muscle. The eggs were collected daily from the first day of immunization until week 12.  
2.2.11 Isolation of IgY from chicken egg yolk 
IgY was isolated from a chicken egg yolk according to Polson et al (1980).  Egg yolk was 
separated from egg white by washing the egg under running water. The yolk sack was 
punctured, and the yolk was measured and suspended in sodium phosphate buffer (100 mM 
Na-phosphate buffer, 0.02% NaN3, pH 7.6) twice the yolk volume. Polyethylene glycol (PEG 
33 
 
6000) 3.5% (w/v) was added and dissolved. The sample was centrifuged (4400 xg, 30 min, RT). 
The supernatant was filtered through cotton wool to remove all the fat cake. PEG 8.5% (w/v) 
was added and dissolved. The sample was centrifuged (12000 xg, 10 min, 4°C). The 
supernatant was thrown away, and the pellet was resuspended in sodium phosphate buffer 
equal to the supernatant volume after filtering. Twelve percent (w/v) PEG was added and 
dissolved by stirring gently. The sample was centrifuged (12000 xg, 10 min, 4°C). The pellet 
was resuspended in 1/6th of the original yolk volume and stored at 4°C.  
2.2.12 Affinity purification of IgY using an Aminolink® column 
The 50% (v/v) Aminolink® resin (4 ml) was equilibrated at room temperature and the 
storage buffer was drained. The resin was washed with 6 ml of coupling buffer (100 mM 
NaH2PO4, 0.05% NaN3, pH 7.2). Recombinant rPfLDH (5 mg) was added to the resin with 40 µl 
cyanoborohydride solution (5M NaBH3CN in 1M NaOH) and incubated (16 hr, 4°C). The resin 
was washed with coupling buffer and incubated with 2 ml quenching buffer (1M Tris-HCl, pH 
7.4) with 40 µl cyanoborohydride (30 min). The solution was drained, and the resin was washed 
with 10 ml of washing solution (100 mM NaH2PO4, 0.2% NaN3, pH 6.5). The crude IgY was 
filtered through Whatman 1 filter paper and incubated with the Aminolink® affinity column (16 
hr., RT) in an end-over-end mixer. The column was washed with PBS until the absorbance at 
280 nm was 0.02. Chicken anti-rPfLDH antibodies were eluted with 8 ml of elution buffer (100 
mM glycine, 0.02% NaN3, pH 2.8). One ml fractions were collected into 1.5 ml tubes containing 
100 µl neutralization buffer (1M NaH2PO4, 0.02% NaN3, pH 8.5).  
2.2.13 Production of mouse anti-rPyLDH and anti-rPyGAPDH polyclonal antibodies 
Polyclonal antibodies were raised in 8 weeks old Balb/c mice against rPyLDH or 
rPyGAPDH. Five mice in each group were immunised with rPyLDH or rPyGAPDH (100 µg) 
complete Freund’s adjuvant (1:1) whilst the second and third immunization was prepared in an 
incomplete Freund’s adjuvant (1:1).  The immunizations were two weeks apart. All the injections 
were intraperitoneal. The mice were euthanized with isoflurane and the blood was collected 
through a cardiac puncture into heparin-coated tubes two weeks after the third immunization.   
2.2.14 Plasmodium berghei parasite challenge 
Mice were immunized for polyclonal antibody production against rPyLDH or rPyGAPDH 
(2.2.12). Mice immunized with PBS and rPkPMT served as vaccine control. Two weeks after the 
third immunization, mice were challenged with 1x105 Plasmodium berghei parasites in the 
intraperitoneal site. The parasites were diluted in RPMI-1640 medium containing glutamate. The 
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parasitaemia was monitored every second-day post infection by bleeding the tail vein of each 
mouse. A microlitre of blood was smeared on a glass microscope slide and the parasites were 
stained and counted.  
2.2.15 Giesma staining of parasites  
A microlitre of blood was smeared on the glass slide. The parasites were fixed with 
100% methanol for 30 sec and air dried. The parasites were stained with 10% (v/v) Giemsa 
stain in 6.7 mM phosphate buffer pH 7.1 for 20 min and washed with distilled water. The slides 
were air dried and viewed on an electron microscope (1000x).  
2.2.16 Enzyme-linked immunosorbent assay (ELISA) 
Antigens were prepared in PBS (1µg/ml) and 100 μl was pipetted into each well and 
incubated (16 h at 4°C) to allow for coating. All the washes were done with 0.1% (v/v) Tween 
20-PBS and repeated three times. After coating, the wells were blocked with 150 µl of 5% (m/v) 
non-fat milk powder (1 h at 37°C). The wells were washed and incubated with 100 µl of primary 
antibody in 0.5% (m/v) BSA-PBS-Tween (2 h at 37°C). The wells were then washed and 
incubated with 100 µl of secondary antibody- HRPO conjugate prepared in 0.5% (m/v) BSA-
PBS- Tween (2 h at 37°C). The wells were washed and incubated with 100 µl of 3,3′,5,5′-
Tetramethylbenzidine (TMB) substrate solution (1 ml TMB diluted in 9 ml citrate-phosphate 
buffer at pH 5.0 and 2 µl H2O2) (1 hr at RT) and colour was developed in the dark. The plates 
were read at 370 nm and 652 nm with an ELISA-plate reader. The background controls included 
a no coat, no primary or secondary antibody. The ELISA for rPyLDH and rPyGAPDH was 
probed with 1/10, 1/100, 1/1000 and 1/10000 dilutions of mouse serum and the un-immunized 
mouse serum was used as a control. Goat anti-mouse antibody (1:6000) was used for 
detection.  
 
2.2.17 Protein staining on SDS-PAGE gels and nitrocellulose 
For staining of all SDS-PAGE gels and nitrocellulose membranes, a 40 ml staining 
solution was used, and the incubations were done with shaking at 60 rpm shaker at room 
temperature. Reactive black 5 and Ponceau S staining solution were prepared at 0.1% (m/v) 
and 1% (v/v) acetic acid in distilled water and Amido black 10B was prepared at 0.1% (m/v) in 
30:10:60 methanol: acetic acid: distilled water and was filtered through Whatman 1 before used. 
SDS-PAGE gels were stained for 1 hour or overnight (16 h) and destained for 16 h or more in 
destain solution (50% methanol, 10% acetic acid, and 40% distilled water). The proteins on a 
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nitrocellulose membrane were stained for 5 minutes and the membrane was washed in running 
water for 2 minutes to remove the unbound stain. 
2.2.18 Staining zymograms  
Papain proteolytic activity was assessed in a zymogram. A 12.5% SDS-PAGE running 
gel containing 1% (w/v) gelatin was prepared with a 4% stacking gel. Papain samples were not 
reduced or boiled. After electrophoresis, the gel was washed with two changes of assay buffer 
(2.5% (v/v) Triton X-100, 100 mM sodium acetate, 1 mM EDTA, 0.02% (w/v) sodium azide, pH 
5.0). The washing step was followed by a 3 h incubation (37°C) in assay buffer without Triton X-
100. The gel was either stained with Reactive black 5 or Amido black 10B stain (1 h at RT). It 
was then destained in 30% (v/v) methanol, 10% (v/v) acetic acid in distilled water for 16 h.  
2.2.19 Bioinformatics analysis of proteins 
2.2.19.1 DNA and amino acid sequences 
Protein and DNA sequences were obtained from PlasmoDB 
(http://plasmodb.org/plasmo/) or PubMed (https://www.ncbi.nlm.nih.gov/pubmed/). The multiple 
sequence alignments were made using clustal omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). 
2.2.19.2 3D modelling of protein structures 
The protein structures were modelled using Swiss model 
(https://swissmodel.expasy.org/).  
2.2.19.3 Immunogenic peptide prediction 
 B cell epitopes were predicted using ABCpred server 











Recombinant expression, purification and analysis of PyGAPDH, PyLDH and 
PfLDH. 
3.1 Introduction 
3.1.1 Recombinant expression of proteins in E. coli bacteria  
Bacterial systems allow genes to be cloned and expressed for purification and 
characterization studies without using large amounts of animal and plant materials (Rosano & 
Ceccarelli, 2014). Escherichia coli is the most popular bacterial system used for recombinant 
protein expression (Sivashanmugam et al., 2009; Terpe, 2006). E. coli genetics are well studied 
and characterized and expressing recombinant proteins in E. coli is advantageous as bacteria 
grow fast in culture media and protein expression can be easily induced (Rosano & Ceccarelli, 
2014; Terpe, 2006). High bacterial cell densities are easily reached with E. coli and the bacterial 
cells can be grown in an inexpensive culture media (Sørensen & Mortensen, 2005). BL21 (DE3) 
is the most commonly used E. coli bacterial host strain (Sørensen & Mortensen, 2005). The 
strain is deficient of OmpT and Lon proteases, which means the recombinant proteins are not 
degraded by proteases (Sørensen & Mortensen, 2005). E. coli cells allow for expression of high 
yields of proteins and an added advantage is the production of membrane proteins (Sørensen & 
Mortensen, 2005; Terpe, 2006).  
 
3.1.2 Plasmids and their advantages for cloning target proteins  
For recombinant protein expression, the genetic material of the target protein is cloned 
into the plasmid, which is then used to transform E. coli cells for over-production of the protein.  
The plasmid should have an origin of replication, a multiple cloning site which contains 
restriction enzyme sites where the gene can be inserted and an antibiotic resistant marker 
(Studier, 2005). The antibiotic resistance marker allows to selectively grow only the transformed 
E. coli cells without contamination. The plasmids used for E. coli systems include pET and 
pBAD vectors (Sørensen & Mortensen, 2005; Studier, 2005). There are about 40 different types 
of pET expression vectors which are commercially available (Sørensen & Mortensen, 2005). 
Expression of proteins in pET vectors is controlled by a T7 RNA polymerase, which is derived 
from bacteriophage T7 and the lac promoter in E. coli (Sørensen & Mortensen, 2005). The 
coding sequence of T7 RNA polymerase is present in the chromosome under the control of 
lacUV5 promoter which is found in E. coli DE3 host cells (Sørensen & Mortensen, 2005; Studier, 
2005). T7 promoters are stronger compared to E. coli promoters and can lead to the production 
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of about 50% of the recombinant protein in the cell’s total proteins (Sørensen & Mortensen, 
2005). Another advantage of using pET expression systems is that they produce low plasmid 
copy number of 20–25 copies per cell which permits the highest production of T7 promoter 
without causing damage to the cells, which is caused by large copy number plasmids (Sørensen 
& Mortensen, 2005).  
 
3.1.3 Comparison of IPTG inducible media and auto inducing media for the expression 
of proteins  
Upon the transformation of E. coli cells with pET vectors, the cells are grown in liquid 
medium (Lysogenic broth) and the production of the recombinant protein is initiated by the 
addition of isopropyl-b-D-thiogalactoside (IPTG). IPTG is an inducer which works by attaching to 
the promoter, which liberates the LacI repressor and initiates the expression of proteins 
(Sivashanmugam et al., 2009). Expression in an inducible media has disadvantages, which 
include continuous observing of the cell’s growth by taking optical densities (OD 600) until they 
reach the mid-log phase where they are induced. This method requires lots of manual work, 
particularly when growing many cultures in parallel and the cells are also susceptible to 
contamination as they are opened every time when taking the OD (Studier, 2005).  In contrast, 
the production of proteins in an autoinducing media (terrific broth) does not involve continuous 
monitoring of cells and no IPTG is added (Studier, 2005). Cells which are grown in terrific broth 
are only inoculated in media containing an antibiotic and are grown to their full capacity to yield 
the recombinant protein (Sivashanmugam et al., 2009). Autoinducing media has been described 
to yield high amounts of proteins compared to the IPTG induced media (Studier, 2005). 
Additionally, lactose can be added in an autoinducing media to increase the yields of proteins 
that are produced in minimal amounts (Studier, 2005). Ethanol can also be added in both 
autoinducing and IPTG induced media enhance the production of recombinant proteins in E. coli 
cells (Chhetri et al., 2015). 
 
3.1.4 Production and isolation of IgY antibodies  
IgY antibodies are the most abundant antibodies in chicken egg yolks, it’s the chickens 
equivalent of human IgG (Yegani & Korver, 2010). IgY antibodies are widely used for 
immunotherapies and immunodiagnostics as they have limited cross-reactions with human 
serum proteins and their isolation methods are simple and non-invasive (Gassmann et al., 
1990). Chicken eggs have been described to produce IgY from 10 days after the initial 
immunization (Polson et al., 1980). Precipitation methods including, water dilution, polyethylene 
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glycol, Xanthan gum and dextran sulfate have been described to isolate IgY from egg yolks. As 
described by Akita and Nakai (1993), water dilution method employs a 9:1 water and yolk 
dilution which isolates plasma proteins from granules and lipids. This step is followed by sodium 
sulfate precipitation and ultrafiltration, which purify IgY from plasma proteins. Polyethylene 
glycol (PEG) precipitation method involves the initial use of 3.5% (w/v) PEG to remove lipids 
and vitelline followed by 12% (w/v) PEG to precipitate IgY (Polson et al., 1980). The dextran 
sulphate method involves the dilution of egg yolk in Tris-buffered saline and precipitating the IgY 
with dextran and sodium sulfate. Lastly, Xanthine gum precipitates the insoluble lipoproteins 
leaving IgY which is then achieved by salting out chromatography (Hatta et al., 1990). Water 
dilution method has been reported to yield 9.8 mg/ml (Akita & Nakai, 1993), while PEG 
precipitation yields 6-12 mg/ml (Polson et al., 1980), Xanthan gum yields 7.3 mg/ml and dextran 
sulfate yields 7.5 mg/ml IgY from a single egg yolk. PEG precipitation is the most commonly 
used IgY isolation method as this isolation procedure is simple, cost-effective and produces a 
high yield of IgY.  
3.1.5 Aims of this chapter 
This study focuses on the recombinant expression and characterization of Plasmodium 
yoelii Lactate dehydrogenase (rPyLDH), P. yoelii glyceraldehyde-3-phosphate (rPyGAPDH) and 
P. falciparum lactate dehydrogenase (rPfLDH). Recombinant PyLDH, rPyGAPDH and rPfLDH 
were expressed and purified as histidine tag fusion proteins in E. coli bacteria. Recombinant 
PyLDH and rPyGAPDH expression was evaluated in the presence of ethanol in the terrific broth 
and Luria broth. Mobilities of rPyLDH and rPyGAPDH in different percentage SDS-PAGE gels 
and in the presence of metal ions were evaluated. This was done to better understand the 
properties of the recombinant proteins as these proteins will later be used to vaccinate mice for 
protection against blood-stage malaria infections. Metal ions that are commonly used in metal-
affinity chromatography were investigated for binding to the rPyLDH and rPyGAPDH. These 
metal ions include zinc (Zn2+), cobalt (Co2+), copper (Cu2+) and nickel (Ni2+). Anti-rPfLDH 
antibodies were made in chickens and isolated from egg yolks using the PEG method (Polson 








3.2 Results  
3.2.1 Recombinant expression of PyGAPDH in Luria and terrific broth containing 
ethanol 
Recombinant Plasmodium yoelii glyceraldehyde-3-phosphate dehydrogenase 
(PyGAPDH) was expressed in E. coli bacteria grown with or without ethanol in Luria and terrific 
broth (Figure 3.1A and B).  The E. coli proteins were not affected by the presence of ethanol in 
the culture as indicated by the same intensity of E. coli protein bands in all ethanol 
concentrations (Figure 3.1A and B). Recombinant PyGAPDH was absent in the uninduced 
cultures and was present as a 40 kDa protein band in the induced cultures (Figure 3.1A). One 
percent (v/v) ethanol had no effect on rPyGAPDH expression while 2% and 3% (v/v) ethanol 
decreased the expression of rPyGAPDH (Figure 3.1A). A similar decrease of rPyGAPDH 
expression was observed when the cells were grown in terrific broth. Ethanol decreased the 









Figure 3.1: Recombinant expression of PyGAPDH in Luria or terrific broth supplemented with 
ethanol. Cultures were grown in Luria (A) induced with 0.3 mM IPTG and terrific (B) media with or without 
ethanol and rPyGAPDH expression was analysed on a 12.5% reducing SDS-PAGE gel. Lane 1: 
molecular weight marker, (A): lanes 2-3: uninduced culture, lanes 4-5, 6-7, 8-9, 10-11: 0%, 1%, 2% and 
3% (v/v) ethanol. (B): lanes 2-4, 5-7, 8-10 and 11-13: 0%, 1%, 2% and 3% (v/v) ethanol. All samples were 
loaded in duplicates. The gels were stained with Coomassie brilliant blue R250. 
 
3.2.2 Recombinant expression of PyLDH in Luria or terrific broth containing ethanol 
Recombinant Plasmodium yoelii Lactate dehydrogenase (PyLDH) was expressed in E. 
coli bacteria grown in Luria and terrific broth with or without ethanol (Figure 3.2A, B and C). The 
37 kDa rPyLDH protein band was absent in the untransformed cells and present in the induced 
cultures (Figure 3.2A and B). The E. coli proteins were not affected by the presence of ethanol 

















kDa        1   2    3   4   5   6   7   8   9 10 11 12 13 
40 
 
in the culture as indicated by a similar intensity of E. coli protein bands in all ethanol 
concentrations. Initially, PyLDH cultures with 2% (v/v) ethanol were observed to have a slight 
increase of rPyLDH (Figure 3.2A) which was not observed in triplicate cultures (Figure 3.2B). 
Although, a reduction in rPyLDH expression was observed in the presence of 2% (v/v) ethanol 
when the experiment was repeated in triplicates (Figure 3.2B).  The rPyLDH expression 




















Figure 3.2: Recombinant expression of PyLDH in Luria or terrific broth supplemented with 
ethanol. Cultures were grown in Luria broth induced with IPTG (A and B) and terrific (C) media with or 
without ethanol and rPyLDH expression was analysed on a 12.5% reducing SDS-PAGE gel.  Lane 1: 
molecular weight marker, (A): lanes 2-3: uninduced culture, lanes 4-5, 6-7, 8-9 and 10-11: induced with 
0%, 1%, 2% and 3% (v/v) ethanol. (B): lanes 2-3: uninduced culture, lanes 4-6 and 7-9: induced 0% and 
2% (v/v) ethanol. (C): lanes 2-4, 5-7, 8-10 and 11-13: culture with 0%, 1%, 2% and 3% (v/v) ethanol. The 
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3.2.3 Comparison of E. coli bacterial growth in the presence of ethanol 
E. coli bacteria expressing PyGAPDH or PyLDH were grown in Luria broth with or 
without ethanol (Figure 3.3A and B). At the first hour of their growth, there was no difference in 
the cell densities of ethanol treated and untreated cells for both PyLDH and PyGAPDH. Growth 
decreased from 2-3 hours (Figure 3.3A and B). The change in growth was concentration- 
dependent (Figure 3.3A and B). Together, these results suggest that ethanol hinder the growth 














Figure 3.3: Effect of ethanol on the growth of PyGAPDH and PyLDH transformed E. coli cells in 
Luria broth.  E. coli cells transformed with PyGAPDH (A) and PyLDH (B) plasmids were grown in Luria 
broth with or without ethanol in a 37°C continuous shaking incubator until they reached OD600 (0.5-0.6) 
and induced with IPTG for 4 hours. Samples were taken every hour to measure the OD600 for the 
construction of the growth curve.  
 
3.2.4 Recombinant expression and affinity purification of rPyGAPDH 
Plasmodium yoelii glyceraldehyde-3-phosphate dehydrogenase (PyGAPDH) was 
recombinantly expressed in E. coli BL21 (DE3) cells grown in a terrific broth. After expression of 
rPyGAPDH, the bacteria were lysed, and the soluble protein fraction was passed over a cobalt 
affinity column to purify rPyGAPDH with a hexa-histidine tag. The 40 kDa rPyGAPDH protein 
band was absent in the untransformed E. coli cells and was in the soluble fraction (Figure 3.4A). 
During the affinity purification, rPyGAPDH was eluted from the column with 250 mM imidazole 
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rPyGAPDH band was consistent with the 40.328 kDa predicted from the genomic and predicted 
amino acid sequence with the histidine tag. Both anti-Histag antibodies and anti-rPyGAPDH 
antibodies detected the 40 kDa PyGAPDH protein in a Western blot (Figure 3.4B and C). Dimer 
and tetramer forms of rPyGAPDH with sizes of 80 kDa and 160 kDa were detected by the 
antibodies (Figure 3.4B and C). A yield of 12.48 mg rPyGAPDH was obtained from a 0.65 g of 


















Figure 3.4: Recombinant expression and affinity purification of rPyGAPDH. Recombinant PyGAPDH 
was expressed in E. coli BL21 (DE3) cells grown in terrific broth and affinity purified with a cobalt affinity 
matrix. Samples were analysed on a 12.5% reducing SDS-PAGE gel (A) and Western blot (B and C). 
Lane 1: molecular weight marker; lanes 2-3: untransformed and transformed E. coli cells expressing 
PyGAPDH; lane 4: unbound proteins from the cobalt resin; lane 5: column wash. Lanes 6-10: rPyGAPDH 
eluted with 250 mM imidazole. The gel was stained with Coomassie brilliant blue R- 250. The Western 
blot was probed with mouse anti-Histag (B) and chicken anti-rPyGAPDH (C) antibodies. 
3.2.5 Recombinant expression and affinity purification of rPyLDH 
Plasmodium yoelii lactate dehydrogenase (PyLDH) was recombinantly expressed in E. 
coli BL21 (DE3) cells grown in a terrific broth. After expression of rPyLDH, the bacteria were 
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lysed, and the soluble protein fraction was passed over a cobalt affinity column to purify 
rPyLDH. The 37 kDa rPyLDH protein band was absent in the untransformed E. coli cells and 
was observed in the soluble fraction (Figure 3.5A). Recombinant PyLDH was eluted from the 
column with 250 mM imidazole and a single rPyLDH protein band was observed (Figure 3.5A). 
The 37 kDa rPyLDH band was consistent with the 37.06 kDa predicted from genomic and 
predicted amino acid sequence with the histidine tag. Recombinant PyLDH was detected by 
both anti-Histag and anti-rPyLDH antibodies in a Western blot (Figure 3.5B and C).  A 74 kDa 
dimer form of rPyLDH was also detected (Figure 3.5B and C).  We could not determine why the 
rPyLDH was not completely reduced during the SDS-PAGE procedure. A yield of 15.31 mg pure 
rPyLDH was obtained from a 0.61 g of wet weight E. coli cell pellet. 
 
 










Figure 3.5: Recombinant expression and affinity purification of rPyLDH. Recombinant PyLDH was 
expressed in E. coli BL21 (DE3) cells grown in a terrific broth and affinity purified with a cobalt affinity 
matrix. Samples were analysed on and a 12.5% reducing SDS-PAGE gel (A) and Western blot (B and C). 
Lane 1: molecular weight marker; lanes 2-3: untransformed and transformed E. coli cells expressing 
PyLDH; lane 4: unbound proteins from the cobalt resin; lane 5: column wash. Lanes 6-10: rPyLDH eluted 
with 250 mM. The gel was stained with Coomassie brilliant blue R- 250.  The Western blot was probed 
with mouse anti-Histag (B) and chicken anti-rPyLDH (C) antibodies. 
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3.2.6 Analysis of the purity of rPyGAPDH and rPyLDH 
Following the affinity purification of recombinant proteins, we assessed the purity of 
proteins using an SDS-PAGE gel stained with silver, which detect 0.1 ng protein (Nesterenko et 
al ., 1994). Decresing concentrations of rPyGAPDH and rPyLDH (200 ng – 5 ng) were analysed 
on an SDS-PAGE gel which was then stained with silver stain. The stain detected a single 
protein band of rPyGAPDH (Figure 3.6A) and rPyLDH (Figure 3.6B) which shows that the 










Figure 3.6: Assessment of the  purity of affinity purified rPyGAPDH  and  rPyLDH with a silver 
stain.  Recombinant PyGAPDH (A) and rPyLDH (B) were loaded on a 12.5% SDS-PAGE gel as follows: 
lane 1: molecular weight marker, lanes 2-5: 200 ng, 100 ng, 10 ng  and 5 ng rPyGAPDH/rPyLDH. The 
gels were stained with silver stain.  
3.2.7 Evaluation of the migration of rPyGAPDH and rPyLDH in presence of metal ions 
in SDS-PAGE gels made from different acrylamide concentrations  
Proteins containing multiple histidine residues are reported to migrate slower on 
polyacrylamide gels and resolve with smaller sizes when treated with metal ions (Shakele et al., 
2017). Recombinant PyGAPDH and rPyLDH were assessed for metal ions binding as they 
contain a hexa-histidine tag. The recombinant proteins were incubated with CuCl2, CoCl2 and 
NiCl2 and their migration was assessed on an SDS-PAGE gel (Figure 3.7). No differences in 
sizes were observed between untreated rPyGAPDH and rPyLDH and metal treated rPyGAPDH 
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Figure 3.7: Effect of metals on rPyGAPDH and rPyLDH in SDS-PAGE gel. Recombinant PyGAPDH 
(A) and rPyLDH (B) were incubated in a 1:6 ratio with metal ions and resolved on a 12.5% reducing SDS-
PAGE gel. Lane 1: molecular weight marker and lane 2: protein without metal ions.  Lanes 3-5: proteins 
incubated with was CuCl2, CoCl2 and NiCl2 respectively. The gels were stained with Coomassie brilliant 








Figure 3.8: Evaluation of rPyGAPDH migration in different concentration of polyacrylamide gel. 
Recombinant PyGAPDH was resolved on a 10% (A), 12.5% (B) and 15% (C) SDS-PAGE gel. Lane 1: 
molecular weight marker, lane 2 and 3: reduced and non-reduced rPyGAPDH. The gels were stained with 
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Figure 3.9: Evaluation of rPyLDH migration in different concentration of polyacrylamide gel. 
Recombinant PyLDH was resolved on a 10% (A), 12.5% (B) and 15% (C) SDS-PAGE gels. Lane 1: 
molecular weight marker, lane 2 and 3: reduced and non-reduced rPyLDH. The gels were stained with 
Coomassie brilliant blue R-250 
3.2.8 Recombinant expression and affinity purification of rPfLDH  
Plasmodium falciparum lactate dehydrogenase (PfLDH) was recombinantly expressed in 
E. coli BL21 (DE3) cells grown in a terrific broth. After expression of rPfLDH, bacterial cells were 
lysed, and the soluble fraction was passed over a cobalt affinity column to purify rPfLDH. 
Recombinant band was absent in the untransformed E. coli cells and the 33 kDa, 36 kDa, 75 
kDa and 150 kDa rPfLDH bands were present in the soluble fraction (Figure 3.10).  
Recombinant PfLDH was eluted from the column with 250 mM imidazole and the resulting 
protein had four bands. The 36 kDa band is consistent with the size predicted from genomic and 
amino acid sequence of PfLDH with the histidine tag. The 33 kDa is also a monomer of rPfLDH. 
Dimer and trimer forms of rPfLDH with sizes of 75 kDa and 150 kDa were observed (Figure 
3.10A). All the forms of rPfLDH were detected by anti-rPfLDH and anti-Histag antibodies in a 
Western blot analysis (Figure 3.10B and C).  A yield of 16.8 mg pure rPfLDH was obtained from 
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Figure 3.10: Recombinant expression and affinity purification of rPfLDH. Recombinant PfLDH was 
expressed in E. coli BL21 (DE3) cells grown in a terrific broth and affinity purified with a cobalt affinity 
matrix. Samples were analysed on and a 12.5% reducing SDS-PAGE gel (A) and Western blot (B and C). 
Lane 1: molecular weight marker; lanes 2-3: untransformed and transformed E. coli cells expressing 
PfLDH; lane 4: unbound proteins from the cobalt resin; lane 5: column wash. Lanes 6-10: rPfLDH eluted 
with 250 mM. The gel was stained with Coomassie brilliant blue R- 250.  The Western blot was probed 
with chicken anti-rPfLDH antibodies (B) and mouse anti-Histag antibodies (C). 
3.2.9 Purification of chicken antibodies against rPfLDH  
Since two chickens were immunized with rPfLDH, the crude IgY isolated from both 
chickens were combined. The crude IgY was passed over an rPfLDH aminolink® column for 
affinity purification of anti-rPfLDH specific antibodies (Figure 3.11). A yield of 31 mg anti-rPfLDH 
antibodies was eluted from the column.  
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Figure 3.11: Elution profile after affinity purification of anti-rPfLDH antibodies. Crude IgY was 
isolated from weeks following high anti-rPfLDH antibody titres. Combined IgY from chicken 1 (week 1 to 
week 12) and chicken 2 (week 6 to week 12) were passed over an aminolink® column.  
The affinity purified anti-rPfLDH antibodies were assessed for the recognition of rPfLDH 
on a Western blot (Figure 3.12). The chicken anti-rPfLDH antibodies did not detect the E. coli 
proteins from untransformed E. coli bacterial lysate. The anti-rPfLDH antibodies recognized 
rPfLDH (Figure 3.12B). A high background signal was observed suggesting that the affinity 











Figure 3.12: Evaluation of affinity purified chicken anti-rPfLDH antibodies for rPfLDH detection. 
Recombinant PfLDH was resolved on a 12.5% reducing SDS-PAGE gel (A) and detected with chicken 
anti-rPfLDH antibodies on a Western blot (B). Lane 1: molecular weight marker, lane 2: BL21 
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3.3 Discussion  
 
3.3.1 Protein expression in the presence of ethanol  
The recombinant expression of proteins is an important step to produce enough material 
for studying the protein of interest for vaccine or drug design or studying bacterial and parasitic 
infections like malaria (Sivashanmugam et al., 2009). This study optimized the expression of 
high yields of rPyGAPDH and rPyLDH in E. coli bacterial cells by supplementing the growth 
media with ethanol.  Ethanol has been described to enhance DNA synthesis in E. coli cells and 
consequently increasing the production of bacterial proteins (Basu & Poddar, 1994; Ingram & 
Buttke, 1985). Chhetri et al (2015) showed that the addition of 3% (v/v) ethanol in the growth 
media caused an increase of the expression of a wide range of yeast proteins. Our observations 
differed from the results by Basu & Poddar (1997) and Chhetri et al (2015).  In the current study, 
ethanol decreased the expression of the recombinant proteins and the decrease was in a 
concentration-dependent manner (Figures 3.1 and Figure 3.2).  
The decrease in recombinant protein expression by ethanol was explored by monitoring 
the growth of E. coli cells expressing both PyLDH and PyGAPDH. The inhibition of bacterial 
growth was proportional to the ethanol concentration. This suggests that ethanol impedes the 
cell growth leading to fewer cells expressing the recombinant proteins. Basu and Poddar (1997) 
found that high concentrations of ethanol reduced cell growth. They found that ethanol 
concentration above 5% (v/v) completely abolished the growth of E. coli cells (Basu & Poddar, 
1997). Ethanol has been reported to instigate chemical stress in bacteria, which causes both the 
pH and temperature of the bacteria to increase to levels which kills the bacteria (Ingram & 
Buttke, 1985). Ingram and Buttke (1985) also reported that when the E. coli cells are grown in 
the presence of ethanol, their membrane lipid composition is altered, which is unfavourable for 
the survival of the bacteria. We suggest that the inhibition of E. coli bacterial growth resulted in 
fewer cells expressing both PyLDH and PyGAPDH.  
3.3.2 Recombinant expression and affinity purification of PyGAPDH 
Plasmodium yoelii GAPDH was recombinantly expressed in E. coli bacterial cells and 
purified using a cobalt affinity column. The expressed rPyGAPDH was soluble and the pure 
protein was obtained with an expected monomeric size of 40 kDa (Sangolgi, et al., 2016; 
Krause et al., 2017). A yield of 12.48 mg rPyGAPDH was obtained. This was higher compared 
to previous studies which obtained 8.95 mg pure rPyGAPDH per 50 ml culture using a cobalt 
affinity column (Krause et al., 2017). Krause et al (2017) expressed rPyGAPDH at 30°C, while 
the current study expressed rPyGAPDH at 37°C. Higher protein yields are reported with higher 
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expression temperatures in E. coli cells (Rosano & Ceccarelli, 2014). However, high growth 
temperatures have been shown to result in the reduction of enzyme activity (de Groot & 
Ventura, 2006). Recombinant PyGAPDH activity was not measured here and we cannot rule out 
the possibility that the protein may have reduced activity.  
3.3.3 Recombinant expression and purification of PfLDH and PyLDH 
Plasmodium falciparum LDH was recombinantly expressed in E. coli cells and affinity 
purified. Recombinant PfLDH was obtained as two monomeric proteins of sizes 36 kDa and 33 
kDa, a 75 kDa dimer and a 150 kDa tetramer (Figure 3.10). These sizes of rPfLDH were also 
observed in other studies (Berwal et al 2008; Turgut-Balik et al., 2001). The PfLDH sequence 
has an internal methionine at position 19, which results in the production of two sizes of the 
protein, a 36 kDa full rPfLDH protein and truncated 32 kDa rPfLDH (Berwal et al 2008; Turgut-
Balik et al., 2001). Plasmodium yoelii LDH was recombinantly expressed and purified as a 
single 37 kDa protein band (Figure 3.5). Unlike PfLDH, PyLDH does not have an internal 
methionine, therefore it purifies as a single monomeric protein. The size of PyLDH was also 
comparable to previous studies which obtained a 39 kDa protein band (Hurdayal et al., 2010). 
Recombinant PyLDH was also expressed and purified as a truncated protein with lower 
concentration. The truncated rPyLDH proteins were recognised by antibodies in a Western blot. 
This was also demonstrated by Hurdayal et al (2010). The yields of rPfLDH and rPyLDH in 50 
ml cultures were 16.8 mg and 15.3 mg respectively. Previous studies obtained 15 mg of rPfLDH 
(Turgut-Balik et al., 2001) and 12 mg of rPyLDH in 1-litre culture (Hurdayal et al., 2010). The 
yields of rPfLDH and rPyLDH in the current study is converted to 336 mg and 306 mg in 1-litre 
cultures respectively, which is high compared to previous studies. The dimer and tetramer form 
of of rPfLDH were not expected. They could be due to incomplete denaturation of the protein. 
Zhang et al., 2019 reported that residual sizes of proteins including antibodies are observed 
when the proteins are not boiled at optimal temperatures and boiling time. 
3.3.4 The influence of acrylamide concentrations and metal ions on protein migration in 
SDS-PAGE gels. 
SDS-PAGE gels are widely used to evaluate the size of proteins (Rath et al., 2013). 
Proteins with helical 3-dimensional structures migrate with lower sizes on SDS-PAGE gels 
(Rath et al., 2013). These proteins include a 39 kDa bovine rhodopsin, which resolves as a 30 
kDa on SDS-PAGE gels. Shelake et al (2017) reported a Helicobacter pylori (Hpn) protein that 
migrated faster following the binding to nickel ions, which could be followed by polyacrylamide 
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electrophoresis. The influence of copper, cobalt and nickel on rPyGAPDH and rPyLDH 
migration on SDS-PAGE gel was evaluated (Figure 3.7A and B); the metals did not affect 
protein migration. Acrylamide concentrations between 4-20% are commonly used for SDS-
PAGE gels (Rath et al., 2013). The influence of acrylamide concentrations on protein migration 
was evaluated. Both reduced and non-reduced forms of rPyGAPDH and rPyLDH migrated in a 
similar manner in different acrylamide concentrations (Figure 3.8A, B and C and Figure 3.9A, B 
and C). Unreduced proteins have been reported to migrate faster on SDS-PAGE gels, their fast 
migration is the consequence of sodium dodecyl sulfate (SDS) binding better to their compact 
structures with disulfide bonds (Rath et al., 2013). This was not observed with unreduced 
rPyGAPDH and rPyLDH.  
3.3.5 Production of chicken antibodies against rPfLDH 
Plasmodial lactate dehydrogenase (pLDH) has been discovered to be an efficient target 
of malaria rapid diagnostic tests (RDTs) (Piper et al., 1999). Mouse IgG antibodies are 
commonly used in RDTs (Moody, 2002). These antibodies have been shown to be unstable at 
high temperatures (Chiodini et al., 2007).  Chickens antibodies (IgY) have been observed to be 
effective for use in immunotherapies and immunodiagnostics (Gassmann et al., 1990). This 
study produced chicken antibodies against rPfLDH. The IgY antibodies were functional in a 
Western blot and recognised rPfLDH and none of the E. coli proteins. A yield of 31 mg anti-














Evaluation of polymorphisms Plasmodium GAPDH and pLDH 
4.1 Introduction  
4.1.1 Polymorphisms in Plasmodium parasites  
Malaria is a deadly disease that claims thousands of lives every year, particularly in sub-
Saharan Africa. Plasmodium falciparum is the most virulent form of malaria and results in the 
majority of deaths in humans.  P. falciparum has been studied and the most extensive genetic 
variation has been described in different strains and isolates from all over the world (Bolad & 
Berzins, 2000). Genetic diversity is particularly prevalent in regions of high malaria transmission 
(Nkhoma et al., 2013). Genetic variation of Plasmodium parasites increases the ability of the 
parasites to attack the host immune system, creating a challenge to produce an immune 
response against many variants of the parasites (Ferreira et al., 2004). There have been many 
efforts to develop malaria vaccines that could aid in the eradication of the disease. There is still 
no blood-stage malaria vaccine that prevents clinical symptoms and deaths due to the disease 
(Cockburn & Seder, 2018). The main contributing factor for this is a substantial genetic variation 
that exists in the parasite (Takala et al., 2009). 
 
4.1.2 Effects of polymorphisms in protein sequences of malaria vaccine candidates  
Plasmodium falciparum proteins that have the greatest polymorphisms are the antigens 
that are expressed on the surface of infected erythrocytes and these antigens are mostly 
vaccine candidates (Nkhoma et al., 2013). Merozoite surface protein (MSP1, MSP2) and 
glutamate-rich protein (GLURP) (Mohammed et al., 2018; Pattaradilokrat et al., 2018) and 
apical membrane protein (AMA1) (Takala et al., 2009) are the leading blood-stage malaria 
vaccine candidates and are all reported to have a high degree of polymorphisms. Polymorphism 
results in an induction of strain-specific antibodies that are not enough to clear all the parasites. 
As a result, the antigens with polymorphism produce low efficacious vaccines and none of the 
blood stage malaria vaccines has progressed to phase II in human clinical trials (Cockburn & 





4.1.3 Effects of polymorphisms in the protein sequences of malaria diagnostic targets 
for RDTs 
Polymorphisms have been reported to influence the performance of rapid diagnostic 
tests (RDTs). Plasmodium falciparum histidine-rich protein (PfHRP-2) and Plasmodium lactate 
dehydrogenase (pLDH) are the common proteins that are targeted by RDTs that detect malaria 
infections (Moody, 2002). Plasmodium LDH is the most reliable antigen for RDTs as it is crucial 
for the parasite survival, present at high concentrations during plasmodial infections and the 
protein clears from the blood at the same time as parasites (Oduola et al., 1997). A study 
performed by Baker et al (2005) revealed that genetic polymorphism in PfHRP-2 results to the 
reduction of the sensitivity of the RDTs detecting it. Polymorphism has been identified in PfLDH 
in Thailand (Simpalipan et al, 2018) and PvLDH in Indian isolates (Keluskar et al., 2014); these 
SNPs were observed to not influence the protein structure therefore, unlikely to influence the 
performance of pLDH base RDTs.  
4.1.4 Aims of this chapter 
Plasmodium lactate dehydrogenase (pLDH) and Plasmodium glyceraldehyde-3-
phosphate dehydrogenase are both enzymes of the glycolytic pathway. The glycolytic pathway 
is crucial in Plasmodium parasites to produce energy for survival inside the host erythrocytes 
(Roth et al., 1988). This study investigates the polymorphism in P. falciparum and P. vivax LDH 
and examines if the same polymorphisms are present in rodent plasmodial LDH including P. 
yoelii LDH. Polymorphisms on P. falciparum GAPDH are also analysed and investigated if they 
are present in rodent plasmodial GAPDH. 
4.2 Results 
 
4.2.1 Investigation of the polymorphisms shared by PfLDH with lactate 
dehydrogenases from rodent plasmodia species. 
 
KU869763.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KU869742.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KU869762.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KU869738.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KX885915.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KU869753.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KU869746.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
PF3D7_1324900      ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KU869747.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KX885919.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KX885920.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGCATGATTGGAGGAGTAATGGCT 60 
KX885921.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
EU330208.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KX885922.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KX885918.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
KU869736.1         ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
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JN547219.1         ATGGCACCAAAAGCGAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
                   **************.*********************** ********************* 
 
KU869763.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KU869742.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KU869762.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KU869738.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KX885915.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KU869753.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KU869746.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
PF3D7_1324900      ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KU869747.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KX885919.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KX885920.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KX885921.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
EU330208.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KX885922.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KX885918.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
KU869736.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
JN547219.1         ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
                   ************************************************************ 
 
KU869763.1         CCACATGGAAAAGCTTTAGATATATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KU869742.1         CCACATGGAAAAGCCTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KU869762.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KU869738.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KX885915.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KU869753.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KU869746.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
PF3D7_1324900      CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KU869747.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KX885919.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KX885920.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KX885921.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
EU330208.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KX885922.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KX885918.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
KU869736.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
JN547219.1         CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
                   ************** ******* ************************************* 
 
KU869763.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KU869742.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KU869762.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KU869738.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KX885915.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KU869753.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KU869746.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
PF3D7_1324900      GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KU869747.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KX885919.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KX885920.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KX885921.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
EU330208.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KX885922.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KX885918.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
KU869736.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
JN547219.1         GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
                   ************************************************************ 
 
KU869763.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KU869742.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KU869762.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
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KU869738.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KX885915.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KU869753.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KU869746.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
JN547218.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
PF3D7_1324900      GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KU869747.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KX885919.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KX885920.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KX885921.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
EU330208.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KX885922.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KX885918.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
KU869736.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
JN547219.1         GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
                   ************************************************************ 
 
KU869763.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KU869742.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KU869762.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KU869738.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KX885915.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KU869753.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KU869746.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
PF3D7_1324900      TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KU869747.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KX885919.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KX885920.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KX885921.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
EU330208.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KX885922.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
KX885918.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTTATATTAAGAAGAATTGTCCAAATGCT 360 
KU869736.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
JN547219.1         TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
                   ********************************* ************************** 
 
KU869763.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KU869742.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KU869762.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KU869738.1         CTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KX885915.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KU869753.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KU869746.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
PF3D7_1324900      TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KU869747.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KX885919.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KX885920.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KX885921.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
EU330208.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KX885922.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KX885918.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
KU869736.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
JN547219.1         TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
                    *********************************************************** 
 
KU869763.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KU869742.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KU869762.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KU869738.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KX885915.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KU869753.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KU869746.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
PF3D7_1324900      GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
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KU869747.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KX885919.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KX885920.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KX885921.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
EU330208.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KX885922.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KX885918.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
KU869736.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
JN547219.1         GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
                   ************************************************************ 
 
KU869763.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KU869742.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KU869762.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KU869738.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KX885915.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KU869753.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KU869746.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
PF3D7_1324900      TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KU869747.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGC 540 
KX885919.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KX885920.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KX885921.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
EU330208.1         TATTACATATCTCAGAAATTAAATGTATGCCCCAGAGATGTAAATGCACACATTGTAGGT 540 
KX885922.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KX885918.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
KU869736.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
JN547219.1         TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
                   ********************************.**************************  
 
KU869763.1         GCTCATGGAAATAAAACGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KU869742.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KU869762.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KU869738.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KX885915.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KU869753.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KU869746.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
PF3D7_1324900      GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KU869747.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KX885919.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAGGATACATTACTGTAGGTGGTATCCCTTTA 600 
KX885920.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KX885921.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
EU330208.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KX885922.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KX885918.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
KU869736.1         GCTCACGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
JN547219.1         GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
                   ***** ********** *************.***************************** 
 
KU869763.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KU869742.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KU869762.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KU869738.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KX885915.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KU869753.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KU869746.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
PF3D7_1324900      CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KU869747.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KX885919.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KX885920.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KX885921.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
EU330208.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KX885922.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
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KX885918.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
KU869736.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
JN547219.1         CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
                   ************************************************************ 
 
KU869763.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KU869742.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KU869762.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KU869738.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KX885915.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KU869753.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KU869746.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
JN547218.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
PF3D7_1324900      ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KU869747.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KX885919.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTACACCAGCT 720 
KX885920.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KX885921.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
EU330208.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KX885922.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KX885918.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
KU869736.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
JN547219.1         ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
                   ***************************************************.******** 
 
KU869763.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KU869742.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KU869762.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGAATTAATTTGC 780 
KU869738.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KX885915.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KU869753.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KU869746.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
JN547218.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
PF3D7_1324900      GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KU869747.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KX885919.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KX885920.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KX885921.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
EU330208.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
KX885922.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGACTTGAAAAAAGTATTAATTTGC 780 
KX885918.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATGTGC 780 
KU869736.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
JN547219.1         GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTGC 780 
                   ************************************** **********:****** *** 
 
KU869763.1         TCAACCTTGTTAGAAGGGCAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KU869742.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KU869762.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KU869738.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KX885915.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KU869753.1         TCAACCTTGTCAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KU869746.1         TCAACCTTGTCAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
PF3D7_1324900      TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KU869747.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KX885919.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KX885920.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KX885921.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
EU330208.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KX885922.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KX885918.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
KU869736.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 
JN547219.1         TCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTGTTGTT 840 




KU869763.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KU869742.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KU869762.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KU869738.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KX885915.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAGATAGTGAGGAAAAAGCT 900 
KU869753.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KU869746.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
PF3D7_1324900      TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KU869747.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KX885917.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KX885919.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KX885920.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KX885921.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
EU330208.1         TTAGGTGCTAATGGTGTCGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KX885922.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KX885918.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
KU869736.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
JN547219.1         TTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAGCT 900 
                   ***************** ************************.***************** 
 
KU869763.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KU869742.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KU869762.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KU869738.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KX885915.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KU869753.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KU869746.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
PF3D7_1324900      AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KU869747.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KX885919.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KX885920.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KX885921.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
EU330208.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KX885922.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KX885918.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
KU869736.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
JN547219.1         AAATTTGATGAAGCCATAGCTGAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
                   *************************************************** 
Figure 4.1: Alignment of Plasmodium falciparum lactate dehydrogenase (PfLDH) from 
patients isolates against the 3D7 strain (PF3D7_1324900). The PfLDH from clinical isolates were 
obtained from PubMed and the 3D7 sequence was obtained from PlasmoDB and they were aligned using 
Clustal Omega.  
The 951 bp DNA sequence of Plasmodium falciparum lactate dehydrogenase (PfLDH) 
translates to a protein sequence with 316 amino acid residues. Single nucleotide 
polymorphisms (SNPs) were investigated on PfLDH DNA sequences. Fifty-four sequences were 
obtained from PubMed and PlasmoDB and aligned using Clustal Omega (Appendix 1) and only 
16 of them contained SNPs (Figure 4.1). Nineteen SNPs were identified (Figure 4.1). Nine of 
the SNPs detected at nucleotide positions 15 (GCA/GCG), 39 (GGT/GGC), 136 (GCT/GCC), 
513 (CCA/CCC), 540 (GGT/GGC), 546 (CAT/CTT), 759 (GAT/GAC), 758 (GGA/GGG) and 858 
(GTT/GTC) resulted in synonymous mutations at amino acid residues 5 (A), 13 (G), 45 (A), 171 
(P), 180 (G), 265 (G) and 286 (V) respectively. Ten SNPs detected at nucleotide positions 143 
(ACA/ATA), 334 (CAT/TAT), 361 (TTT/CTT), 557 (ATG/ACG), 571 (AGA/GGA), 711 
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(GCA/ACA) ,770 (GTA/GAA), 791 (TTA/TCA) and 873 (AAT/GAT) resulted in non-synonymous 
mutations at amino acid residues 48 (T/I), 112 (H/I), 121 (F/P), 186 (M/T), 191 (R/G), 238 (A/T), 
257 (I/T) and 263 (L/S) respectively. The SNP at 873 (AAT/GAT) did not correspond to any 
amino acid in the protein sequence. All the SNPs only occurred in (1/54) sequences except for 
the SNP at 791 codon which occurred in 2 sequences (2/54). Only two PfLDH SNPs are 
documented on PlasmoDB and they occur at positions 21 (C/T) and 272 (G/D) and the 
sequences containing these SNP’s are not available on PubMed databases. Simpalipan et al 
(2018) identified 7 PfLDH non-synonymous SNPs that were not observed from sequence 
alignments. These SNPs were located at positions 25 (Q/K), 29 (G/R), 87 (G/R), 136 (L/S), 151 
(G/R), 187 (V/G) and 188 (L/P). Therefore, PfLDH has a total of 18 non-synonymous SNPs.  
PF3D7_1324900         MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVLFDIVKNMPHGKALDTSHTNVMAYSNCK 60 
PCHAS_1344700.1       MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVMFDIVKDMPHGKALDTSHTNVMAYSNCQ 60 
PBANKA_1340100.1      MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVMFDIVKNMPHGKALDTSHTNVMAYSNCK 60 
PY17X_1344800.1       MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVLFDIVKNMPHGKALDTSHTNVMAYSNCK 60 
                      ********************************:*****:********************: 
 
PF3D7_1324900         VSGSNTYDDLAGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKKNCPNA 120 
PCHAS_1344700.1       VSGSNTYDDLKGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKKHCPHA 120 
PBANKA_1340100.1      VSGSNTYDDLKDADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKNNCPNA 120 
PY17X_1344800.1       VSGSNTYDDLKDADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKNNCPNA 120 
                      ********** .******************************************::**:*  
 
PF3D7_1324900         FIIVVTNPVDVMVQLLHQHSGVPKNKIIGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
PCHAS_1344700.1       FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
PBANKA_1340100.1      FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
PY17X_1344800.1       FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
                      ***************************:******************************** 
 
PF3D7_1324900         AHGNKMVLLKRYITVGGIPLQEFINNKLISDAELEAIFDRTVNTALEIVNLHASPYVAPA 240 
PCHAS_1344700.1       AHGNKMVLLKRYITVGGIPIQEFINNKKISDQDLEAIFDRTINTALEIVNLHASPYVAPA 240 
PBANKA_1340100.1      AHGNKMVLLKRYITVGGIPLQEFINNKKITDQELDAIFDRTINTALEIVNLHASPYVAPA 240 
PY17X_1344800.1       AHGNKMVLLKRYITVGGIPLQEFINNKKITDQELDAIFDRTVNTALEIVNLHASPYVAPA 240 
                      *******************:******* *:* :*:******:****************** 
 
PF3D7_1324900         AAIIEMAESYLKDLKKVLICSTLLEGQYGHSDIFGGTPVVLGANGVEQVIELQLNSEEKA 300 
PCHAS_1344700.1       AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
PBANKA_1340100.1      AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
PY17X_1344800.1       AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
                      **********::**:***************.***.***:*:*.************::**  
 
PF3D7_1324900         KFDEAIAETKRMKALA 316 
PCHAS_1344700.1       KFDEAVAETSRMKALV 316 
PBANKA_1340100.1      KFDEAVAETSRMKALI 316 
PY17X_1344800.1       KFDEAVAETSRMKALI 316 
                      *****:***.*****  
Figure 4.2: Alignment of PfLDH (3D7_1324900) amino acid sequence with PcLDH 
(PCHAS_1344700.1), PbLDH (PBANKA_1340100.1) and PyLDH (PY17X_1344800.1). The positions of 
SNPs are underlined, and lysine residues are highlighted.  
 
Many of the PfLDH sequences did not have SNPs including PF3D7_1324900 (Figure 
4.1). This sequence (3D7) was used as a reference to examine whether the PfLDH SNPs are 
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found in rodent malaria LDH. The PfLDH sequence was aligned with LDH sequences from P. 
berghei (PbLDH), P. chabaudi (PcLDH) and P. yoelii (PyLDH) (Figure 4.2). Two non-
synonymous SNPs at positions 21 (C/T) and 272 (G/D) are conserved between PfLDH, PbLDH, 
PcLDH and PyLDH.   
Lysine residues play a crucial role in the protein structure and are the regions of post-
translational modification. This study investigated the lysine residues on PfLDH and compared 
them with rodent plasmodial species. A total of 26 lysine residues are found in PfLDH sequence 
and 21 lysine residues are conserved amongst all four pLDH sequences (Figure 4.2). Four 
lysine residues are conserved amongst PbLDH, PcLDH and PyLDH but not found in PfLDH. 
These lysine residues are at amino acid position 71, 208, 271 and 300 and are replaced by 
alanine, leucine, serine and alanine in the PfLDH sequence respectively. Three lysine residues 
located at position 252, 255 and 310 are unique in PfLDH. Lysine-252 and 255 are replaced by 
arginine which is conserved in all three-rodent Plasmodium LDH and lysine-300 is replaced with 
serine which is also conserved in all three-rodent plasmodia species. Lysine-115 is only found in 
PfLDH and PcLDH and is replaced with asparagine both in PbLDH and PyLDH. Lysine-60 is 
replaced by glutamine in PcLDH sequence but conserved between PfLDH, PbLDH and PyLDH. 
None of the lysine residues is polymorphic (Figure 4.2). 
4.2.2 Investigation of the polymorphisms in PvLDH DNA sequences 
JX865771.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 60                                                                         
PVX_116630.1    ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547223.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC  
KM226653.1      ----------------AAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
KM226660.1      ----------------AAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547224.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547222.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547226.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547221.0      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGAGGGCC 
FJ527750.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
DQ060151.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JX872280.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547225.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547220.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGATGGCC 
JN547221.1      ATGACGCCGAAACCCAAAATTGTGCTCGTCGGGTCGGGCATGATCGGAGGCGTGAGGGCC 
                                *************************************** **** 
 
JX865771.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 120 
PVX_116630.1    ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547223.1      ACGCTGATTGTGCAGAAGAACCTGCGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG        
KM226653.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
KM226660.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547224.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547222.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547226.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547221.0      ACGCTGATTGTGCAGAAGAACCTGTGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
FJ527750.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
DQ060151.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
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JX872280.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547225.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547220.1      ACGCTGATTGTGCAGAAGAACCTGGGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
JN547221.1      ACGCTGATTGTGCAGAAGAACCTGTGGGACGTAGTGATGTTTGACGTAGTGAAAAACATG 
                ************************ *********************************** 
 
JX865771.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 180 
PVX_116630.1    CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547223.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG        
KM226653.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
KM226660.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547224.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547222.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547226.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547221.0      CCCCAAGGAAAGGCACTAGATATGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
FJ527750.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
DQ060151.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JX872280.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547225.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547220.1      CCCCAAGGAAAGGCACTAGATACGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
JN547221.1      CCCCAAGGAAAGGCACTAGATATGTCTCACTCGAATGTGATGGCTTATTCCAATTGCAAG 
                ********************** ************************************* 
 
JX865771.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 240 
PVX_116630.1    GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JN547223.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG       
KM226653.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
KM226660.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JN547224.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JN547222.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JN547226.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JN547221.0      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
FJ527750.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
DQ060151.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JX872280.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JN547225.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGCCACTGCG 
JN547220.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
JN547221.1      GTGACTGGCTCGAACTCGTATGATGACTTGAAGGGAGCCGACGTGGTGATCGTCACTGCG 
                **************************************************** ******* 
JX865771.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 300 
PVX_116630.1    GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547223.1      GGATTTACTAAAGCACCAGGAAAGAGCAACAAGGAATGGAACCGAGATGATTTACTCCCC        
KM226653.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
KM226660.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547224.1      GGATTTACTAAAGCACCAGGAAAGAGCGTCAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547222.1      GAATTTACTAAAGCACCAGGAAAGAGCGTCAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547226.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547221.0      GGATTTACTAAAGCACCAGGAAAGGGCAACAAGGAATGGAACCGAGATGATTTACTCCCC 
FJ527750.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
DQ060151.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
JX872280.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547225.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547220.1      GGATTTACTAAAGCACCAGGAAAGAGCGACAAGGAATGGAACCGAGATGATTTACTCCCC 
JN547221.1      GGATTTACTAAAGCACCAGGAAAGGGCAACAAGGAATGGAACCGAGATGATTTACTCCCC 
                *.**********************.**.:******************************* 
 
JX865771.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 360 
PVX_116630.1    TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
JN547223.1      TTGAATAACAAATTTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC      
KM226653.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
KM226660.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
JN547224.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTATGAACCTTTGCCCCAATGCC 
JN547222.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATACC 
62 
 
JN547226.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTCGCCCCAATGCC 
JN547221.0      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
FJ527750.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
DQ060151.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
JX872280.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
JN547225.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
JN547220.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
JN547221.1      TTGAATAACAAAATTATGATTGAGATTGGGGGACATATTAAGAACCTTTGCCCCAATGCC 
                ************:***************************:******* ********.** 
 
JX865771.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 420 
PVX_116630.1    TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JN547223.1      TTTATCATTGTGGAGACGAACCCAGTGGACGTGATGGTGCAGTTACCCTTCGAGCATTCC       
KM226653.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
KM226660.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JN547224.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JN547222.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAACATTCC 
JN547226.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JN547221.0      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
FJ527750.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
DQ060151.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JX872280.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JN547225.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JN547220.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
JN547221.1      TTTATCATTGTGGTGACGAACCCAGTGGACGTGATGGTGCAGTTACTCTTCGAGCATTCC 
                *************:******************************** ******.****** 
 
JX865771.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 480 
PVX_116630.1    GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
JN547223.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA       
KM226653.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
KM226660.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
JN547224.1      GGAGTCCCAAAAAATAAAATCATCGGATTGGGTGGTGTGCTAGATACATCTAGACTGAAA 
JN547222.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
JN547226.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGATA 
JN547221.0      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
FJ527750.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
DQ060151.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
JX872280.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGCGTGCTAGATACATCTAGACTGAAA 
JN547225.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
JN547220.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
JN547221.1      GGAGTCCCAAAAAATAAAATCATCGGATTAGGTGGTGTGCTAGATACATCTAGACTGAAA 
                *****************************.***** **********************:* 
  
JX865771.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 540 
PVX_116630.1    TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547223.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT       
KM226653.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
KM226660.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547224.1      TATTACATATCGCAGAAGTTGAACGTCTGTCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547222.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547226.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547221.0      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
FJ527750.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
DQ060151.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JX872280.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547225.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547220.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
JN547221.1      TATTACATATCGCAGAAGTTGAACGTCTGCCCGAGAGATGTTAATGCACTCATTGTCGGT 
                ***************************** ****************************** 
  
JX865771.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 600 
PVX_116630.1    GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
63 
 
JN547223.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG       
KM226653.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
KM226660.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JN547224.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JN547222.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JN547226.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JN547221.0      GCACATGGGAACAAGATAGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
FJ527750.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
DQ060151.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JX872280.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JN547225.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JN547220.1      GCACATGGGAACAAGATGGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
JN547221.1      GCACATGGGAACAAGATAGTTCTCCTGAAAAGGTACATCACAGTTGGAGGTATCCCATTG 
                *****************.****************************************** 
                                                
JX865771.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 660 
PVX_116630.1    CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JN547223.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC       
KM226653.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
KM226660.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JN547224.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGGAGAAGTGGAAGGCATATTTGATCGC 
JN547222.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JN547226.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JN547221.0      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
FJ527750.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
DQ060151.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JX872280.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JN547225.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JN547220.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
JN547221.1      CAAGAATTTATTAATAACAAAAAGATTACAGATGAAGAAGTGGAAGGCATATTTGATCGC 
                **********************************.************************* 
                                
JX865771.1      ACTGTCAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 720 
PVX_116630.1    ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547223.1      ACTGTCAACACTGCTTTGGAGATTGTGAACCTCCTCGCCTCTCCTTATGTTGCCCCAGCT       
KM226653.1      ACTGTCAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
KM226660.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547224.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547222.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547226.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547221.0      ACTGTGAACACTGCTTCGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
FJ527750.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
DQ060151.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JX872280.1      ACTGTCAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547225.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547220.1      ACTGTGAACACTGCTTTGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
JN547221.1      ACTGTGAACACTGCTTCGGAGATTGTGAACCTCCTTGCCTCTCCTTATGTTGCCCCAGCT 
                ***** ********** ****************** ************************ 
 
JX865771.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 780 
PVX_116630.1    GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
JN547223.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT      
KM226653.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
KM226660.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
JN547224.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGGAGGATATAAAGAAAGTGCTTGTTTGT 
JN547222.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
JN547226.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
JN547221.0      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
FJ527750.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
DQ060151.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
JX872280.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
JN547225.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
JN547220.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
64 
 
JN547221.1      GCTGCCATCATCGAAATGGCCGAATCTTATTTGAAGGATATAAAGAAAGTGCTTGTTTGT 
                *********************************.************************** 
 
JX865771.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 840 
PVX_116630.1    TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547223.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT      
KM226653.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
KM226660.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547224.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547222.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547226.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547221.0      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
FJ527750.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
DQ060151.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JX872280.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547225.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547220.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
JN547221.1      TCCACTCTACTAGAGGGACAATACGGCCACAGCAACATCTTTGGTGGTACTCCTCTCGTT 
                ************************************************************ 
 
JX865771.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 900 
PVX_116630.1    ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JN547223.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACT        
KM226653.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
KM226660.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGATC 
JN547224.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JN547222.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JN547226.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JN547221.0      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
FJ527750.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
DQ060151.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JX872280.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JN547225.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JN547220.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
JN547221.1      ATCGGGGGCACCGGAGTTGAGCAAGTCATCGAGTTGCAGCTGAATGCCGAGGAGAAGACC 
                **********************************************************   
 
JX865771.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA----          951 
PVX_116630.1    AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
JN547223.1      AAGTTCGACGAGGCAGTTGCGGAAACTAAAAGGATGAAGGCGCTCATTTAA----        
KM226653.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAAAGGT 
KM226660.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAAAGGT 
JN547224.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
JN547222.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGAAGAAGGCGCTCATTTAA---- 
JN547226.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
JN547221.0      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
FJ527750.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
DQ060151.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
JX872280.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
JN547225.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
JN547220.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
JN547221.1      AAGTTCGACGAGGCAGTTGCGGAGACTAAAAGGATGAAGGCGCTCATTTAA---- 
                ***********************.**********:****************     
Figure 4.3: DNA sequence alignment of Plasmodium vivax lactate dehydrogenase from Cheorwon 
4 isolate (JX865771.1) with PvLDH sequences from other strains and field isolates. The sequences 




SNPs were investigated in PvLDH DNA sequences. P. vivax isolates Bucheon 4 
(JX872279.1), Bucheon 2 (JX872278.1), Bucheon 1 (JX872277.1), Gangwha 4 (JX872276.1), 
Gangwha 3 (JX872275.1 ), Paju 3 (JX865774.1), Gimpo 4 (JX865779.1), Gimpo 3 
(JX865778.1), Gimpo 2 (JX865777.1), Gimpo 1 (JX865776.1), Paju 4 (JX865775.1), Paju 1 
(JX865772.1), Cheorwon 4 (JX865771.1), Cheorwon 3 (JX865770.1), Cheorwon 2 
(JX865769.1) and Cheorwon 1 (JX865768.1) are identical and contain no SNPs.  The PvLDH 
sequence from Cheorwon 4 isolate (JX865771.1) was used as a reference to identify SNPs 
from other PvLDH (Figure 4.3). Nineteen SNPs were detected at nucleotide positions 56 
(ATG/AGG), 85 (GGG/GTC/GCT), 143 (ACG/ATG), 233 (GTC/GCC), 242 (GGA/GAA), 265 
(AGC/GGC), 313 (ATT/TTT), 341 (AAG/ATG), 348 (TGC/CGC), 358 (GCC/ACC), 374 
(GTG/GAG), 407 (CTC/CCC), 479 (AAA/ATA), 558 (ATG/ATA), 635 (GAA/GGA), 677 
(TTG/TCG), 754 (AAG/GAG), 899 (ACC/ATC) and 935 (ATG/AAG) resulted in non-synonymous 
mutations at position 19 (M/R), 29 (G/V/A), 48 (T/M), 78 (V/A), 81 (G/K), 87 (S/G), 105 (I/F), 114 
(K/M), 117 (C/R), 118 (A/N), 124 (V/E), 135 (L/P), 159 (K/I), 186 (M/I), 212 (K/G), 226 (L/C), 251 
(K/G), 300 (T/I) and 311 (M/K). Five SNPs were detected at nucleotide positions 450 
(TTA/TTG), 456 (GGT/GGC), 510 (TGC/TGT), 666 (GTG/GTC) and 696 (CTT/CTC) resulted in 
synonymous mutations at amino acid residue 138 (G), 150 (L), 152 (G), 170 (C), 222 (V) and 
232 (L) respectively (Figure 4.4). The synonymous SNPs at 414 (GAG/GAA) and 924 
(GAG/GAA) did not correspond with glycine in the protein sequence. All the SNP’s only occured 
in 1/30 and 2/30 sequences except for the SNP at 666 which occurred in 11/30 sequences. 
JN547221.1, JN547221.0, JN54722.1 sequence have the highest number of SNPs while 
KM2226660.1, KM226653.1 and JN547220.1 had only 1 SNP per sequence (Figure 4.3).  
JX865771.1         MTPKPKIVLVGSGMIGGVMATLIVQKNLGDVVMFDVVKNMPQGKALDTSHSNVMAYSNCK 60 
PCHAS_1344700.1    MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVMFDIVKDMPHGKALDTSHTNVMAYSNCQ 60 
PBANKA_1340100.1   MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVMFDIVKNMPHGKALDTSHTNVMAYSNCK 60 
PY17X_1344800.1    MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVLFDIVKNMPHGKALDTSHTNVMAYSNCK 60 
                   *:** ***************************:**:**:**:********:********: 
 
JX865771.1         VTGSNSYDDLKGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKNLCPNA 120 
PCHAS_1344700.1    VSGSNTYDDLKGADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKKHCPHA 120 
PBANKA_1340100.1   VSGSNTYDDLKDADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKNNCPNA 120 
PY17X_1344800.1    VSGSNTYDDLKDADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKNNCPNA 120 
                   *:***:*****.******************************************: **:* 
 
JX865771.1         FIIVVTNPVDVMVQLLFEHSGVPKNKIIGLGGVLDTSRLKYYISQKLNVCPRDVNALIVG 180 
PCHAS_1344700.1    FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
PBANKA_1340100.1   FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
PY17X_1344800.1    FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
                   ****************.:*********:**************************** *** 
 
JX865771.1         AHGNKMVLLKRYITVGGIPLQEFINNKKITDEEVEGIFDRTVNTALEIVNLLASPYVAPA 240 
PCHAS_1344700.1    AHGNKMVLLKRYITVGGIPIQEFINNKKISDQDLEAIFDRTINTALEIVNLHASPYVAPA 240 
PBANKA_1340100.1   AHGNKMVLLKRYITVGGIPLQEFINNKKITDQELDAIFDRTINTALEIVNLHASPYVAPA 240 
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PY17X_1344800.1    AHGNKMVLLKRYITVGGIPLQEFINNKKITDQELDAIFDRTVNTALEIVNLHASPYVAPA 240 
                   *******************:*********:*::::.*****:********* ******** 
 
JX865771.1         AAIIEMAESYLKDIKKVLVCSTLLEGQYGHSNIFGGTPLVIGGTGVEQVIELQLNAEEKT 300 
PCHAS_1344700.1    AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
PBANKA_1340100.1   AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
PY17X_1344800.1    AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
                   **********::*::***:***********.:**.********.************:**. 
 
JX865771.1         KFDEAVAETKRMKALI 316 
PCHAS_1344700.1    KFDEAVAETSRMKALV 316 
PBANKA_1340100.1   KFDEAVAETSRMKALI 316 
PY17X_1344800.1    KFDEAVAETSRMKALI 316 
                   *********.*****: 
Figure 4.4: Alignment of PvLDH (JX865771.1) amino acid sequences with PcLDH 
(PCHAS_1344700.1), PbLDH (PBANKA_1340100.1) and PyLDH (PY17X_1344800.1). The positions of 
SNPs on PvLDH sequence are underlined and lysine residues are highlighted.  
The PvLDH sequence from Cheorwon 4 isolate (JX865771.1) was aligned with PbLDH, 
PyLDH and PcLDH to investigate whether the SNPs of PvLDH are found in rodent plasmodial 
sequences (Figure 4.4). The DNA sequences of PvLDH and PbLDH shows that only the 
synonymous SNP at position 666 is conserved between PvLDH and PbLDH. This SNP results 
in valine residue at amino acid position 222 and is not found in PyLDH and PcLDH sequences. 
All the non-synonymous substitutions that occurred in PvLDH sequences did not occur in 
PbLDH, PyLDH and PcLDH (Figure 4.4).  
Lysine residues in PvLDH sequence were evaluated and 27 lysine residues were 
identified and only 23 are conserved between PvLDH, PbLDH PcLDH and PyLDH (Figure 4.4). 
Lysine-252, 255 and 310 are unique in PvLDH sequence. Lysine-252 and 255 are replaced by 
arginine residues and lysine-310 is replaced by serine residues in PbLDH, PcLDH and PyLDH.  
Lysine-271 and 300 are conserved in rodent plasmodial species and replaced by serine and 
threonine in PvLDH respectively. Lysine-115 is only found in PcLDH and it is replaced by 
asparagine in PvLDH, PbLDH and PyLDH. Lysine-60 is conserved between PvLDH, PbLDH 
and PyLDH and replaced by glutamine in PcLDH. Lysine-114 is mutated to methionine in 
PvLDH sequences and this mutation does not occur in rodent plasmodial LDH sequences 
(Figure 4.4).  
4.2.3 Investigation of the polymorphisms in PfGAPDH protein sequence and 
comparison with GAPDH from rodent plasmodia species 
Seven PfGAPDH SNPs are documented on PlasmoDB and they are located at position 
50 (D/A), 51 (S/T), 140 (Q/C), 74 (V/C), 143 (T/C), 228 (N/A) and 277 (L/T). More PfGAPDH 
SNPs were identified in this study. The DNA sequences of 17 Plasmodium falciparum strains; 
3D7, TG01, GB4, GA01, GN01, CD01, 7G8, KE01, Dd2, SD01, KH01, KH02, IT, TG01 and 
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SN01 showed that the protein is 100% conserved. Four PfGAPDH sequences that contain 
SNPs were obtained from PubMed and aligned with PfGAPDH sequence from the 3D7 strain 
(Figure 4.5). Three non-synonymous substitutions were observed at positions 140 (Q/K), 272 
(P/L) and 276 (I/V) and they occurred from mutations at nucleotide positions 418 (CAA/AAA), 
815 (CCA/CTA) and 826 (ATC/GTC) respectively. Cha et al (2016) identified 7 non-synonymous 
SNPs in PfGAPDH sequences from field isolates and they included 51 (S/T), 53 (H/P), 59 (E/D), 
61 (T/S), 71 (E/D), 140 (Q/K) and 142 (D/S). Together, these results suggests the presence of 
12 SNPs (51 (S/T), 53 (H/P), 59 (E/D), 61 (T/S), 71 (E/D), 140 (Q/K) and 142 (D/S), 143 (T/C), 
228 (N/A), 272 (P/L), 276 (I/V) and 277 (L/T)) in the PfGAPDH sequence.  
PF3D7_1462800.1  MAVTKLGINGFGRIGRLVFRAAFGRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQFPCEV   60 
AAD10249.1       MAVTKLGINGFGRIGRLVFRAAFGRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQFPCEV 60 
AAK30144.1       MAVTKLGINGFGRIGRLVFRAAFGRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQFPCEV 60 
ETW58610.1       MAVTKLGINGFGRIGRLVFRAAFGRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQFPCEV 60 
EWC73547.1       MAVTKLGINGFGRIGRLVFRAAFGRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQFPCEV 60 
                 ************************************************************ 
 
PF3D7_1462800.1 THADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLKGGAKKVI    120 
AAD10249.1      THADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLKGGAKKVI 120 
AAK30144.1      THADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLKGGAKKVI 120 
ETW58610.1      THADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLKGGAKKVI 120 
EWC73547.1      THADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLKGGAKKVI 120 
                ************************************************************ 
 
PF3D7_1462800.1 MSAPPKDDTPIYVMGINHHQYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVEGLMTTVH    180 
AAD10249.1      MSAPPKDDTPIYVMGINHHQYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVEGLMTTVH 180 
AAK30144.1      MSAPPKDDTPIYVMGINHHQYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVEGLMTTVH 180 
ETW58610.1      MSAPPKDDTPIYVMGINHHKYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVEGLMTTVH 180 
EWC73547.1      MSAPPKDDTPIYVMGINHHKYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVEGLMTTVH 180 
                *******************:**************************************** 
 
PF3D7_1462800.1 ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI    240 
AAD10249.1      ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
AAK30144.1      ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
ETW58610.1      ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
EWC73547.1      ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
                ************************************************************ 
 
PF3D7_1462800.1 GTVSVVDLVCRLQKPAKYEEVALEIKKAAEGPLKGILGYTEDEVVSQDFVHDNRSSIFDM    300 
AAD10249.1      GTVSVVDLVCRLQKPAKYEEVALEIKKAAEGLLKGVLGYTEDEVVSQDFVHDNRSSIFDM 300 
AAK30144.1      GTVSVVDLVCRLQKPAKYEEVALEIKKAAEGLLKGVLGYTEDEVVSQDFVHDNRSSIFDM 300 
ETW58610.1      GTVSVVDLVCRLQKPAKYEEVALEIKKAAEGPLKGILGYTEDEVVSQDFVHDNRSSIFDM 300 
EWC73547.1      GTVSVVDLVCRLQKPAKYEEVALEIKKAAEGPLKGILGYTEDEVVSQDFVHDNRSSIFDM 300 
                ******************************* ***:************************ 
 
PF3D7_1462800.1 KAGLALNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN 337 
AAD10249.1      KAGLALNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN  337 
AAK30144.1      KAGLALNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN  337 
ETW58610.1      KAGLALNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN  337 
EWC73547.1      KAGLALNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN  337 
                ************************************* 
Figure 4.5: Alignment of PfGAPDH from 3D7 strain (PF3D7_1462800.1) with PfGAPDH sequences 
from field isolates. The SNPs are underlined. 
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The PfGAPDH amino acid sequence was aligned with GAPDH sequences from P. 
chabaudi (PcGAPDH), P. yoelii (PyGAPDH) and P. berghei (PbGAPDH) to compare whether 
the SNPs of PfGAPDH are conserved across rodent plasmodial species (Figure 4.6). Only the 
SNP at position 140 (Q/K) is found in PbGAPDH, PcGAPDH and PyGAPDH sequences (Figure 
4.6).   
PF3D7_1462800.1       MAVTKLGINGFGRIGRLVFRAAFGRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQFPCEV 60 
PCHAS_1329700.1       MAVTKVGINGFGRIGRLVFRSAHERSDIEVVAINDPFMDIHHLIYLLKHDSVHGKFPCEV 60 
PBANKA_1326400.1      MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDISHLIYLLKHDSVHGKFPCEV 60 
PY03280-t26_1         MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDINHLIYLLKHDSVHGKFPCEV 60 
                      **:**:**************:*  *.*************: ** ****:*****:***** 
 
PF3D7_1462800.1       THADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLKGGAKKVI 120 
PCHAS_1329700.1       TPTEGGIMVGNKKVVVYNEKDPAQIPWGKHAIDVVCESTGVFLTKELSSAHIKGGAKKVI 120 
PBANKA_1326400.1      TPTEGGIMVGNKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI 120 
PY03280-t26_1         TPTEGGIMVGSKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI 120 
                      * ::* :::*.*** *: *:**:******  :***************:.:*:******** 
 
PF3D7_1462800.1       MSAPPKDDTPIYVMGINHHQYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVEGLMTTVH 180 
PCHAS_1329700.1       MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
PBANKA_1326400.1      MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
PY03280-t26_1         MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
                      ******************.:*::.* **************:****::.************ 
 
PF3D7_1462800.1       ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PCHAS_1329700.1       ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PBANKA_1326400.1      ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PY03280-t26_1         ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
                      ***********************.** ********************************* 
 
PF3D7_1462800.1       GTVSVVDLVCRLQKPAKYEEVALEIKKAAEGPLKGILGYTEDEVVSQDFVHDNRSSIFDM 300 
PCHAS_1329700.1       GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTEEEVVSQDFVHDSRSSIFDL 300 
PBANKA_1326400.1      GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTEEEVVSQDFVHDSRSSIFDL 300 
PY03280-t26_1         GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTDEEVVSQDFVHDSRSSIFDL 300 
                      ************:******:** :**:*:***********::**********.******: 
 
PF3D7_1462800.1       KAGLALNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN 337 
PCHAS_1329700.1       KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITHH 337 
PBANKA_1326400.1      KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKN 337 
PY03280-t26_1         KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKH 337 
                      ************:*************:****:***:: 
Figure 4.6: Alignment of PfGAPDH (PF3D7_1462800.1) amino acid sequence with PcGAPDH 
(PCHAS_1329700.1), PbGAPDH (PBANKA_1326400.1) and PyGAPDH (PY03280-t26_1). The SNPs 
are underlined, and lysine residues are highlighted (green).  
Lysine residues have influence on the structure of the protein. Plasmodial GAPDH has 
been reported to have post-translational modification, which results in moonlighting functions 
(Sirover, 2011). Lysine residues of proteins are often acetylated during post-translational 
modification of proteins (Yang & Seto, 2008). The current study evaluated lysine residues in 
PfGAPDH amino acid sequence, and 26 lysine residues were identified (Figure 4.6). The 
PfGAPDH sequence was aligned with PbGAPDH, PcGAPDH and PyGAPDH sequences to 
evaluate whether the lysine residues on PfGAPDH are conserved in rodent plasmodial species 
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(Figure 4.6). Twenty-two lysine residues are conserved in GAPDH of all four plasmodial 
species. Four lysine residues were only found in PfGAPDH and they were in position 26, 80, 
144 and 267. Four lysine residues were absent in PfGAPDH but conserved between rodent 
malaria GAPDH and were in position 55, 140, 263 and 264. Only PfGAPDH and PcGAPDH 
possessed lysine-80 while Lysine-336 was only found in PyGAPDH and PbGAPDH. Only one 
lysine residue (140) was polymorphic.  
4.2.4 Investigation of the polymorphisms in PvGAPDH protein sequence and 
comparison with GAPDH from rodent plasmodia species 
Four SNPs have been identified in the Plasmodium vivax glyceraldehyde-3-phosphate 
dehydrogenase (PvGAPDH) DNA sequence and are documented on PlasmoDB. The SNPs 
were identified on PvGAPDH sequences using PO1 strain of Plasmodium vivax as a reference 
and these SNPs are located at nucleotide position 33, 87, 910 and 1002.  The SNP at position 
87 (GAG/ GAA) was identified on PvGAPDH from Sal-1 strain (PVX_117322) and it results in a 
synonymous mutation at 29 (E). The SNPs at position 33 (TTC) and 1002 (ATA) resulted in 
synonymous substitutions at amino acid position 11 (F) and 334 (I) (Figure 4.6 and Figure 4.7). 
The SNP at position 910 (CTG) causes a non-synonymous substitution that changes leucine-
304 (Figure 4.7). This mutation could either produce valine (GTG) or methionine (ATG). 
Unfortunately, the DNA sequences of PvGAPDH isolates with these SNPs are not available on 
PubMed databases.  
PVP01_1244000.1   ATGGCCGTAACAAAGCTTGGAATTAATGGATTCGGACGTATCGGACGTTTAGTTTTTAGG 60 
PCHAS_1329700.1   ATGGCAGTAACAAAAGTAGGAATTAACGGATTTGGCCGTATCGGTCGTTTAGTATTCAGA 60 
PBANKA_1326400.1  ATGGCAATAACAAAAGTCGGAATTAATGGATTTGGCCGTATCGGTCGTTTAGTATTCAGA 60 
PY03280-t26_1     ATGGCAATAACAAAAGTAGGAATTAATGGATTTGGCCGTATCGGTCGTTTAGTATTCAGA 60 
                  *****..*******. * ******** ***** **.********:********:** **. 
 
PVP01_1244000.1   GCTGCTTATGAAAGGAGTGACATCGAGGTAGTCGCGGTTAATGACCCATTTATGGACATC 120 
PCHAS_1329700.1   TCTGCTCATGAAAGGAGTGACATCGAAGTAGTTGCTATCAATGACCCATTTATGGATATC 120 
PBANKA_1326400.1  TCTGCCCAAGAAAGAAGTGACATTGAAGTAGTTGCTATCAATGACCCATTTATGGATATT 120 
PY03280-t26_1     TCTGCCCAAGAAAGAAGTGACATTGAAGTAGTTGCTATCAATGACCCATTTATGGATATT 120 
                  ****  *:*****.******** **.***** ** .* ***************** **  
 
PVP01_1244000.1   AAGCACTTGTGCTACTTGCTCAAGTATGACTCCATCCACGGTGTATTCCCAGCAGAGGTA 180 
PCHAS_1329700.1   CATCACTTAATCTACTTATTAAAACATGATTCAGTTCATGGAAAATTCCCATGTGAAGTA 180 
PBANKA_1326400.1  AGTCACTTGATCTACTTATTAAAGCATGATTCAGTTCATGGAAAATTCCCATGTGAGGTA 180 
PY03280-t26_1     AACCACTTGATCTACTTATTAAAGCATGATTCAGTTCATGGAAAATTCCCATGTGAAGTA 180 
                  .. *****.: ******. *.**. **** **..* ** **:.:*******  :**.*** 
 
PVP01_1244000.1   ACCCCAGGCGATGGCTGCTTCACCGTTGGTAACAAGAAAATCTTTGTGCACAGCGAAAAG 240 
PCHAS_1329700.1   ACCCCAACTGAAGGAGGTATAATGGTTGGAAACAAAAAAGTCGTTGTTTACAACGAAAAA 240 
PBANKA_1326400.1  ACCCCAACTGAAGGAGGTATCATGGTTGGAAACAAAAAAGTCGTTGTATATAACGAAAGA 240 
PY03280-t26_1     ACCCCAACTGAAGGAGGTATCATGGTTGGAAGCAAAAAAGTCGTTGTATATAACGAAAGA 240 
                  ******.  **:**. * :*.*  *****:*.***.***.** ****  * *.*****.. 
 
PVP01_1244000.1   GACCCAGCACAAATCCCATGGGGCAAATACGAAATTGATGTTGTGTGCGAATCCACTGGT 300 
PCHAS_1329700.1   GACCCAGCTCAGATTCCATGGGGAAAACACGCCATTGATGTTGTATGTGAATCAACTGGT 300 
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PBANKA_1326400.1  GACCCAGCTCAAATTCCATGGGGAAAACACGCCATTGATGTTGTATGTGAATCAACTGGT 300 
PY03280-t26_1     GACCCAGCTCAAATTCCATGGGGAAAACACGCCATTGATGTTGTATGTGAATCAACTGGT 300 
                  ********:**.** ********.*** ***..***********.** *****.****** 
 
PVP01_1244000.1   GTGTTCTTAACCAAGGAATTGTCCAATGCACATCTTAAGGGAGGAGCAAAGAAGGTTATC 360 
PCHAS_1329700.1   GTATTTTTAACCAAGGAATTATCCAGTGCTCACATTAAGGGAGGTGCAAAAAAAGTTATC 360 
PBANKA_1326400.1  GTATTCTTAACCAAGGAATTATCCAATGCTCACATTAAGGGAGGTGCAAAAAAAGTTATC 360 
PY03280-t26_1     GTATTCTTAACCAAGGAATTATCCAATGCTCACATTAAGGGAGGTGCAAAAAAAGTTATC 360 
                  **.** **************.****.***:** .**********:*****.**.****** 
 
PVP01_1244000.1   ATGTCCGCCCCACCAAAGGACGACACCCCTATTTACGTTATGGGTATTAACCATGATAAG 420 
PCHAS_1329700.1   ATGTCAGCACCACCAAAAGATGACACTCCAATTTATGTCATGGGTATTAACCACGAGAAA 420 
PBANKA_1326400.1  ATGTCAGCACCACCAAAAGACGACACACCAATTTATGTCATGGGTATTAACCACGAGAAA 420 
PY03280-t26_1     ATGTCAGCACCACCAAAAGACGACACACCAATTTATGTCATGGGTATTAACCACGAGAAA 420 
                  *****.**.********.** ***** **:***** ** ************** ** **. 
 
PVP01_1244000.1   TATGACCCAAAACAACTCATCGTTTCAAATGCATCATGTACCACCAACTGTTTATCTCCA 480 
PCHAS_1329700.1   TATAACAGTTCTCAAACCATCGTTTCCAATGCCTCATGTACTACCAACTGTTTAGCACCA 480 
PBANKA_1326400.1  TATAACAGTTCCCAAACCATCGTCTCCAATGCCTCATGTACTACAAATTGCTTAGCCCCA 480 
PY03280-t26_1     TATAACAGCTCTCAAACCATCGTTTCCAATGCCTCATGTACTACAAATTGCTTAGCCCCA 480 
                  ***.**.  :. ***. ****** **.*****.******** **.** ** *** * *** 
 
PVP01_1244000.1   ATTGCAAAAGTACTTCATGACAACTTCGGAATTGTTGAGGGTTTGATGACCACTGTCCAC 540 
PCHAS_1329700.1   ATTGCTAAGGTAATTCATGAAAACTTTGGAATCGTTGAAGGTTTAATGACCACTGTCCAT 540 
PBANKA_1326400.1  ATTGCTAAGGTAATTCATGAAAACTTCGGAATTGTTGAAGGTTTAATGACCACTGTCCAT 540 
PY03280-t26_1     ATTGCTAAAGTAATTCATGAAAACTTCGGAATTGTTGAAGGTTTAATGACCACTGTCCAT 540 
                  *****:**.***.*******.***** ***** *****.*****.**************  
 
PVP01_1244000.1   GCTTCGACGGCCAACCAGTTGGTAGTTGATGGACCATCCAAGGGTGGAAAGGACTGGAGA 600 
PCHAS_1329700.1   GCCTCAACAGCCAACCAATTAGTTGTTGATGGACCATCAAAGGGAGGTAAAGACTGGAGA 600 
PBANKA_1326400.1  GCCTCAACAGCCAACCAATTAGTTGTTGATGGACCATCAAAGGGAGGTAAAGACTGGAGA 600 
PY03280-t26_1     GCCTCAACAGCCAACCAATTAGTTGTTGATGGACCATCAAAGGGAGGTAAAGACTGGAGA 600 
                  ** **.**.********.**.**:**************.*****:**:**.********* 
 
PVP01_1244000.1   GCAGGCAGATGTGCATTGTCAAACATTATTCCCGCCTCCACTGGTGCAGCTAAGGCCGTA 660 
PCHAS_1329700.1   GCAGGTAGATCAGCTTTGTTAAACATTATCCCAGCTTCAACTGGTGCAGCCAAAGCTGTA 660 
PBANKA_1326400.1  GCAGGTAGATCAGCTTTGTTAAACATTATCCCAGCTTCAACTGGTGCAGCTAAAGCTGTA 660 
PY03280-t26_1     GCAGGTAGATCAGCTTTGTTAAACATTATCCCAGCTTCAACTGGTGCAGCTAAAGCTGTA 660 
                  ***** **** :**:**** ********* **.** **.*********** **.** *** 
 
PVP01_1244000.1   GGTAAGGTCTTACCCGAATTGAATGGAAAGCTCACTGGTGTTGCCTTCAGAGTCCCCATC 720 
PCHAS_1329700.1   GGAAAAGTTTTACCAGAATTAAACGGAAAATTAACTGGTGTTGCCTTTAGAGTTCCAATT 720 
PBANKA_1326400.1  GGAAAAGTTTTACCAGAATTAAACGGGAAATTAACTGGTGTTGCCTTTAGAGTTCCAATT 720 
PY03280-t26_1     GGAAAAGTTTTACCAGAATTAAACGGAAAATTAACTGGTGTTGCCTTTAGAGTTCCAATT 720 
                  **:**.** *****.*****.** **.**. *.************** ***** **.**  
 
PVP01_1244000.1   GGTACCGTGTCAGTTGTTGATTTAGTGTGCAGATTGGAAAAACCAGCGAAATATGAAGAA 780 
PCHAS_1329700.1   GGTACCGTCTCTGTTGTTGATTTAGTATGCAGATTAGAAAAACCAGCCAAATATGAAGAT 780 
PBANKA_1326400.1  GGTACAGTCTCAGTTGTCGATTTAGTATGCAGATTAGAAAAACCAGCCAAATATGAAGAT 780 
PY03280-t26_1     GGTACAGTATCTGTTGTCGATTTAGTATGTAGATTAGAAAAACCAGCCAAATATGAAGAT 780 
                  *****.** **:***** ********.** *****.*********** ***********: 
 
PVP01_1244000.1   ATTGCCGCCCAAATGAAGAAAGCAGCAGAAGGACCACTCAAGGGAATATTGGGTTACACT 840 
PCHAS_1329700.1   GTTGCTAAAAAAATTAAAGAAGCATCTGAGGGACCACTTAAGGGAATCTTAGGTTATACC 840 
PBANKA_1326400.1  GTAGCTAAAAAAATTAAAGAAGCATCTGAGGGTCCACTTAAGGGAATATTAGGTTATACC 840 
PY03280-t26_1     GTAGCTAAAAAAATTAAAGAAGCATCTGAAGGACCACTTAAGGGAATATTAGGTTATACC 840 
                  .*:** ....**** **..***** *:**.**:***** ********.**.***** **  
 
PVP01_1244000.1   GAAGATGAAGTTGTTTCCCAAGATTTCGTCCACGACAAGAGGTCCTCCATTTTTGACTTG 900 
PCHAS_1329700.1   GAAGAAGAAGTTGTATCTCAAGATTTCGTCCATGATAGCAGATCATCTATCTTTGACTTA 900 
PBANKA_1326400.1  GAAGAAGAAGTTGTATCTCAAGATTTCGTCCATGATAGCAGATCATCAATCTTTGACTTA 900 
PY03280-t26_1     GACGAAGAAGTTGTATCTCAAGATTTCGTCCATGATAGCAGATCATCTATCTTTGACTTA 900 




PVP01_1244000.1   AAGGCTGGTCTGGCATTGAACGACAACTTTTTCAAAATCGTTTCATGGTACGATAATGAG 960 
PCHAS_1329700.1   AAAGCTGGTCTTGCCTTAAATGATAACTTTTTCAAAATTGTCTCATGGTATGACAATGAA 960 
PBANKA_1326400.1  AAAGCTGGTCTTGCCTTAAATGATAACTTTTTCAAAATTGTTTCATGGTATGACAATGAA 960 
PY03280-t26_1     AAAGCTGGTCTTGCCTTAAATGATAACTTTTTCAAAATTGTCTCATGGTATGACAATGAA 960 
                  **.******** **.**.** ** ************** ** ******** ** *****. 
 
PVP01_1244000.1   TGGGGATACTCAAACCGTGTGCTAGACTTGGCTGTCCACATAACAAAACATTAA 1014 
PCHAS_1329700.1   TGGGGATATTCAAACCGTCTTTTAGATTTGGCTATCCACATCACCCACCATTAA 1014 
PBANKA_1326400.1  TGGGGATATTCAAACCGTCTTTTAGATTTGGCTATCCACATCACCAAAAATTAA 1014 
PY03280-t26_1     TGGGGATATTCAAACCGTCTTTTAGATTTGGCTATCCACATCACCAAACATTAA 1014 
                  ******** ********* *  **** ******.*******.**..*..***** 
Figure 4.7: DNA sequence alignment of PvGAPDH (PVP01_1244000.1) with GAPDH sequences 
from P. chabaudi (PCHAS_1329700.1), P. berghei (PBANKA_1326400.1) and P. yoelii (PY03280-
t26_1). The SNPs are underlined. 
The PvGAPDH was aligned with GAPDH sequences from P. chabaudi, P. yoelii and P. 
berghei to evaluate whether the similar SNPs are found in rodent malaria GAPDH (Figure 4.7). 
Two SNPs at positions 87 and 910 are conserved between PvGAPDH, PcGAPDH, PbGAPDH 
and PyGAPDH (Figure 4.7).  
PVP01_1244000.1    MAVTKLGINGFGRIGRLVFRAAYERSDIEVVAVNDPFMDIKHLCYLLKYDSIHGVFPAEV 60 
PCHAS_1329700.1    MAVTKVGINGFGRIGRLVFRSAHERSDIEVVAINDPFMDIHHLIYLLKHDSVHGKFPCEV 60 
PBANKA_1326400.1   MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDISHLIYLLKHDSVHGKFPCEV 60 
PY03280-t26_1      MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDINHLIYLLKHDSVHGKFPCEV 60 
                   **:**:**************:* *********:******* ** ****:**:** **.** 
 
PVP01_1244000.1    TPGDGCFTVGNKKIFVHSEKDPAQIPWGKYEIDVVCESTGVFLTKELSNAHLKGGAKKVI 120 
PCHAS_1329700.1    TPTEGGIMVGNKKVVVYNEKDPAQIPWGKHAIDVVCESTGVFLTKELSSAHIKGGAKKVI 120 
PBANKA_1326400.1   TPTEGGIMVGNKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI 120 
PY03280-t26_1      TPTEGGIMVGSKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI 120 
                   ** :* : **.**:.*:.*:*********: *****************.**:******** 
 
PVP01_1244000.1    MSAPPKDDTPIYVMGINHDKYDPKQLIVSNASCTTNCLSPIAKVLHDNFGIVEGLMTTVH 180 
PCHAS_1329700.1    MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
PBANKA_1326400.1   MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
PY03280-t26_1      MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
                   ******************:**: .* ************:*****:*:************* 
 
PVP01_1244000.1    ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PCHAS_1329700.1    ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PBANKA_1326400.1   ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PY03280-t26_1      ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
                   ***********************.** ********************************* 
 
PVP01_1244000.1    GTVSVVDLVCRLEKPAKYEEIAAQMKKAAEGPLKGILGYTEDEVVSQDFVHDKRSSIFDL 300 
PCHAS_1329700.1    GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTEEEVVSQDFVHDSRSSIFDL 300 
PBANKA_1326400.1   GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTEEEVVSQDFVHDSRSSIFDL 300 
PY03280-t26_1      GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTDEEVVSQDFVHDSRSSIFDL 300 
                   *******************::* ::*:*:***********::**********.******* 
 
PVP01_1244000.1    KAGLALNDNFFKIVSWYDNEWGYSNRVLDLAVHITKH 337 
PCHAS_1329700.1    KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITHH 337 
PBANKA_1326400.1   KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKN 337 
PY03280-t26_1      KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKH 337 
                   **************************:****:***:: 
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Figure 4.8: Alignment of PvGAPDH (PVP01_1244000.1) amino acid sequence with PcGAPDH 
(PCHAS_1329700.1), PbGAPDH (PBANKA_1326400.1) and PyGAPDH (PY03280-t26_1). The SNPs 
are underlined, and lysine residues are highlighted (green).   
Lysine residues of PvGAPDH were evaluated and 29 were identified (Figure 4.8). The 
PvGAPDH sequence was aligned with the amino acid sequences of PbGAPDH, PyGAPDH and 
PcGAPDH to evaluate whether the lysine residues on PvGAPDH are conserved between the 
Plasmodium species. Twenty-three lysine residues are conserved between all four Plasmodium 
species. Lysine-41, 144, 267 and 293 residues are unique in PvGAPDH.  Lysine-55, 263 and 
264 are not found in the PvGAPDH sequence but conserved between rodent plasmodial 
species. Lysine-80 is found only in PvGAPDH and PcGAPDH and is replaced with arginine in 
PyGAPDH and PbGAPDH. None of the lysine residues is mutated, which implicates that they 
are all crucial in forming the structure of plasmodial GAPDH.  
4.2.5 Genetic polymorphisms deduced for PyLDH sequences 
Lactate dehydrogenases from Plasmodium parasites are highly conserved (Bzik et al., 
1993). Sequence alignments revealed a 90.19% identity between PvLDH and PyLDH, while 
there was a 93.04% identity between PfLDH and PyLDH. However, PfLDH and PyLDH only 
share 2 SNPs while none of the SNPs of PvLDH occurs in PyLDH (Figure 4.2 and 4.4).  
Therefore, the PyLDH sequence possesses two non-synonymous mutations at amino acid 
positions 21 (C/T) and 272 (G/D).  
4.2.6 Genetic polymorphisms deduced for PyGAPDH sequences 
Plasmodium GAPDH enzymes are highly conserved (Dauberger et al., 2000). Plasmodium 
falciparum GAPDH has been found to share 1 SNP with PyGAPDH sequence. This SNP was 
located at amino acid position 140 (Q/K) (Figure 4.6). PvGAPDH has been observed to share 2 
SNPs with PyGAPDH. These SNPs include a synonymous and non-synonymous mutation at 
amino acid position 29 and 304 respectively (Figure 4.7). Therefore, the PyGAPDH sequence 
has 3 SNPs.  
4.2.7 Genetic polymorphisms on B cell epitopes and T cell epitopes predicted from 
PyLDH and PyGAPDH sequences  
Four CD8+ T cell epitopes were predicted in the PyGAPDH amino acid sequence and 2 
in PyLDH amino acid sequence (Table 4.1). None of the PyGAPDH CD8+ T cell epitopes 
contained an SNP while 1 of the PyLDH CD8+ T cell epitopes had an SNP. The SNP results in 
a non-synonymous substitution at amino acid 272 (G/D).  
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Table 4.1: Prediction results of PyGAPDH and PyLDH CD8+ T cell epitope obtained by 
NetMHCpan Server using the HLA-A02:01 allele. The rank threshold for Strong binding peptides 
on MHC I was 0.5.   
Antigen  Epitope  Start position % Rank threshold  
PyGAPDH FMDINHLIYL 37 0.03 
KLTGVAFRV 330 0.20 
ALNDNFFKI 305 0.09 
RLLDLAIHI 326 0.07     
PyLDH KDIFAGTPLV 271 0.50 
FIIVVTNPV 121 0.07 
 
Table 4.2: PyGAPDH and PyLDH B cell epitopes using ABCpred server. A score of 0.85 was 
used as a cutoff. The polymorphic amino acid residues are underlined. 
Antigen Sequence    Start position Score  
PyGAPDH  FPCEVTPTEGGIMVGS 56 0.89 
KELSNAHIKGGAKKVI 105 0.89 
KEASEGPLKGILGYTD 266 0.88 
YVMGINHEKYNSSQTI 132 0.87 
KGILGYTDEEVVSQDF 274 0.86 
IVEGLMTTVHASTANQ 171                                                                            0.85
PyLDH AGFTKAPGKSDKEWNR 80 0.95 
SGSNTYDDLKDADVVI 62 0.88 
MIEIGGHIKNNCPNAF 106 0.88 
HIKNNCPNAFIIVVTN 112 0.87 
IVLVGSGMIGGVMATL 7 0.85 
AESYIRDLRKVLICST 247 0.85 
 Six B cell epitopes were predicted in both PyGAPDH and PyLDH sequence (Table 4.2). 
The PyGAPDH B cell epitope (Y132-I147) had one SNP which is 140 (Q/K). One of the PyLDH 






4.3 Discussion  
4.3.1 Identification of polymorphisms in Plasmodium yoelii lactate dehydrogenase 
sequence  
Plasmodium lactate dehydrogenase has been well studied and its crystal structure has 
been determined (Dunn et al., 1996). Plasmodium LDH has been targeted for antimalarial 
compounds (Dunn et al., 1996) and as a diagnostic biomarker for malaria rapid diagnostic tests 
(Piper et al., 1999). The study of genetic polymorphisms of pLDH could determine whether the 
protein is an effective diagnostic and therapeutic target and could improve the effectiveness of 
malaria RDTs using pLDH. Genetic polymorphism of PfLDH and PvLDH were evaluated in this 
study in order to deduce the polymorphism in the PyLDH sequence. The DNA sequences were 
obtained from PlasmoDB and PubMed. The PfLDH sequence revealed 17 non-synonymous 
substitutions. These SNPs were investigated in three rodent plasmodial LDH sequences 
(P.chabaudi, P. berghei and P. yoelii) and only 2 SNPs were conserved (Figure 4.2).  Genetic 
polymorphism was also investigated in PvLDH sequences (Figure 4.3). Twenty-six polymorphic 
sites were observed in the PvLDH sequence and 19 of them were non-synonymous mutations 
(Figure 4.3). Keluskar et al (2014) described only a single non-synonymous mutation 15 (A/G) in 
PfLDH sequence. Although, this SNP did not match any field isolate and PfLDH strain. 
Simpalipan et al (2018) detected 15 SNPs of PfLDH sequence and these did not include 15 
(A/G). The PvLDH sequence has been observed to contain more polymorphism than PfLDH 
(Keluskar et al., 2014; Talman et al., 2007) and that was also observed in the current study. It 
was also observed that numerous PfLDH and PvLDH sequences from field isolates that have 
been reported in previous studies (Keluskar et al., 2014; Simpalipan et al., 2018) are not 
uploaded on the databases PlasmoDB and PubMed. Only 2 PfLDH SNPs are documented on 
PlasmoDB and no genetic polymorphism has been documented in PvLDH on PlasmoDB. 
Combining the SNPs shared by PfLDH and PvLDH with PyLDH, a total of 2 non-synonymous 
SNPs were deduced from PyLDH sequence.  
4.3.2 Polymorphisms in pLDH do not affect the performance of the enzyme in RDTs  
Talman et al (2007) described the polymorphisms in pLDH sequence to have no 
influence on the sensitivity of RDTs unlike PfHRP-2 based RDTs. Hurdayal et al (2010) 
identified plasmodial LDH epitopes that could be targeted for malaria diagnosis and differentiate 
between P. vivax and P. falciparum infections. The common pLDH epitope 
(APGKSDKEWNRDDLL), PfLDH unique epitope (LISDAELEAIFDC) and PvLDH 
(KITDEEVEGIFDC) epitope were identified and antibodies against the peptides were produced 
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in chickens. The common peptide is located between amino acid A82-97L;  this region has a 
non-synonymous substitution at position 87 in both PfLDH and PvLDH.  PfLDH specific epitope 
(L108-120C) has a single SNP at position 112, while the PvLDH epitope (K108-120C) has three 
SNPs at 114, 117 and 118 respectively. These SNPs are less frequent, occur in 1/54 
sequences. The P. falciparum detection based on PfLDH unique peptide and pan-malaria 
detection (common peptide) is unlikely to be affected by this mutation. The detection of P. vivax 
based on the PvLDH specific peptide could be affected by polymorphisms since 3 of 13 amino 
acids on the peptide are polymorphic.   
4.3.3 Identification of polymorphisms in Plasmodium yoelii glyceraldehyde-3-
phosphate dehydrogenase sequences  
Genetic polymorphisms were assessed in PfGAPDH and PvGAPDH sequences. The 
enzyme is essential in Plasmodium parasites as it catalyses glycolysis which is important for 
parasites survival in the host red blood cells. Plasmodium GAPDH has been identified as a 
diagnostic target (Krause et al., 2017). PfGAPDH is also a pre-erythrocyte vaccine candidate 
(Cha et al., 2016). A study of genetic polymorphisms could provide information on whether the 
antigen is an efficient diagnostic and vaccine target. Twelve and four SNPs have been detected 
on PfGAPDH and PvGAPDH sequence respectively. Seven of PfGAPDH SNPs are 
documented on PlasmoDB. A study by Cha et al (2016) identified five PfGAPDH SNPs from 
field isolates, these SNPs included 53 (H/P), 59 (E/D), 61 (T/S), 71 (E/D) and 142 (D/S). These 
PfGAPDH sequences are not available on the database PubMed. The PfGAPDH sequence 
shares one SNP with PyGAPDH (Figure 4.6) and PvGAPDH shares two SNPs with PyGAPDH 
(Figure 4.7). Therefore, a total of 3 SNPs were deduced for PyGAPDH sequence and they are 
located at positions 29 (E), 140 (Q/K) and 304 (V or M/L). 
4.3.4 Polymorphisms in pGAPDH do not affect the performance of the enzyme in 
RDTs 
 Krause et al (2017) identified the pGAPDH common peptide (K126-H138) and 
PfGAPDH unique peptide (A78-V92) for the detection of malaria infections using a pGAPDH 
based RDT’s. Both the common and unique peptide are not located in the region with 
polymorphisms. Therefore, this suggests that the RDTs targeting pGAPDH will not be affected 
by genetic polymorphisms.  
4.3.5 Lysine residues in PyGAPDH and PyLDH are not polymorphic  
76 
 
Lysine residues play a role in the formation of a 3D structure of proteins through the 
formation of hydrogen bonds and salt bridges to stabilize the protein (Sokalingam et al., 2012). 
Lysine residues are the regions of post-translational modification, acetylation (Yang & Seto, 
2008). Post-translational modifications on GAPDH from Plasmodium parasites and humans 
have been implicated with the moonlighting functions of the enzyme.  The current study 
evaluated the lysine residues in PfGAPDH, PvGAPDH and PyGAPDH sequences and whether 
they have polymorphisms.  None of the lysine residues on the PyGAPDH sequence was 
polymorphic. Lysine-140 was polymorphic and this non-synonymous polymorphism was 
conserved in PfGAPDH and rodent plasmodial GAPDH. It is unlikely that a single SNP could 
have a major effect on the protein structure. No SNPs were identified on PfLDH and PvLDH and 
PyLDH lysine residues. 
4.3.6 Effect of polymorphisms in PyLDH and PyGAPDH vaccine candidates 
Genetic polymorphisms of malaria vaccine candidates have been shown to lower the efficacy of 
vaccines. As a result, there is still no licensed blood-stage malaria vaccine. Two non-
synonymous substitutions were identified in both PyLDH and PyGAPDH sequences. The SNPs 
identified on PyGAPDH and PyLDH are low compared to the SNPs in PfRH5 the most 
promising malaria vaccine candidate. PfRH5 has 10 non-synonymous mutations (Ouattara et 
al., 2018) unlike other malaria vaccine candidates with a lot of genetic variation. The low genetic 
variation of PfRH5 causes the vaccine to produce an immune response that is not strain specific 
(Hayton et al., 2008). As a result, this vaccine has high efficacy and it is currently being tested in 
a phase 1/2a clinical trial. Immunogenic peptides were predicted in PyLDH and PyGAPDH 
sequences. Four and two CD8+ T cell epitopes were predicted in PyGAPDH and PyLDH 
sequences respectively.  Six B cell epitopes were predicted in both PyGAPDH and PyLDH 
sequences. The PyGAPDH CD8+ T cell epitopes did not have polymorphisms while one of the 
B cell epitopes had a single SNP. One CD8+ T cell and B cell epitope of PyLDH had a single 
SNP. The immune response produced by the PyGAPDH and PyLDH vaccine would not be 
strain specific since the proteins have minimal polymorphisms. Both PyGAPDH and PyLDH 
catalyses glycolysis, which is crucial for the parasite’s survival and the enzymes are produced 
by the parasites during blood stage infections (Le Roch et al., 2003). The vaccine targeting 
these proteins is hypothesized to produce immunity that would inhibit the growth of the parasites 
inside the erythrocytes. Both these vaccines are predicted to have high efficacies as the 




                                                           Chapter 5 
Mice immunizations and challenge 
 
5.1 Introduction  
5.1.1 Pre-erythrocyte stage malaria vaccines  
An effective malaria vaccine would contribute towards the control and the eradication of 
the disease that claims about 438 000 lives annually, particularly in sub-Saharan Africa (World 
Health Organization, 2016). RTS, S/AS01 vaccine is the only malaria vaccine that has been 
approved for use by the European Medicines Agency (RTS, 2015). The vaccine is based on the 
Plasmodium falciparum circumsporozoite protein (PfCSP) a sporozoite antigen and its targets 
the pre-erythrocyte stage of the infections (Stoute et al., 1997). RTS, S/AS01 is only approved 
for its uses in malaria-endemic areas for vaccination of older children and not infants. It has 
been reported to have a low efficacy that declines in 4 years. Therefore, other vaccine 
candidates are required for the development of a malaria vaccine and many are under 
development. These include vaccines targeting the blood stages of malaria (Cockburn & Seder, 
2018), which causes the clinical symptoms and deaths due to the disease (Miller et al., 2002). 
Blood stage malaria vaccines could potentially decrease parasite development in the blood, 
therefore reducing the disease in young children and pregnant women living in endemic areas 
(Good & Miller, 2018). The leading blood-stage malaria vaccine candidates for P. falciparum 
include apical membrane antigen-1 (PfAMA-1) (Thera et al., 2011), merozoite surface protein-1 
(PfMSP1-19) (Murhandarwati et al., 2009), GMZ2 vaccine based on PfMSP3 and glutamate-rich 
protein (PfGLURP) (Esen et al., 2009), reticulocyte homolog 5 (PfRH5) (Jin et al., 2018) and 
MSP3 (Lusingu et al., 2009).  Unfortunately, none of the blood stage vaccines has proceeded to 
Phase III clinical trials (Cockburn & Seder, 2018).  New strategies for blood-stage malaria 
vaccine development are needed to produce an effective vaccine. P. falciparum depends 
entirely on glycolysis for development and large increases in glycolytic enzymes activities have 
been reported following the infection with P. falciparum (Roth et al., 1988). These phenomena 
make glycolytic enzymes possible target for anti-malarial compounds. 
 
5.1.2 Glycolytic enzymes as parasite drug and vaccine targets 
Glycolysis is a 10 step energy producing pathway that is found in all living organisms 
(Pilkis & Granner, 1992). The pathway involves 10 enzymes and some enzymes including 
fructose 1, 6 -bisphosphate aldolase (aldolase), enolase, glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH), triose phosphate isomerase (TPI) and pyruvate kinase have been 
identified to have moonlighting functions (Sriram et al., 2005).  Enzymes with moonlighting 
functions have been reported to be associated with the pathogenesis of many human infections 
and some of these enzymes are vaccine and drug targets (Mendonça et al., 2016; Srinam et al., 
2005). GAPDH has been reported to build up in the brain of Alzheimer’s disease patients (Wang 
et al., 2005). GAPDH is involved in the invasion of liver cells by Plasmodium sporozoites where 
the enzyme interacts with CD68 on Kupfer cells (Cha et al., 2016).  P. falciparum enolase has 
been identified to be involved in the invasion of erythrocytes by merozoites (Bhowmick et al., 
2009). Aldolase from P. falciparum and Toxoplasma gondii was reported to bind to 
thrombospondin-related anonymous protein (PfTRAP) and micronemal protein 2 (MIC2) 
respectively and this interaction is critical for the invasion to erythrocytes (Jewett & Sibley, 
2003). Immunization with recombinant aldolase and rGAPDH of Streptococcus pneumoniae 
induced protection in mice against S. pneumoniae (Ling et al., 2004). Aldolase has been 
identified as a potential diagnostic target for Listeria (Mendonça et al., 2016). Antibodies against 
aldolase from Onchocerca volvulus were observed in immune individuals in endemic areas and 
the enzyme has been identified as a potential vaccine candidate for O. volvulus (McCarthy et 
al., 2002). Vaccination of hamsters with TPI induced protective immune response against 
Leishmania donoravi infections (Kushawaha et al., 2012). High levels of lactate dehydrogenase 
(LDH), an enzyme catalyzing the last step of glycolysis has been implicated with many diseases 
including cancer, leukaemia and malaria infections (Miao et al., 2013; Piper et al., 1999). LDH is 
a diagnostic target for these diseases. Plasmodial GAPDH has been identified as a diagnostic 
target for malaria (Krause et al., 2017). P. falciparum LDH is a possible target for chloroquine, a 
first line anti-malarial drug (Waingeh et al., 2013).  
 
5.1.3 Aims of this chapter 
The current study evaluated the immunogenicity of recombinant P. yoelii GAPDH and 
rPyLDH in mice and whether the immunization with the two proteins could offer protection 
against a P. berghei infection challenge in mice. 
 
5.2 Results  
5.2.1 Comparison of P. yoelii and P. berghei LDH and GAPDH amino acid sequences 
 
PyGAPDH      MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDINHLIYLLKHDSVHGKFPCEV  60 
PbGAPDH      MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDISHLIYLLKHDSVHGKFPCEV  60 
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             ****************************************.******************* 
 
PyGAPDH      TPTEGGIMVGSKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI  120 
PbGAPDH      TPTEGGIMVGNKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI  120 
             **********.************************************************* 
 
PyGAPDH      MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH   180 
PbGAPDH      MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH   180 
             ************************************************************ 
 
PyGAPDH      ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI   240 
PbGAPDH      ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI   240 
             ************************************************************ 
 
PyGAPDH      GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTDEEVVSQDFVHDSRSSIFDL  300 
PbGAPDH      GTVSVVDLVCRLEKPAKYEDVAKKISQDFVHDSRSSIFYTEEEVVSQDFVHDSRSSIFDL  300 
             *************************.:      :. : **:******************* 
 
PyGAPDH      KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKH  337 
PbGAPDH      KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKN  337 
          ************************************: 
Figure 5.1: Amino acid sequence alignment of PbGAPDH and PyGAPDH. Developed using clustal 
omega on 20 November 2018. 
PyLDH      MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVLFDIVKNMPHGKALDTSHTNVMAYSNCK 60 
PbLDH      MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVMFDIVKNMPHGKALDTSHTNVMAYSNCK 60 
           ********************************:*************************** 
 
PyLDH      VSGSNTYDDLKDADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKNNCPNA 120 
PbLDH      VSGSNTYDDLKDADVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKNNCPNA 120 
           ************************************************************ 
 
PyLDH      FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
PbLDH      FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYYISQKLNVCPRDVNAHIVG 180 
           ************************************************************ 
 
PyLDH      AHGNKMVLLKRYITVGGIPLQEFINNKKITDQELDAIFDRTVNTALEIVNLHASPYVAPA 240 
PbLDH      AHGNKMVLLKRYITVGGIPLQEFINNKKITDQELDAIFDRTINTALEIVNLHASPYVAPA 240 
           *****************************************:****************** 
 
PyLDH      AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
PbLDH      AAIIEMAESYIRDLRKVLICSTLLEGQYGHKDIFAGTPLVIGGNGVEQVIELQLNADEKK 300 
           ************************************************************ 
 
PyLDH      KFDEAVAETSRMKALI  316 
PbLDH      KFDEAVAETSRMKALI  316 
           **************** 
Figure 5.2: Amino acid sequence alignment of PbLDH and PyLDH. Developed using clustal omega 
on 21 November 2018. 
Amino acid sequences of P. yoelii and P. berghei LDH and GAPDH were obtained from 
PlasmoDB and aligned to compare the similarities between the sequences (Figure 5.1 and 5.2). 
The PyGAPDH and PbGAPDH sequences reveal a 94.96% identity. There are 4 single amino 
acid differences and a unique short peptide from 265-279 between PyGAPDH and PbGAPDH 
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sequences. The amino acid differences between PyGAPDH/PbGAPDH include asparagine 41 
/serine 41, asparagine 71/serine 71, aspartate 282/ glutamate 282 and histidine 337/ 
asparagine 337 (Figure 5.1). An alignment of PyLDH and PbLDH amino acid sequences 
revealed a 99.37% identity between the sequences. Only two amino acid differences are 
observed between PyLDH/PbLDH, and they are leucine 33/ methionine 33 and valine 
221/isoleucine 221.   
5.2.2 Assessment of rPyGAPDH and rPyLDH immunogenicity in mice 
To investigate the immunogenicity of the recombinant proteins, mice were immunized 
with the affinity-purified rPyGAPDH and rPyLDH. After 3 immunizations over 6 weeks, mouse 
anti-serum was obtained and evaluated for the presence of anti-rPyGAPDH or anti-rPyLDH 
antibodies in an ELISA (Figure 5.3A and B).  Mouse serum taken 2 weeks after final 
immunization with rPyGAPDH and rPyLDH vaccines contained IgG antibodies that detected the 
corresponding recombinant proteins by ELISA at serum dilution greater than 1:10000 (Figure 
5.3A and B). This was observed with all the serum of immunized mice. The serum taken from 










Figure 5.3: Examination of mouse anti-serum obtained from immunization of Balb/c mice with 
affinity purified rPyGAPDH and rPyLDH. Five Balb/c mice were immunized with rPyGAPDH (A) or 
rPyLDH (B). After 3 immunizations in 2 weeks intervals, mice serum was collected for the assessment of 
immunogenicity of the recombinant proteins with an ELISA.  
5.2.3 Reactivity of mouse antiserum with rPyGAPDH and rPyLDH 











































Serum samples obtained from rPyGAPDH and rPyLDH immunized mice were tested for 
the recognition of rPyGAPDH (Figure 5.4B) and rPyLDH (Figure 5.4D) in a Western blot. The 
antisera detected the monomer, dimer and the tetramer forms of rPyGAPDH and rPyLDH 











Figure 5.4: Reactivity of mouse anti-serum with rPyGAPDH and rPyLDH in a Western blot. 
Recombinant PyGAPDH (A) and rPyLDH (C) were analysed on a 12.5% reducing SDS-PAGE gels and a 
Western blot probed with rPyGAPDH (B) and rPyLDH (D) mouse antiserum. Lane 1: molecular weight 
marker and lane 2: rPyGAPDH (A and D) or rPyLDH (C and D). 
5.2.4 Evaluation of the blood-stage parasites following a challenge infection  
The progress of parasitemia was evaluated on mice immunized with PyLDH and 
PyGAPDH in Freund’s adjuvant (Figure 5.5).  All infected mice developed the blood stage 
infections and their parasitemia was monitored from day 2. Mice were euthanized when they 
showed fever symptoms and high parasitemia. Three mice in the PkPMT group were 
euthanised on day 9, one with 21% parasetimia and the other two with 8% and 3.8% 
parasitemia but with severe fever symptoms and paralysis (Figure 5.5A). The last two mice 
were euthanised on day 11 and 12 with 16% parasitemia and fever symptoms.  Two mice in 
PyLDH group were euthanised on day 7 and 9 with 13% and 7.4% parasitemia respectively 
(Figure 5.5B). The last three mice survived until day 12, one of them had 26% parasitemia and 
showing severe fever symptoms and the other two had 16% parasitemia and were euthanised. 
Two mice in the PyGAPDH group were euthanised on day 8 and 9 both with 26% parasitemia 
and severe fever symptoms (Figure 5.5C). Three mice survived till day 12 and two of them had 
12% and 14% parasitemia. One mouse in the PyGAPDH immunization group maintained the 
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parasitemia below 5% throughout the study and had no fever or any symptoms of discomfort on 




















Figure 5.5: Evaluation of protection offered by rPyLDH or rPyGAPDH formulated in Freund’s 
adjuvant against blood stage infections with P. berghei parasitized red blood cells. Mice were 
immunized with rPkPMT (A), rPyLDH (B) or rPyGAPDH (C) in Freund’s adjuvant and challenged with 
1x105 parasites/μl P. berghei infected red blood cells. Blood stage infections were monitored by staining 
blood with Giesma and counting parasites under 1000x microscope.  
5.3 Discussion  
5.3.1 Evaluation of immunogenicity of rPyGAPDH and rPyLDH in mice 
Malaria is a disease that claims about 438 000 lives annually, in poor countries 
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immunogenicity of GAPDH and LDH from Plasmodium yoelii in mice. E. coli produced 
rPyGAPDH and rPyLDH antigens were prepared in Freund’s adjuvant and mice were 
immunized to evaluate the immunogenicity of the antigens. Antibody titers > 1/10000 were 
detected in mouse serum two weeks after the last immunization with rPyGAPDH and rPyLDH 
vaccines (Figure 5.3). Vaccination of animals with proteins in Freund’s adjuvant generally 
produce high titers of antibodies against the proteins (Arevalo-Herrera et al., 2005).  Antibody 
titers between 1/5000 and 1/10000 in mouse serum have been shown to induce protection 
against sporozoite challenge following vaccination with a circumsporozoite protein immunogenic 
peptide (Wang et al., 1995). Rabbit sera following immunization with Plasmodium falciparum 
reticulocyte-binding protein homolog 5 (PfRH5) exhibited antibody titers with the endpoint of 
1/10000 which inhibited merozoite invasion (Douglas et al., 2011). Therefore, immunization of 
mice with rPyGAPDH and rPyLDH produced antibody titers, which suggested that the proteins 
were immunogenic.    
5.3.2 Challenge infection in immunized mice 
The current study evaluated whether immunization with rPyLDH and rPyGAPDH could 
induce protective immunity against challenge with P. berghei blood-stage infections. P. berghei 
parasites were used for infections in this study. Amino acid alignments of GAPDH and LDH from 
P. yoelii and P. berghei (Figure 5.1 and 5.2) revealed 94.96% and 99.37% similarities, which 
suggest high levels of  cross-reactivity between antibodies against the enzymes from the two 
parasites. Recombinant Plasmodium knowlesi phosphoethanolamine methyltransferases 
(rPkPMT), an enzyme involved in the biogenesis of lipids in human Plasmodium parasites was 
used as a control as the enzyme is not found in mammals and non-human Plasmodium 
parasites (Bobenchik et al., 2011).  There was no difference in parasitemia between PyLDH 
immunized mice and the control group. Four of the rPyGAPDH developed high parasitemia, 
while one mouse in this group showed mild protection and maintained the parasitemia below 
5% throughout the study. Lactate dehydrogenase LDH has not been evaluated for protection 
against malaria infections. On the other hand, GAPDH from P. berghei has been shown to 
protect mice against sporozoite challenge (Cha et al., 2016). Most malaria vaccine candidate 
studies generally challenge mice with 105-106 infected red blood cells (Hirunpetcharat & Good, 
1998; White et al., 1991). The current study challenged with 105, which is often used and 1/5 
mice in rPyGAPDH group appeared to not develop high parasitemia and did not show fever 
symptoms throughout the study. Future studies could challenge mice with a lower dose of 
parasites, this could possibly prevent the immune response from being overwhelmed by 
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parasites and protection might be observed in more animals. The serum of challenged mice 
following immunization should be evaluated for the presence of anti-rPyLDH and anti-


























Reactive black 5, a novel stain for proteins on nitrocellulose. 
6.1 Introduction  
6.1.1 Protein staining in polyacrylamide electrophoresis gels 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a commonly 
used procedure for separating and calculating the molecular weight and analysis of proteins and 
for following purification steps. After resolving proteins on SDS-PAGE gels, anionic dyes that 
bind to proteins are used to visualize the proteins. Commonly used dyes include Coomassie 
brilliant blue (Meyer & Lamberts, 1965), Amido black (Wilson, 1979) and a very sensitive silver 
stain (Nesterenko et al., 1994) to name a few. Coomassie brilliant blue is the most commonly 
used staining technique owing to its sensitivity and its simple staining process.  
6.1.2 Coomassie brilliant blue staining of proteins in SDS-PAGE gels 
Coomassie brilliant blue R-250 was discovered as a stain to detect proteins on cellulose-
acetate strips by Groth et al (1963). The staining technique included fixing the proteins to the 
cellulose-acetate strip with sulfosalicylic acid. Coomassie brilliant blue R-250 was later modified 
and used to detect parotid saliva proteins in polyacrylamide gels (Meyer & Lamberts, 1965). The 
staining method was more convenient as the fixing and staining of proteins was done in a single 
procedure. The stain consisted of 0.25% (w/v) Coomassie brilliant blue R-250 in 5:1:5 (v/v) 
methanol/acetic acid/water. Coomassie brilliant blue R-250 stain detects as little as 0.1-0.5 μg 
proteins (Brunelle & Green, 2014). Coomassie brilliant blue G-250 in trichloroacetic acid or 
perchloric acid is more sensitive than Coomassie brilliant blue R-250 and it does not bind 
acrylamide so a destaining procedure is not necessary (Neuhoff et al., 1985). The sensitivities 
of both stains can be enhanced by using their colloidal properties and colloidal Coomassie 
brilliant blue R-250 detects 0.7 ng of proteins on SDS-PAGE gels without any background 
staining (Neuhoff et al., 1985).  
6.1.3 Stains for staining proteins on nitrocellulose membranes 
From the time the Western blot technique was developed (Towbin et al, 1979), there has 
been a need to detect proteins on the nitrocellulose paper to localize them after the transfer step 
(Hancock & Tsang, 1983). Stains including Coomassie brilliant blue R-250, Amido black 10B, 
Ponceau S and fast green are commonly used to stain proteins on nitrocellulose. Amido black 
10B is an irreversible dye and has been reported to interfere with subsequent antibody 
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detection, while the reversible stains, fast green and Ponceau S allow for antibody-based 
detection (Dunn et al., 1999).  
6.1.4 Reactive black 5 dye 
There are a wide variety of dyes, amongst them are azo dyes. Azo dyes are the biggest 
group of dyes used in the textile industry (van der Zee, 2002). These dyes are distinguished 
from other dyes by their possession of an azo group which is made up of two nitrogen atoms (-
N=N-). Azo (mono, dis, tria or polyazo) dyes include anthraquinone, phthalocyanine and 
triarylmethane dyes (van der Zee, 2002). Reactive dyes contain reactive groups often fluoride or 
chloride which make covalent bonds with OH, SH or NH groups in fabric materials. Reactive 
black 5 has not been reported to stain proteins.  
6.1.5 Aims of this chapter 
We recognized Reactive black 5 dye in our laboaratory and decided to investigate 
whether it could stain proteins. The dye appreared to stain proteins on nitrocellulose membrane 
and SDS-PAGE gels. We then conducted the current study to explore the staining properties of 
Reactive black 5 dye in order to determine if it could be an alternative of Ponceau S stain.    
6.2 Results  








Figure 6.1: Comparison of staining the E. coli proteins with Coomassie brilliant blue R-250 and 
Reactive black 5 on SDS-PAGE gels. An E. coli BL21 (DE3) lysate was analyzed on a 12.5% reducing 
SDS-PAGE gel and stained with Coomassie brilliant blue R-250 (A) or Reactive black 5 (B) for 3 h and 
destained with 50% methanol and 10% acetic acid.  
E. coli proteins on SDS-PAGE gel were stained with Reactive black 5 and staining was 
compared with Coomassie blue (Figure 6.1). Though the same proteins were stained, the 
staining intensity of proteins stained with Reactive black 5 is low compared to that of Coomassie 
  A                     B 
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blue (Figure 6.1A and B).  The destain solution did not completely remove the background 
staining of Reactive black 5.  
To evaluate whether Reactive black 5 stains DNA on polyacrylamide gels, a DNA ladder 
and an E. coli lysate was analyzed on SDS-PAGE gel and stained with either Reactive black 5 
or ethidium bromide. Ethidium bromide stained both DNA ladder and the DNA in the E. coli 
lysate (Figure 6.2A and B). Reactive black 5 did not stain the DNA ladder and only stained E. 








Figure 6.2: Reactive black 5 stains proteins and not DNA.  DNA ladder (lane 1) and the E. coli lysate 
(lane 2) was analyzed on a 12.5% reducing SDS-PAGE gel which was stained with ethidium bromide (A) 









Figure 6.3: Comparison of the limit of detection of Coomassie brilliant blue R-250 and Reactive 
black 5. Decreasing concentrations of BSA (10 µg – 5 ng) were analysed on a 12.5% reducing SDS-
PAGE gel and stained with Reactive black 5 (A) or Coomassie brilliant blue R-250 (B) for 16 h.  
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Reactive black 5 does not detect low concentration of proteins, it stained 500 ng of 
protein while Coomassie brilliant blue R-250 stained up to 5 ng (Figure 6.3A and B).  
6.2.2 Staining zymograms with Reactive black 5 
Zymography is a sensitive technique used to investigate the activity of proteolytic 
enzymes on a substrate containing SDS-PAGE gels. Amido black 10B is a commonly used 
stain to stain zymograms. We investigated whether Reactive black 5 can be used to stain 
zymograms and compared to Amido black 10B (Figure 6.4).  Papain digestion was observed 
when staining with both Reactive black 5 and Amido black 10B (Figure 6.4A and B). The clear 
areas when the gel was stained with Reactive black 5 were more visible compared to Amido 
black 10B stained gels. The background staining for both Reactive black 5 and Amido black 10B 










Figure 6.4: Comparison of Reactive black 5 and Amido black 10B staining of zymograms.  Papain 
(10 μg – 1 μg) was resolved on a non-reducing 12.5% SDS-PAGE gel containing 1% (w/v) gelatin. The 
gel was stained with Reactive black 5 (A) and Amido black 10B (B).  
The sensitivity of Reactive black 5 and Amido black 10B staining on a zymogram was 
investigated. Reactive black 5 detected 0.1 µg of Papain which was not detected by Amido 
black 10B (Figure 6.5A and 5B). Reactive black 5 digestion band intensity was higher compared 
to Amido black 10 B. 
 
 













Figure 6.5: Comparison of the limit of protein detection of Reactive black 5 and Amido black 10B 
staining on zymograms.  Papain (1 μg – 1 ng) was resolved on a non-reducing 12.5% SDS-PAGE gel 
containing 1% (w/v) gelatin. The gel was stained with Reactive black 5 (A) and Amido black 10B (B).  








Figure 6.6: Comparison of protein staining on a nitrocellulose membrane with Reactive black 5 
and Ponceau S. Protein molecular weight marker (lane M) and Rabbit albumin (lane 1 and 2) were 
resolved on a 12.5% reducing SDS-PAGE gel and transferred overnight on a nitrocellulose membrane 
which was stained with either Reactive black 5 (A) and washed with distilled water with 1M NaOH (B) or 
with destain I (C).  Ponceau S stained nitrocellulose (D) and washed with distilled water with 1M NaOH 
(E).   
To assess whether Reactive black 5 stained proteins on the nitrocellulose paper, protein 
molecular weight markers and rabbit albumin were resolved on an SDS-PAGE gel and 
transferred onto nitrocellulose and stained (Figure 6.6).  Reactive black 5 stained all molecular 
weight marker proteins and rabbit albumin (Figure 6.6A). Ponceau S also stained all the 
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molecular weight marker proteins and rabbit albumin but with lower intensity compared to 
Reactive black 5 (Figure 6.6D). Reactive black 5 was not removed when washed with distilled 
water with NaOH or destain I (Figure 6.6B and C).  In contrast, Ponceau S stain is removed by 
washing with distilled water with NaOH for 5 min (Figure 6.6E).   
The sensitivity of Reactive black 5 and Ponceau S stain was compared using BSA. 
Different BSA concentrations were analyzed on a nitrocellulose membrane which was stained 
with either Reactive black 5 or Ponceau S stain (Figure 6.7). Reactive black 5 stained 5 ng of 
BSA on a nitrocellulose membrane (Figure 6.7A). The stain was not removed with multiple 
washes. Ponceau S detected 5 ng of BSA on a nitrocellulose membrane. Since Ponceau S is 
reversible, the washing step removes some of the stain that is bound to the proteins. This 








Figure 6.7: Comparison of the limit of protein detection of Reactive black 5 and Ponceau S stain. 
Decreasing concentrations of BSA (10 µg – 5 ng) were analyzed on a 12.5% SDS-PAGE gel, transferred 
onto the nitrocellulose and stained with Reactive black 5 (A) or Ponceau S stain (B) for 5 min.  
Reactive black 5 and Ponceau S stains were compared with an E. coli lysate on a 
nitrocellulose membrane (Figure 6.8A and B). Both stains stained different proteins with 


















Figure 6.8: Comparing staining of an E. coli lysate with Reactive black 5 and Ponceau S stain.  An 
E. coli lysate (10 μg – 625 ng) was resolved on a 12.5% SDS-PAGE gel and transferred overnight on 









Figure 6.9: Staining proteins with Reactive black 5 does not affect the interaction with antibodies 
in a Western blot. Proteins were loaded as follows: lane 1: molecular weight marker, lane 2: rPyLDH, 
lane 3: BSA, lane 4: uninfected mouse red blood cell (RBC) and lane 5: Plasmodium berghei infected 
mouse RBC.  Proteins were resolved on a 12.5% reducing SDS-PAGE gel and transferred to 
nitrocellulose and stained with Reactive black 5 (A). The obtained membrane was probed with anti-Histag 
antibodies and the signal was detected with chemiluminescence. B, C and D are the blot with ECL, ECL 
signal and nitrocellulose after antibody detection steps. 
Reactive black 5 was assessed to evaluate if the stained proteins could be detected by 
antibodies. Proteins were transferred to nitrocellulose and stained with Reactive black 5 (Figure 
6.9A). The stained proteins were probed with anti-Histag antibodies to detect rPyLDH (Figure 
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6.9B and C).  Mouse proteins on lane 4 and 5 were also detected as the secondary antibody 
was a goat anti-mouse antibody. The stain did not interfere with the chemiluminescence signal. 
The figure also showed that nitrocellulose membrane stained with Reactive black 5 makes a 
good Western blot reference as the stain can stain both the molecular weight markers and the 
proteins being analyzed. After all, the antibody detection steps, Reactive black 5 stain 











Figure 6.10: Comparison of Western blot reference with Coomassie brilliant blue R-250 stained 
SDS-PAGE gel and Reactive black 5 stained nitrocellulose. Recombinant PyGAPDH purification was 
analysed on a 12.5% SDS-PAGE gel and transferred overnight to a nitrocellulose membrane. Coomassie 
brilliant blue R-250 stained gel (A) and Reactive black 5 stained nitrocellulose (B). 
Reactive black 5 stained nitrocellulose was compared with Coomassie brilliant blue R-
250 stained SDS-PAGE gel for a Western blot reference (Figure 6.10). Reactive black 5 stains 
the same proteins on nitrocellulose as Coomassie brilliant blue R-250 stained SDS-PAGE gel 
(Figure 6.10A and B).  Reactive black 5 stained nitrocellulose has proteins with higher 
intensities compared to Coomassie brilliant blue R-250 stained SDS-PAGE gel. Therefore, 
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6.3 Discussion  
6.3.1 Staining proteins in polyacrylamide gels with Reactive black 5 
Staining proteins with Reactive black 5 was evaluated. Reactive black 5 dye is used in 
the textile industry to stain fabrics. Reactive black 5 has not been documented as a protein stain 
on polyacrylamide gels or nitrocellulose membranes. Proteins in SDS-PAGE gels were stained 
with Reactive black 5 and the dye stained the same E. coli bacterial proteins as Coomassie 
brilliant blue R-250 but with poor intensity. Reactive black 5 had a high background on SDS-
PAGE gels unlike Coomassie blue. Reactive black 5 showed to be a protein specific stain that 
does not stain DNA in SDS-PAGE gels and allows for staining zymograms. Zymogram staining 
with Reactive black 5 was more sensitive than staining with Amido black 10B stain.  
6.3.2 Staining proteins on nitrocellulose with Reactive black 5 
A Western blot (Towbin et al., 1979) allows for transfer of proteins from SDS-PAGE to 
nitrocellulose where proteins are more accessible for further analysis. Various stains for proteins 
in nitrocellulose have been described. These stains include Coomassie blue, Amido black, fast 
green, India ink and Ponceau S. Ponceau S is the most commonly used stain owing to its 
reversible properties that allow antibody-based detection (Dunn et al., 1999). Reactive black 5 
stained rabbit albumin (Figure 6.6), bovine serum (Figure 6.7), proteins in an E. coli bacterial 
lysate (Figure 6.8), recombinant proteins and mouse red blood cell proteins (Figure 6.9). 
Reactive black 5 stained proteins in 5 min like Ponceau S. Washing Reactive black 5 stained 
nitrocellulose with water and sodium hydroxide did not remove the stain. Reactive black 5 had 
the same limit of detection as Ponceau S. Reactive black 5 staining did not prevent the antibody 
detection unlike other irreversible stains like Coomassie blue and Amido black 10B (Dunn et al., 
1999). 
6.3.3 Reactive black 5 stained nitrocellulose as a reference for a Western blot 
Stains for nitrocellulose membranes are important to ensure that the transfer of proteins 
was efficient before blocking the membrane for antibody detection and for localizing the 
molecular weight markers (Hancock & Tsang, 1983). Duplicate gels are stained to compare the 
size and position of the blotted proteins. SDS-PAGE gels increase in size after staining making 
it difficult to accurately compare proteins on nitrocellulose and the reference gel (Hancock & 
Tsang, 1983). Stained nitrocellulose membranes would provide an accurate comparison of 
protein bands and save reagents. India ink has been reported for staining nitrocellulose. India 
ink stains 80 ng proteins in 2 hr and its sensitivity varies for different proteins (Hancock & 
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Tsang, 1983). Reactive black 5 is sensitive, stains the molecular weight markers and the 
stained nitrocellulose is comparable with a stained SDS-PAGE reference gel (Figure 6.10).   
6.3.4 Reactive black 5 decolorizes during the antibody detection step 
Proteins on Western blots are often detected with a method that involves a specific 
antibody, followed by a secondary antibody conjugated to an enzyme like horseradish 
peroxidase (HRP) (Sennepin et al., 2009). HRP detection requires hydrogen peroxide and a 
substrate to initiate an oxidation reaction that results in the formation of a coloured precipitate 
with a chromogenic substrate, or the emission of light with a chemiluminescent substrate (Haan 
& Behrmann, 2007). Oxidation involving hydrogen peroxide and ferrous ions have been 
reported to decolourize Reactive black 5 dyes in aqueous solutions (Lucas & Peres, 2006). The 
colour of the Reactive black 5 stain disappears after the enzyme reaction process (Figure 6.9D).   
6.3.5 The Reactive black 5 staining mechanism 
Reactive black 5 is an anionic dye like Coomassie blue, both dyes contain charged 
sulfonic groups (SO3-) (Lucas & Peres, 2006; Tal et al., 1985).  Coomassie blue binds to the 
amine groups of amino acids through its sulfonic groups when it is prepared in acidic conditions 
forming van der Waals, electrostatic interactions and hydrogen bonding (Tal et al., 1985). 
Reactive black 5 dye forms covalent bonds with fabric when it is employed in textile staining 
(van der Zee, 2002). The ability of Reactive black 5 to stain nitrocellulose irreversibly could be 
afforded by the formation of covalent bonds with nitrocellulose.  
6.3.6 The Reactive black 5 stain is economical 
Reactive black 5, Amido black 10B and Ponceau S stains are all prepared in 0.1% (w/v) 
in 1% acetic and with 30% methanol for Amido black 10B. According to catalogue prices 
(Sigma-Aldrich, accessed 9/11/2018), Reactive black 5 is 2.2 times cheaper than Amido black 
10B and 2.95 times cheaper than Ponceau S. Staining of zymograms is even cheaper as Amido 
black preparation requires additional methanol. Staining Nitrocellulose membranes with 
Reactive black 5 and taking images for Western blot reference could save a lot of money than 









7.1 Overview  
Malaria is a disease that claims many lives in sub-Saharan Africa. Plasmodium 
falciparum is responsible for the majority of these deaths. People who are most affected are 
children who are 5 years old and younger, pregnant women and non-immune visitors to 
endemic areas (World Health Organization, 2016). Many strategies have been implemented in 
the past to control the disease. These strategies include insecticide-treated bed nets and 
antimalarial drugs. These methods have resulted in the clearance of the disease in Europe, 
Russia and some parts of Asia (Guerin et al., 2002). The increase of insecticide-resistant 
mosquitoes and drug-resistant Plasmodium parasites have made it difficult to control the 
disease using insecticide-treated bed nets and common antimalarial drugs (Ranson et al., 
2011). New strategies to control the disease are required and a malaria vaccine could prevent 
the disease in young children and could also aid in eliminating the disease. The RTS, S/AS01 
vaccine targets the liver stage of malaria infection, reducing parasites that develop and invade 
erythrocytes resulting in disease symptoms and death. RTS, S/AS01 is the only malaria vaccine 
that has been endorsed for use (RTS, 2015). Although, it has low efficacy and provides 
protection that diminishes over 3-4 years and it is not approved for infant vaccination.  There are 
many vaccines that are currently being investigated for blood-stage malaria vaccine candidates 
including PfAMA1, MSP1, MSP3, GLURP and RH5 (Cockburn & Seder, 2018). These vaccines 
are based on the production of vaccine-induced antibodies to block the invasion of erythrocytes 
by malaria parasites, thereby, preventing the blood stage infection. None of these vaccines has 
made it to phase III clinical trials. More vaccine candidates and new approaches to developing a 
vaccine that could meet the World Health Organization goal to eliminate the disease are 
required.  
7.2 Major findings, future work and conclusions 
IgY is the most plentiful immunoglobulin in chicken serum and it’s passed to the yolk for 
the embryo’s immunity against infectious pathogens (Yegan & Korver, 2010).  IgY does not 
interact with complement (Gardner & Kaye, 1982) nor Rheumatoid factor (Larsson & Sjöquist, 
1988) and has been reported to not cross-react with mammalian proteins hence making it ideal 
for human immunodiagnostics (da Silva & Tambourgi, 2010). This study produced chicken IgY 
antibodies against recombinant Plasmodium falciparum lactate dehydrogenase (rPfLDH). The 
antibodies were isolated (Polson et al., 1980) and affinity purified with rPfLDH coupled to an 
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aminolink® affinity column. High yields of anti-rPfLDH IgY antibodies were obtained. The 
antibodies were specific for rPfLDH and did not recognize E. coli bacterial proteins. The 
performance of RDTs is influenced by temperature (Chiodini et al., 2007). Chiodini et al (2007) 
reported a reduction of pLDH and HRP-2 RDTs sensitivity when the tests are stored and 
operated in high ambient temperatures.  Mouse IgG antibodies are commonly used in RDTs 
(Moody, 2002). Further work could include a comparison of the stability of mouse IgG and 
chicken IgY antibodies at different temperatures.  
Polymorphisms of diagnostic candidate proteins affect the performance of the proteins in 
rapid diagnostic tests (RDTs) (Baker et al., 2005). The current study evaluated polymorphisms 
in plasmodial lactate dehydrogenase (pLDH) and glyceraldehyde-3-phosphate dehydrogenase 
(pGAPDH). The pLDH common and unique peptides identified for the detection of P. falciparum 
and P. vivax infections by RDTs had minimal polymorphisms which suggest that pLDH is a good 
diagnostic target. The pGAPDH common and P. falciparum unique peptide also had no 
polymorphisms. During the blood stages of P. falciparum parasite development, higher levels of 
PfGAPDH are produced compared to PfLDH (Bozdech et al., 2003). Together these results 
suggests that the pGAPDH based RDTs could be potentially more sensitive than pLDH based 
RDTs. Many vaccine candidates have failed due to polymorphisms in their sequences which 
results in strain-specific immune responses (Takala et al., 2009). Evaluation of polymorphisms 
in PyLDH and PyGAPDH sequences revealed only two synonymous mutations in both proteins 
which are low compared to the PfRH5 vaccine which induces immunity that is not strain-
specific. These observations imply that PyLDH and PyGAPDH based vaccines could be 
potentially effective and therefore should be further evaluated in animals.  
Development of a malaria vaccine could aid in the prevention of morbidity and mortality 
due to the disease and facilitate elimination of malaria (Cockburn & Seder, 2018). The study 
evaluated PyGAPDH and PyLDH immunogenicity in mice and whether vaccination of mice with 
these proteins could be protective against P. berghei infection challenge. Immunogenicity of 
rPyGAPDH and rPyLDH was demonstrated from the mouse serum following vaccination. 
Although, vaccination with rPyLDH did not show protection against P. berghei infection when 
compared with rPkPMT vaccinated mice. All the rPyLDH vaccinated mice developed high 
parasitemia and suffered from the disease. Only 1/5 rPyGAPDH vaccinated mice suppressed 
the blood stage parasitemia below 5% throughout the study. Further work includes repeating the 
rPyGAPDH and rPyLDH immunization and infecting mice with lower levels of parasetimia. 
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Passive immunization with purified anti-rPyGAPDH and anti-rPyLDH antibodies could be 
evaluated for protection against blood-stage malaria infection.  
Reactive black 5 is a dye used in the textile industry to stain fabrics. This study 
evaluated protein staining with Reactive black 5. The dye stained a variety of proteins on SDS-
PAGE gels, zymograms and nitrocellulose. Reactive black 5 stained the same proteins as 
Coomassie blue but with lower intensity on SDS-PAGE gels. The dye stained zymograms and 
the digestion bands were clearer than those of Amido black 10B stained zymograms. Reactive 
black 5 detected the same lowest concentration of proteins like Ponceau S on nitrocellulose. 
Unlike Ponceau S, Reactive black 5 binds strongly to proteins and the dye is not easily removed 
by changing pH and washing with water. Unlike Coomassie blue, Reactive black 5 did not 
interfere with antibody detection on nitrocellulose. An enzyme reaction involving horseradish 
peroxidase and hydrogen peroxide decolourized the dye on nitrocellulose. Reactive black 5 
stain is economical, being 2.2 times cheaper than Amido black 10B and 2.95 times cheaper 
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